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ABSTRACT, 
The Problem 
Corticosteroids may be necessary to control the symptoms of many 
patients with chronic bronchial asthmay their useq howeverp is frequently 
complicated by side effects, which are unpleasant for the patient and 
often worrying for the physician. Any meam=e, therefore, which would 
permit a useful anti-infla tory effect of these drugs whilst minirnising 
side effects would be of benefit to patients. It is for this reason that, 
for over twenty years, repeated attempts have been madeq with every cortico- 
steroid as-they have been introduced, to administer them directly onto the 
bronchial mucous membrane by inhalation in one form or another. These 
attempts have failed, probably because the steroids used have had potent 
syst emic glucocorticoid effects following any route of administration. The 
use of inhaled beclomethasone-17,21-dipropionate9 however, is in no ed 
contrast to the earlier experiences with inhaled corticosteroids, because 
the symptoms of bronchial asthma are controlled without important. cortico- 
steroid induced side effects* The aim of this thesisAs twofoldp, first, 
to establish. by simple means, the properties. of beclomethasone-171,21- 
dipropionate in inan attempt to discover, the reasons why this cortico- 
steroid should be successful when given by inhalation whilst others were 
not, and secondlyp to discover whether the regular use of an inhaled 
corticosteroid may be complicated by any side effects, peculiar to this 
route of administration. 
of the Present Work 
The use of corticosteroids in the treatment of bronchial asthma, and, 
the attempts to reduce side effects by clinical means, including the local, 
inhaled use of corticosteroids are reviewed. The work of steroid chemists 
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aimed at producing compounds where tlýere may be some separation of anti- 
infla tory from other glucocorticoid effects is outlined. The literature 
on inhaled beclomethasone-l7v2l-dipropionate is reviewed and contrasted with 
the earlier studies on inhaled corticosteroidse 
The properties of beclomethasone-17,21-dipropionate in mam are 
investigated. These original studies include an assessment of its topical 
anti-infl tory potency on the skin; the effects following its 
administration by inhalationt by mouthl intra-nasally and intravenously 
on. the Iýy-pothalamic-Pituitary-Adrenal (H. P. A. ) axist together with an 
investigation of its absorption, and metabolic fate after oral and intra- 
venous administration are described. The effects of beclomethasone-l7g2l- 
dipropionate upon circulating white blood cells and fasting blood sugar 
levels have also been investigated. 
Particular attention has been paid to describing and reviewing the 
evidence in animals and in man concerned with potential toxic effects on the 
tissues of the respiratory tract. The incidence of bacterial infection in 
the lungs of patients treated with beelomethasone-17,21-dipropionate has 
also been Investigated. Increased colonisation of the oro-phaxynx with 
candida, albicans, and, less frequentlys, clinical candidiasis is a com- 
plication of treatment with beolomethasone-17921-dipropionate. This, 
together with possible predisposing factors is assessed. 
It is concluded, oneq that high topical activity together with lower 
systemic activity and. metabolic inactivation of the swallowed portion of 
beelomethasone-17t2l-dipropionate are the likely reasons why this cortico- 
steroid, in the doses employed, controls bronchial asthma in most patients 
without causing important glucocorticoid. side effects. And twos although 
no clinical or experimental evidence exists at present to suggest that this 
drug is exerting any deleterioup effect on the tissues of the respiratory' 
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tract, this cannot be excluded and continued vigilance is necessary. 
Oro-pharyngeal candidiasis is a complication of this treatment, but, at 
present, the advantages to the patient of reduced or no oral dosage with 
corticosteroids, outweighs the disadvantages of candidiasis, because this 
does not occur invariablyg it is frequently symptomless, easily treated and 
has only occurred superficially. 
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nMODUCTION I 
Compaund E, an adrenocortical ho=one (17-hydromy-11- 
debydrocorticosterone), was introduced into clinical medicine in 1949- 
Hench and his colleaguesl from the Mayo Clinict demonstrated prompt 
improvement in the joints of patients with rheumatoid arthritis during 
the administration of cortisone. During the same year, cortisone acetate, 
100 mg. injected daily, was administered for one month to three "volunteer" 
patients with bronchial asthma and hay fever resulting from their sensitivity 
to Ragweed pollen (Carryer, Koelsche, Prickwn, Maytumq Iake and Williams). 
Each patient experienced rapid relief from their symptoms, and this relief 
was greater than had previously been achieved bysuch measures as hypo- 
sensitisation or the use of anti-histamines. 
Quicklyq other workers confirmed the value of cortisone in controlling 
bronchial asthma. Over the past two decades the effectiveness of cortico- 
steroids in the management of patients with bronchial asthma has been 
recognised, and their use accepted. It is now mandatory to use-cortico- 
steroids in status asthmaticus, when they may be life saving. In many 
patients with chronic bronchial asthmat their only hope of leading tolerable 
and useful lives, may depend on corticosteroid therapy. 
Unfortunately there are few compounds in widespread clinical use, more 
liable to cause unwanted effects than corticosteroids. Some of these 
effects are dangerous and may be life threatening themselves. They may be 
listed under three broad headings: - 
an exaggeration of the physiological effects produced 
by natural corticosteroids 
ii) a suppression of the inflammatory response which 
leads to a failure to respond to infection, or 
may msk infection 
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and 
iii) loss of natural response to stress caused by 
adrenal insufficiency or atrophyp leading to a 
failure in adrenal responsiveness following 
withdrawal of corticosteroids, or stressful 
situations such as trauma, surgery or infection. 
Under the first heading,, electrolyte disturbances, retention of salt and 
water and loss of potassium may be seeng leading to oedemat hypertensiont 
congestive heart failure and renal disturbances. To this list can be 
added metabolic problems of obesityg glycosurial and growth retardation in 
children. In additiony effects on skin, blood vessels and bone, 
exacerbation of peptic ulceration, eye changes and mental disturbance my 
also occur. Many of these changes are seen following long-term administration 
of corticosteroids to patients. 
The suppression of the inflammtory response may have undesirable 
effects when infections occur; the warning pain associated for example, 
with peritonitis or pleurisy may be absent, peptic ulcers my perforate 
silentlYt and latent tuberculosis may be activated. Local infections may 
be unrecognised until they have become widespread. 
But perhaps the most dangerous complication is adrenal insufficiencyl 
which mays depending on the dose of corticosteroids used and the duration 
of their use, be revealed when corticosteroids are withdrawn and this will 
result in an Addisonian crisis. Thus withdrawal of steroids must be made 
gradually, and tests of adrenal responsiveness carried out from time to time, 
after corticosteroids have been withdrawn. It must be remembered týat it 
may take many months for adrenal responsiveness to return. Malone, Dreverp 
Grant and Percy-Robb recently (1972) examined the endocrine response in 
seventeen asthmatic children following the substitution of corticotrophin 
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for oral prednisolone. The plasma corticosteroid response to insulin- 
induced hypoglycaemia returned to no 1 in four children within six 
weeks, took up to thirty-six months to become normal in nine and remained 
abnormal after thirty-six months in one child. During treatmentq the 
possibility of adrenal insufficiency must constantly be borne in mind, 
and the dose increased when the patient is subjected to any stressful 
situation. 
The literature on the subject is overwhelming, an extensive review 
of the clinically relevant consequences by David, Grieco and Cushman (1970) 
involving 848 references in the English language aloneg emphasises the 
sequellae of corticosteroids, involving almost every tissue in the boays 
which may seriously limit their usefulness. Neilsonj Drivsho. 1m, Fischer 
and Mortensen (1963) in a careful review of fifty patients with rheu toid 
arthritis over a period of nine to twelve years, describe the side effects 
I have already outlined; treatment had to be withdrawn in sixteen patients 
because of side effects, and nine of these died, three from adrenal in- 
sufficiency. On the other hand, twelve patients were able to work, whereas 
only one had been able to before, and of six completely incapacitated patients, 
only one remained in that state. A retrospective controlled study of 
mortality and morbidity of the incidence of serious complications of cortico- 
steroid therapy in respiratory disease was carried out at the Brompton 
Hospital (Snyllie and Connolly, 1968) involving 550 patients and 499 controls. 
They found a similar incidence of I'side effects" in both groupsq but an 
increase in the incidence of gastro-intestinal bleeding, diabetes and mental 
disturbances in the corticosteroid group. A study aa the prevalance of 
corticosteroid administration in the general population was carried oat by 
the Wessex Baculty of the Royal College of General Practitioners (Sleett 1969) 
where a high incidence (16. eo) of side effects was noted in patients on 
23 
prolonged therapyt and leo of all patients on corticosteroids developed 
at least one complication. A similar survey by the North-East England 
Faculty of the Royal College of General Practitioners (Hurrell, 1972) noted 
a higher incidence of side effects than in the Wessex survey, 2Wo exhibiting 
at least one minor side effect, and lVo major effects, with one death due to 
adrenal insufficiency. Women tended to develop side effects more readily 
than men and aver 50 of the steroids prescribed were for asthma. 
With this list of complications and their incidence, the decision to 
use corticosteroids obviously depends on the seriousness of the condition 
to be treated, and the consequences of not using steroids when they may be 
indicated. The failure to use steroids, in obviously worsening asthma, 
may have been partly responsible for some of the increase in the death rate 
in young asthmatic patients which occurred between 1959 and 1966. In these 
patients it was found that corticosteroids had never been prescribed in over 
one quarter of them (fifty out of 173 patients) and no increase in dosage 
had been recommended in a further thirty-one patients. The judicious use 
or corticosteroids may have saved some of these lives, although the brevity 
of the terminal episodes might not have given sufficient time for them to 
be introduced (Speizer, Doll, Heaf and Strang, 1968). 
Organic chemists have been successful in producing synthetic 
corticosteroids with minimal mineralocorticoid effects, so that electrolyte 
disturbances in patients receiving corticosteroids have been greatly reduced. 
The chemists have also been successful in producing corticosteroids with 
enhanced anti-infl-q tory activity, this, however, is associated with an 
overall increase in glucocorticoid activity, so that at therapeutic doses, 
there is no separation of anti-infla=atory from other glucocorticoid 
functions, and, thereforet no reduction in the incidence of unwanted effects. 
Clinicallyt with increasing experienceg the dosage of corticosteroids 
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may be adjusted to minimise complications. Intermittent long-term 
therapy (for example, on three consecutive days each week) has been 
advocated to minimise unwanted effects, and is said that this regimen 
will control about 6Wo of patients (Walsh and Grant, 1966; Grantp 1970). 
Long-acting corticotrophin preparations may be used instead of cortico- 
steroidst they may be less liable to retard growth in childrent but the 
other unwanted metabolic effects are similar to those seen with cortico- 
steroids, and they my lead to pituitary suppression. The administration 
of drugs by inhalation, particularly bronchodilators, has long been 
accepted to treat patients with asthma. It is, therefore, not surprising 
that this route of administration should have been tried from time to time 
over twenty years (1951 to 1971) as a means of administering corticosteroids, 
where they have been indicated to control asthma. These attempts have been 
based on the concept that by placing the corticosteroid directly where it is 
required to act, smaller doses could be used and unwanted effects thereby 
reduced. The results have been largely disappointing, and are fully 
reviewed in Chapter I. 
A letter to the British Medical Journal'in September 1971 by Smith, 
Booth and Daveyq reported their early results with-an-aerosol of 
beclomethasone dipropionate in the treatment of five patients with 
allergic asthma in a double-blind crossover study comparing beclomethasone 
dipropionate with a placebo. They found that 400 pg. daily of inhaled 
beclomethasone, dipropionate led to a significant improvement in Peak 
Expiratory Plow Rate together with riarked subjective improvement; as 
evidenced by a reduction in the need for bronchodilators and other 
medications. Synaothen tests indicated normal adrenal responsiveness 
during and after treatment with beclomethasone, dipropionate. These authors 
were sufficiently encouraged to proceed to a larger controlled trial. 
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Morrow Brown, Storey and George (1972)9 in an uncontrolled study 
involving sixty patients, found that twenty-eight out of thirty-seven 
patients dependent on oral corticosteroids to control their asthma, and 
nineteen out of twenty-three patients not requiring oral corticosteroids, 
were completely controlled by inhaling between 400 pg. and 600 pg. of 
beclomethasone dipropionate daily. They found no biochemical evidence 
of adrenal suppression, and reversal of Cushingoid features in some 
patients. Mild adrenal withdrawal symptoms were a problem in some 
patientsv and they suggested that this was evidence of lack of systemic 
absorption of the drug. 
This report prompted two letters to the British Medical Journal in 
April 1972. The first from Mr. Ian Gregg reported similar findings to 
those of Dr. Morrow Brownp together with a plea that the absorption 
characteristics of this compound be studied urgently, and that this I! new 
and promising treatment" be used carefully when it became generally 
available. The other letter, from Dr. Ian Grant and his colleagues in 
Edinburght was highly critical of Dr. Morrow Brown's paper and reported 
that their findings were in sharp contrast to hisp they were able to 
helpfully reduce oral corticosteroids in many patients by the addition 
of beclomethasone dipropionate, but'rarely were they able to discontinue 
oral steroids entirely. 
T. J. H. Clark (1972) reported the successful control of seventeen 
patients with this corticosteroid for periods of two to six monthswith 
no effects on the pituitary-adrenal axis, suggesting that'beclomethasone 
dipropionate acts in a similar way to systemic corticosteroids in patients 
with asthmap but seems to have less systemic effects. Many more references 
to the use of beolomethasone dipropionate in asthma have subsequently 
appeared, and these are reviewed later (Chapter VIII pages 110 to 120) 
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INTRODUCTION II 
Aims of the Present Stucly 
In the first part of the Introduction, I have said that attempts to 
control bronchial asthma by administering corticosteroids by inhalation 
have been largely disappointingl although many such attempts have been 
made over the past twenty-two years. The early experiences with inhalations 
of the corticosteroid, beclomethasone dipropionate, axe in maxked contraSt 
with all the work carried out with other corticosteroids. 
The drug administered by Inhalation is effective in controlling the 
symptoms of bronchial asthma. Other inhaled corticosteroids controlled 
asthma, but the doses required were similar to or even larger than the dose 
of the same steroid by mouth. The therapeutic dose of beclomethasone 
dipropionate is small, about 400 pg. a day. At this dose no effect on 
Pituitary-adrenal function has been observed. Following the transfer of 
patients from oral corticosteroids to inhaled beclomethasone diproPionate, 
a reduction in corticosteroid induced side effects has been noted. 
Similarly, other allergic phenomena, such as rhinitis or eczema have been 
un sked, and, occasionally mild symptoms suggestive of adrenal in- 
sufficiency have occ urr ed. All these findings suggest that systemic 
effects following inhaled beclomethasone dipropionate at therapeutic 
doses are negligible or absent. Beolomethasone dipropionate is one of a 
series of corticosteroids with ma ed topical potency synthesised about 
twelve years ago. Although these compounds have been used widely in 
dermatology, their effects on other body surfaces were not investigated 
until beclomethasone dipropionate was formulated as an aerosol for trial in 
asthmatic patients. 
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Smithp Booth and Davey (1971) and Morrow Brown, Storey and George 
(1972) both suggested that the drug was poorly absorbed and that this 
probably accounted for its apparent lack of systemic effects. Clark (1972) 
suggested that it "seems to have less systemic effect". 
Beclomethasone dipropionate appears to be the first corticosteroid 
administered by inhalation which fulfils the criteria mentioned on page 36 
(Chapter I ). That by plaoing the cortioosteroid where it is required 
to act smaller doses could be used and unwanted effects reduced. 
The purpose of this thesis is to establish why this corticosteroid 
should be successful in controlling the symptoms of bronchial asthma in 
many patients without other systemic effects, which other earlier steroids 
failed to do. 
This workg thereforep comprises: - 
1.1) A review of the earlier attempts (between 1951 
and 1971) to control asthma with inhaled 
steroids (Chapter I, pages 30 to 37 )- 
ii) A brief accountg outlining the development of 
synthetic analogues of cortisone and hydro- 
cortisone by steroid chemists. These develop- 
ments being largely designed to separate mineral 
effects from glucocorticoidl and to attempt some 
separation of activity within the glucocorticoid 
function (Chapter II, pages 38 to 52 ). 
2. Experimental Work 
i) To establish the topical potency of 
beclomethasone dipropionate when applied to 
human skin, and to compare it with other 
corticosteroids which have been used by 
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inhalation (Chapter My pages 53 to 61 ). 
To investigate the absorption, metabolism and 
excretion of the drug in wn, following its 
oral and intravenous administration (Chapter 
IV, pages 62 tO 72 ). 
iii) To establish the dose of beclomethasone 
dipropionate necessary, by the oral, inhaled 
intravenous routes, to cause suppression 
of the Ilypothalamic-Pituitary-Adrenal (H. P. A. ) 
axis in man, and to compare it in these 
experiments with dexamethasone (Chapter V, 
Pages 73 to 94 )- 
iv) To investigate the effect of beclomethasone 
dipropionate compared with other cortico- 
steroids on circulating white blood cells and 
fasting blood sugar (Chapter VI, pages 95 to 
109). 
V) To assesi its therapeutic anti-infla tory 
effect in patients with bronchial asthma. 
This is achieved by reviewing the literature 
on beclomethasone dipropionate. In addition, 
by this review any problems associated with 
its therapeutic use are noted (Chapter VII, 
pages 110 to 120). 
A review of the animal toxicological experiments carried 
out with this compound. Some human histological evidence 
following several months treatment with beclomethasone 
dipropionate, and the results of a survey designed to 
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give information on potential long-term effects on the 
lungs is presented (Chapter VIII9 pages 121 to 137)- 
A general discussion of the work and the conclusions. 
The properties necessary in a corticosteroid intended 
for topical use by inhalation are described (Chapter IX, 
Pages 138 to 142)- 
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CHAPTER I 
The Intra-Bronchial Use of Corticosteroids 
Between 1951 and 1971 
Shortly after Carryer and his colleagues had demonstrated the 
beneficial effects of cortisone in patients with bronchial asthma, Reeder 
and Mackay (1950) caused a remission of symptoms in a patient with bacterial. 
pneumonia by delivering nebulised cortisone directly onto the bronchial 
mucous membrane. 
This apparently useful, local use of cortisone, together with the 
need to try any means of reducing the side effects of corticosteroid therapy, 
which were already proving troublesomep prompted Gelfand in 1951 to try 
nebulised cortisone acetate, 50 mg. daily, in ten hourly doses each of 5 mg- 
delivered by a De Vilbiss nebuliser. Five patients with long standing 
bronchial asthma were chosen in whom there were no contra-indications to 
COrtiCOBteroid therapy. They were treated for two weeks, four out of five 
responding favourably. The patient who did not respond being an elderly 
woman with marked emphysema and pulmonary fibrosis. 
No objective measurements'of respiratory function, nor any assess- 
ment of adrenal function were carried out, neither were any side effects 
noted. The lack of objective evidence and the shortness of the treatment 
period in this studys does not permit any conclusions that the local use 
of cortisone would reduce the likelihood of side effects developing. In 
fact, this relatively high dose of a corticosteroid with no topical activity 
means that its effect was exerted systemicallyt and that longer treatment 
would have revealed potent corticosteroid effects. 
Hydrocortisone has some local effect on the skin or when injected 
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into the joints, and became available in Great Britain in 1954, when it 
was administered as an inhaled powder to fifteen patients with bronchial 
asthma (Foulds, Greaves, Hertheimer and Kingdom, 1955)- Between 7-5 mg- and 
15 mg. of hydrocortisone powder with an average particle size of 5 microns 
was inhaled daily; patients whose daily use of isoprenaline did not vary 
much were chosen. A reduction in the number of these inhalations required 
by the patient was taken as an index of improvement and this was observed in 
eleven out of fifteen patients where the number of daily isoprenaline in- 
halations dropped to half or less. These workers concluded that the local 
use of hydrocortisone permitted a considerable reduction of dosage and mightt 
thereforet reduce side effects. 
This work was subsequently criticised (Brockbank, Brebner and Pengellyp 
1956), these workers, in a blind controlled study, found that 15 109- 
hydrocortisone hemisuccinate dailyp administered as a wet aerosol was less 
effective than an inert inhalation in controlling asthma. Cotes and her 
colleagues in 1956, at Dr. Hencheimerts suggestiong investigated whether 
inhaled bydrocortisone powder was absorbed. They noted an increase in the 
urinary excretion of 17-bydroxycorticosteroidE3 following inhalation of 
hydrocortisone only slightly less than that following a similar oral dose. 
Thus it would seem possible that unwanted systemic effects could occur 
following inhaled hydrocortisone. 
Brockbank and his colleagues in 1956 although critical of the methods 
of Foulds et al, had not carried out their blind studY with hydrocortisone 
powder. In 1958 Brockbank and Pengel3, y reported their results of a blind 
trial comparing hydrocortisone and prednisolone powders with an inert 
material. Their results on this occasion were in contrast with their 
earlier findings using a wet aerosol. A significant number of patients 
benefitted from hydrooortisone although no improvement was noted following 
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prednisolone. Again no objective measurements of respiratory or adrenal 
functian were mde. 
11'rednisolone phosphate as a 0.5% solution given with 1: 200 iso- 
prenaline, when inhaled, was said (Peters and Henderson, 1958) to benefit 
ten out of eleven patients. It is difficult to evaluate this short study, 
as no details of assessment are giveng and as other treatments, including 
isoprenaline are involved, These authors state, howevert that the improve- 
ment was less striking than they would have expected following systemic 
nee. 
Franklin, Lowellq Michelson and Schiller also in 1958 administered 
separate3, yp preparations of prednisolone and hydrocortisone in Freon 
propellants from pressurised metered dose aerosols using a double-blind 
technique, a total dose of 18 mg. daily of either drug being given. 
Maximmm forced expiratory measurements were made to assess the effect of 
these drugs in two separate studies, each lasting a month. There was some 
evidence that prednisolone exerted a topical effect, lung function was, 
maintained at far lower doses than those required by mouthp 18 mg. being 
apparently-equivalent to 40 mg- and some patients experienced muscle 
weakness and wastingr symptoms suggestive of adrenal insufficiency, possibly 
presumptive evidence of lack of absorption. Six out of seven patients 
benefitted from prednisolone. Bydrocortisone was more readily available 
than prednisolone and so more patients could be treated with this steroid, 
thirty-one out of thirty-nine were able to significantly reduce their oral 
hydrocortisone whilst maintaining their respiratory function. 
During 1958 three more reports on the local use of hydrocortisone 
in bronchial asthma appeared. Two involving dry powder (Helm and Heyworthl 
1958) and (Hencheimero McAllen and Williams, 1958) and one, (Mo=ison Smith, 
1958) a solution. In both the studies where hydrocortisone powder was , 
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usedp a total of 132 patients were involved, ten of whom had "wheezy 
bronchitis" and forty-five of whom were included in a controlled trial. 
The bronchitic patients did not respondl although thirty-three of the forty- 
five in the controlled study obtained some beneift as did the remaining 
patientst although there was a considerable tendency for relapses as 
treatment was continued. These studies tend to confirm the earlier ones, 
and the opinion that only a minority of patients appear to benefit from 
inhaled hydrocortisone is expressed. Morrison Smith's (1958) blind trial 
comparing hydrocortisone hemisuccinate solution with a placebo in children 
with asthma, using the forced expiratory volume in 0-75 seconds, confirms 
the earlier controlled trial of Brockbank, Brebner and Pengelly (1956) that 
this preparation was of no value in controlling bronchial asthma. This was 
further confirmed two years later by Langlands and McNeill (1960), who in 
a double-blind study, found no improvement in any parameter measurede 
E[ydrocortisone in this instance being administered from a pressurised 
aerosolt the total daily dose being 15 mg. On every occasion where solutions 
of hydrocortieone were inhaled in controlled blind trialso this drug was. 
found to be less effective than the accompanying inert preparations. 
Interest in the further local use of hydrocortisone and prednisolone 
waned. In 1962P a steroid with great2, y enhanced anti-infla tory potency 
was introduced - dexamethasone, interest in the local use of the inorganic 
ester of this steroidl dexam thasone sodium phosphate was considerable, 
underlining both the value of steroids in asthma and the problem of side 
effects associated with their use. 
A clinical trial (Bickerman and Itkin, 1963) of a pressurised aerosol 
of dexamethasone sodium phosphate 1 mg. per day in divided doses involving 
seventy-one patients, with objective measurements of expiratory functiont 
showed a clinical improvement in over 80% of patients, a similar percentage 
being able to discontinue oral steroids or greatly reduce their existing 
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doses. These patients were treated for aver twelve months and no side 
effects were noted. These encouraging results prompted a favourable 
leading article in the Lancet of June 19739 and a month later 
Dr. Morrow Brown of Derby in a letter to the lancet reported that his 
findings with this steroid aerosol in eighty-five patients coincided 
exactly with those reported by Bickerman and Itkin. 
Other reports concerning dexamethasone sodium phosphate at total 
daily doses of 1.0 mg. mainly from the United States of Americaq appeaXed 
over the next four years. (Arbesmam, Bonstein and Reisrmnt 1963) found 
this steroid aerosol to be effective in 123 patients with mild to moderate 
extrinsic asthma, particularly in children. They did, however, notice 
"Moon face" in two of the younger patients, which would indicate a 
significant absorption of the drug. A controlled trial involving twenty- 
six patients (Snider, Frankp Aaronsonj Radnerg Kaplan and Mosko, 1963) 
showed good control in 4Vo of patients with no side effects other than 
bronchoconstriction in one patient, no doubt due to a local irritant effect 
of the aerosolised steroid, which the addition of isoprenaline abolished* 
Dennis and Itkin (1964) again confirmed the effectiveness of this steroid 
in controlling asthma in a group of twenty-five young patients (average age 
31-1 years), in whom an effective reduction of oral corticosteroid dosage 
was possible. They noted,, however, "signs of hypercortism" and a decreased 
excretion of urinary corticosteroids in two patients, and 2Wo of their 
patients developed candidiasis of the mouth, phaz7nx and laxynx. They 
considered that inhaling corticosteroids was contra-indicated in any 
patient with a positive mouth culture of Candida Albicans. 
Rmther confirmation of the effectiveness of this steroid in thirty- 
two children using a double-blind crossover studyp in which 75% of the 
patients definitely improved was reported by Siegel, Heimlichq Richards 
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and Kelley (1964)- These authors, however, also determined the effects 
of such aerosol therapy on adrenal function, no similax study having been 
carried out with this steroid, The plasm corticosteroid levels and 
the twenty-four hour urinary excretion of 17-hydroxycorticosteroids were 
measured following the administration of ACTH in twenty-four children, 
and in every child adrenocortical suppression was observed. Linder (1964) 
too# found that, inhaled dexam thasone was as effectively absorbed as the 
steroid given by mouth, and just as effectively led to adrenocortical 
suppression. Novey and Beall (1965) tried substituting this aerosol for 
oral corticosteroids in twenty patients who had signs of induced Cushing's 
syndrome. In nineteen these signs persistedt although the symptoms of 
asthm were suppressed. Toogood and Lefcoe (1965) from Canada observed 
hypercortism in a series of thirty-one patients over a period between one 
and thirteen months. They also noted an improvement in co-existing rhinitis, 
confirming the absorption of this active, anti-inflammatory steroid. 
Kravis and Leeks (1966) found that a favourable response occurred in 
4W- of childrent that maintenance doses of oral steroids could be reduced 
in many, and that unwanted effects could be reduced although not abolished. 
This oral steroid sparing effect was thought to be useful in some patients. 
An aerosol of dexamethasone sodium phosphate has been available in the 
United States since 19629 marketed with and without isoprenaline, as 
Pro Decadron and Decadron Respihalers (Merckt Sharp and Dohme Iaboratories). 
Another ester of dexamethasone, dexamethasone 17-isonicotinate, has 
recently become available in Prance and Genmny as a pressurised metered 
dose aerosol (Auxisone - Boehringer). The daily dosage of this preparation 
is similar to that of the dexamethasone sodium phosphate aerosol, around 
1.0 mg. per day in divided doses. Using a larger dose (1-5 mg- to 2.0 mg. 
daily) Turiaf I Guerot and Amsel (1970) from Paris found in an uncontrolled 
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studyp that this aerosol was effective in seventy-five out of one hundred 
and one patients with chronic asthma. These workers carried out some 
objective respiratory function measurements, although the adrenal state 
was not investigated. Significant absorption of this steroid must have 
occurred because Cushingoid signs persisted in those patients previously 
receiving oral steroidst and these signs appeared in those patients new 
to corticosteroid therapy. Biedermann (1971) from Germany treated forty- 
six children successfully with this aerosol, 8Vo being able to completely 
or partially cut down on their oral steroid requirements. No side effects 
were noted in this trial. This preparation like the sodium diphosphate 
aerosol appears to be effective in suppressing asthmaq probably as a result 
of systemic absorption rather than. by any selective topical action on the 
bronchial mucous membrane. This is shown to be so in a later chapter M 
where the effects of the commercially available aerosolq at therapeutic 
doses on the Hypothalamic-Pituitary-Adrenal are described. 
Comment 
Since corticosteroids were shown to be useful in controlling the 
symptoms of bronchial asthma there have been repeated attempts to use 
most steroids by inhalation as they become available. These attempts 
have been based on the concept that high local concentrations of steroids 
on the bronchial mucous membrane might relieve the symptoms of asthma with 
fewer of the complications encountered following systemic corticosteroid 
I 
therapy. 
The results reviewed are disappointing. Undoubtedly the symptoms 
of asthma have been controlleds bat without eliminating the side effects 
so that there are no advantages in using amy of the steroids described by 
the inhaled route. 
These steroids, hydrocortisonep prednisolone and the eaters of 
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dexamethasoney are all potent glucocorticoids by any route of administration, 
thus any reduction in the dose of oral steroid is in fact replaced by that 
given by inhalation -a high proportion of which will be deposited in the 
mouth and oropharynx and subsequently swallowed anyway (Dollery, Davies and 
Conolly, 1971)- 
However, many points emerge from these studies concerning the proper 
conduct of trials to assess inhaled steroids in asthmae The trials must 
be controlled and wherever possible double-blind techniques should be used. 
In the work reviewed, particularly in those studies involving hydrocortisone, 
wherever controlled blind studies were carried out9 the active drug was not 
significantly better than placebo. 
The pharmaceutical presentation of the steroid was also important. 
Powders., or particles suspended in Freon propellants were superior to 
solutions. This was particularly true of hydrocortisone and prednisolone. 
Such powders or suspensions should be microfine, having a particle size of 
between one and five microns in diameter to assist penetration to the 
srDaller bronchi. 
Lastlys objective measurements of respiratory function must be made. 
Tests of adrenal function or steroid blood level estimations should also 
be carried out. In every study where these tests were done, evidence of 
absorption of the steroid, either from high blood levels or from adreno- 
cortical suppression were obtained. 
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CHAPTER II 
An Outline of the Work carried out by Steroid Chemists since 1954 to 
develop Synthetic AnalogtWs of Cortisone. The Aim of this Work being 
a_Separation of the Anti-InflammatoEX Effects from other 
Glucocorticoid Effects 
When adrenocortical hormones axe used clinically, other than for 
replacement therapy, they. are used to suppress infla tory responses in 
various disease entities. The physiological effects of corticosteroids 
are divided into mineralocorticoid and glucocorticoid, the former referring 
to the sodium and water retaining properties, and the latter to the effects 
of corticosteroids on glucose metabolism. The so called anti-infla tory 
effect is apparently an inseparable part of the glucocorticoid activity 
of corticosteroids. The mineralocorticoid function although important in 
replacement therapyq otherwise represents a potent source of unwanted effects. 
This Chapter outlines the work c arr ied out over the past twenty years, 
by organic chemists, to develop analogues of cortisones, in which the anti- 
inf1aMMtOrY Propertiesp either systemically or topically, are enhanced, 
hopefully aiming at some separation of anti-infla tory effect aver 
other glucocorticoid effects. 
The name sterol is derived from the Greek work stereosq meaning 
solid, and was originally applied to solid alcohols obtained after 
saponifying vegetable and animal fats. Many chemically related sub- 
stances were later found and the generic name "steroid" was coined to cover 
the general class of compounds. 
The adrenocortical steroid hormones are secreted by the adrenal 
cortex. The amounts of these hormones in the adrenal cortex are extremely 
lp 
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small so that the possibility of obtaining large quantities by isolation 
was never seriously considered. The proceedure of partial synthesis 
from other steroids has received most chemical attentiont and it is by 
this proceedure that all synthetic corticosteroid-like substances for 
use in medicine are made (Hems, 1962). 
All steroids are derivatives of perhydrocyclopentenophenanthrenej 
a complex hydrocarbon consisting of four fused ringsp three cyclohexane 
rings containing six carbon atoms and one cyclopentane ring containing five 
carbon atoms. Each carbon atom, has four valenciesq those not involved 
in carbon-to-carbon bondst bind hydrogen atoms. 
The basic lettering and numbering of the steroid structure is 
given in Figure 1. 
21 CH2 
I 
2-V 0 
18 
16 
2 
3 
15 
FIGURE 1- Steroid Structure, Lettering and Numbering - Plan View 
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This two dimensional delineation is misleading, as these rings are never 
flatl they exist in two fo=s , chair,, and lfboatilt 
chair fo= 
FIGURE 2 
boat fo= 
of which the former is more stable. Substituents on the chair form of 
the ring fall into two groupst either in the median plane or vertical to 
it (Figure 
is 
0 
21 CH20H 
FIGURE 3- Steroid Structure (chair form) side view (prednisolone)- 
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The vertical valencies either above or below the plane are called axial 
bondso whilst those approximately in the plane are called equatorial. 
Groups above the plane are designated P and are shown by a continuous 
linet whilet those below the plane are designated a and are depicted by 
a dotted line. 
These configurations axe of the greatest importance to both 
chemistry and physiology. Both chemical reactivity and physiological 
activity are greatly altered depending whether a group is axial or 
equatorial. In cortisol for example (Pigure 
CH20H 
I 
Cý 0 
- -' OH 
FIGURE 4- Cortisol (IT3rdrocortisone) 
the hydroxyl at carbon 11 is P, and that at 17 is a. If either is altered 
the compound is inactive. Most adrenocortical hormones have hydroxyl 
groups in these two positionsp they must be in those configurations and 
in no other. Chemieal2, vl configuration is important as it effects the 
positions of reactive groups in spacet influencing freedom of access by 
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reagents. Groups overcrowded on one side of the molecule lead to 
inertia and poor chemical reactivity. Changes in configuration, 
altering the distances between groups, may affect the facility the 
molecule possessed for interaction with enzyme or proteinsy which 
would speed up or slow down physiological action as well as biochemical 
inactivation (Hems, 1962)e 
Considering the structural formula of cortisone (Figure 5) 
CH20H 
I 
C =-- 0 
-- OH 
PIGURE 5- Cortisone 
the methyl groups at C18 and C19s the ketone group at C11 and the two 
carbon ketol side chain at C17 all project above the plane of the steroids 
and are designated P and in the spatial and flat structure diagrams are 
connected to the ring system by uninterrupted lines. The hvdrcxyl group 
at C17 projects below the planes and is designated a and joined to the 
ring system by a dotted line. 
Figure 5 shows that cortisone differs from cortisol only by the 
substitution of the ketone group at the 11 position for a hydrozyl group. 
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At this stage it is possible to insert on the basic structure those 
functions necessary for typical corticosteroid activity (Figure 6)p 
(0=) or 
21 C112 
I 
C-V v ýýo 
. 
17 
- OH 
16 
15 
FIGURE 
6 
they are a double bond between positions 4 and 5 in ring A, a keto group 
(0. ) at positions 3 and 20, and either a hydroxyl group (HO-) or a keto 
group (0-) in the P configuration at position 11 and the same groups in 
the a configuration at l7v or an isopropyl-idenedioxy group (CH, )2*C(O-)2 
linking the 16 and 17 Positions. 
Cortisoneg the first corticosteroid used for its anti-infl tory 
effects, possesses equally potent mineralocorticoid and glucocorticoid 
properties. The earliest chemical. effort was directed towards producing 
corticosteroids which retained anti-inflarowtory activity but in which 
the sodium and water retaining properties were significantly reduced. 
The first great advance in corticosteroid therapy was the 
discovery of prednisone and prednisolone (Heftmant 1970)p the &I an logaes 
of cortisone and cortisol respectively. 
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Prednisone and prednisolonep differ from cortisone and cortisol 
only by an additional double bond between positions 1 and 2 (Figures 
and 8). 
CH20H 
0 
- OH 
FIGURE 7- Prednisone (lp2-Dehydrocortisone Deltacortisone) 
CH20H 
C- 0 
- OH 
FIGURE 8- Prednisolone (192-Debydrocortisol Deltacortisol) 
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This modification enhances the glueocorticoid activity and thus the 
anti-inflanmatory activity, by three to four times, without any corresponding 
increase in mineralocorticoid activity. 
Further effort to attempt the separation of anti-inflammatory from 
other glucocorticoid. effects has not yet been successful although cortico- 
steroids with greatly enhanced anti-infla tory potencyq as part of an 
overall increase in glucocorticoid. activity have been synthesised. 
Deka, methasone and betamethasone are examples, and they differ from 
prednisone by fluorination in the ga position, and methylation at position 
16. Differing only from each other in the configuration of the 16 
methylationg being 16a in dexamethasone and 16P in betamethasone as 
shown by their structural formulae (Figures 9 and 10). 
CH20H 
0 
- OH 
-- CH3 
FIGURE 9- Dexamethasone (ga-Fluoro-16a-Mothyl-Prednisolone) 
46 
CH20H 
I 
Cýo 
CH3 
0 
FIGURE 10 - Betamethasone (9a-Fluoro-16P-Methyl-Prednisolone) 
An analogue of cortisol was Eýmthesised earlier than prednisolone, 
and differed from cortisol only by fluorination on the ga position (FigL=e ll). 
CH20H 
I 
Cýo 
-- OH 
0 
FIGURE 11 - Fludrocortisone (ga-Fluorohydrocortisone) 
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This modification increased the anti-infla tory potency over cortisol by 
about ten timeBt but, its sodium retaining potency was 125 - 150 times 
greater than cortisol. 
Triamcinolone (Figure 12) combines the structural features of 
prednisolone and ga fluorocortisol, and, has a 16a hydroxyl group in 
addition. 
CE20H 
- OH 
-- OH 
0 
FIGURE 12 - Tria=inolone (ga-Fluoro-16a-Ilydroxylprednisolone) 
This compound has five to ten times the anti-inflammatory activity of 
cortisol with practically no mineralocorticoid activity. This cortico- 
steroid occupies as an anti-infl tory steroid a position midway between 
prednisone and dexamethasone. The relative anti-infla tory and 
sodium retaining properties of the corticosteroids mentioned are listed 
in Table 1, and equivalent milligram doses for comparative purposes are 
shown in Table 2. 
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TABIE 1 
Relative Anti-Inflammatory and Sodium Retaining 
Properties of some Corticosteroids 
Compound Origin 
Relative 
Sodium Retaining 
Potency 
Relative 
Anti-Inflanmatory 
Potency 
Cortisone Adrenal Cortex 0.8 0.8 
Hydrocortisone 
(Cortisol) Adrenal Cortex 1.0 1.0 
Prednisone Synthetic 1.0 5-0 
Prednisolone Synthetic 1.0 5-0 
Triamcinolone Synthetic 1.0 6. o 
Dexam sone Synthetic 0 25-0 
Betametbasone Synthetic 0 25-0 
ga Fluorocortisol I Synthetic 125-0 10.0 
TABLE 2 
Comparative Equivalent Milligram Doses of Various 
Corticosteroids when used as Anti-Inflanmatory Agents 
Cortisone 25-0 
Iýydrooortisone 20.0 
Prednisone 5-0 
Prednisolone, 5-0 
Triaminolone 4-0 
Dex=ethas=e 0-75 
Betamethasone, 0-75 
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Some successful chemical effort has occurred in the synthesising 
of steroids with enhanced topical anti-inflammatory activity. These 
compounds have the essential features for anti-inflamnatory activity 
I 
already outlined on page 41, but in additions corticosteroids possessing 
the greatest topical activity have resulted from esterification, of the 
17 positions esterification of the 17 and 21 positions and the formtion 
of 16,17-acetonide derivatives. 
Rraurples of the structures of some typical compounds follow 
(Figures 13v 14 and 15)- 
9112011 
Cýo 
0 
0 
c - 
11 
(CH2 ) 
3- CH3 
CH3 
FIGURE 13 - Betamethasone Valerate (gcc-Fluoro-16P-Methyl-Prednisolone-17- 
Valerate 
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CHi-- 0-C- CH. -CH. 3 1 11 
Cýo 0 
C --CH, 2-CH, 
FIGURE 14 - Beclomethasone Dipropionate (ga-Chloro-16P-Methyl-Iliednisolone- 
17921-Dipropionate 
This steroid is the on3y topically active anti-infla tory steroid 
possessing a chlorine atom in the ga configuration, the. others being ga 
fluorine compounds. 
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Cý30H 
0 CH3 
0 C113 
0 
KGURE 15 - Triamoinolone Acetonide (got-Fluoro-16a-uyclroxy-Prednisolone- 
16,17-Acetonide) 
Having enhanced topical activityr these compounds have been in 
widespread dermatological use for some yearst under the proprietory names 
Betnovater Propadermg and Adcortyl respectively. Here some separation 
of anti-infla tory from other glucocorticoid effects when Propaderm 
(beclomethasone dipropionate) is applied to the skin in therapeutic 
concentrations has been observed. Raffle and Prain-Bell (1967) failed 
to establish any evidence of adrenal suppression in patients following 
the topical application of beclomethasone dipropionate. The steroid 
being present as a microfine suspension in white soft paraffin. in 
1968 it was found (Caldwelll Hall-Smith, Main, Ashurst, Kirtong Simpson 
.. and 
Williams) that the addition of 5% propylene glycol significantly 
-impraved the anti-inflammato: L7 effect. Raffle and Prain-Bell (1968) then 
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repeated their experiments with the new basep and again failed to 
demonstrate any effect on adrenal function in patients being treated 
by the topical application of this steroid. In both studies, and in 
the commercially available ointment and creamt the concentration of the 
steroid was the same (0.02%). 
Beelomethasone-17,, 21-dipropionate having marked topical potency, 
with apparently no effect at therapeutic concentrations on adrenal function, 
seemed worth investigating an another body surface, the bronchial mucous 
membrane. 
The following three Chapters describe experiments to establish its 
topical potency when applied to the sking its metabolic fate following 
oral administrationg and its effects by inhalationg by mouth and intra- 
venouBly on the Wpothalamo-Pituitary-Adrenal axiB (H. P. A. ). 
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CHAPTER III 
The Assessment of TopiCal Potency of Corticosteroids in Man 
Introduction 
The glucocorticoid potency of corticosteroids is usually measured 
in animals by increased glycogen deposition in the liver and by a re- 
duction in the weight of the thymas. In man, their effect on the 
H. P. A. axis is probably the most sensitive index of glucocorticoids, 
and, therefore, of anti-infla to: L7 potency. 
The appearance of corticosteroids with enhanced topical anti- 
inflammatory effects led to attempts to devise methods of testing topical 
anti-inflanmatory activity in human subjects. Several workers measured 
the inhibitory effects of topically applied steroids on experimentally 
induced inflammation (Wells# 1957; Witkowski and Kligmanp 1959; 
Schlagel and Northam, 1959; and Br=er and Finkelsteint 1960). , At I 
about the same time Garb (1960) first used a thin plastic film to occlude 
Podophyllin Ointment, finding occluded treatment was considerablymore 
successful in treating a patient with a verrucous naevus* than open 
applications had been. Good results with occluded fluocinolone cream 
in patients with stubborn psoriasis were reported by Scholtz (1961). 
Sulzberger and Witten (1961) using triancinolone acetonide ointment under 
plastic filmag again in obstinate psoriasis, considered that the results 
they achieved by this method were equal to those obtained by intra-lesional 
Naevus ve=ucous is the name given to a pigmented mole with by-per- 
keratosis. 
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injection of the steroid. They concluded that the enhanced activity 
of the steroid applied under a plastic film could be attributed to 
accurate localisatiaa of the steroidq better contact between ointment 
and eking and to increased peroutaneous absorption as a result of 
increased skin temperatures and epidermal hydration. 
McKenzie and Stoughton in 1962 had also achieved good therapeutic 
results with ointments under occlusion. They noticed that steroid 
ointments under a plastic film produced pallor of the lesion and of the 
surrounding normal skin. This finding suggested that vasoconstriction 
might be used as an index of percutaneous absorption of the steroid. 
Although the literature contained no reports of vasoconstriction activity 
of steroids applied to healthy skin, vasoconstriction of the blood 
vessels in rabbit ear chamberst (Ashton and Cookt 1952) and following 
intra-axticular injection of steroids had been observed (Hollander, Stoner, 
Brown and De Moor, 1950)- McKenzie and Stoughton felt it reasonable to 
postulate that at least part of the anti-inflammatory activity of steroids 
could be explained in terms of vasoconstriction. Using this as an index 
of absorption they found that occlusion with a plastic film resulted in a 
. one hundred 
fold increase in absorption over simple topical application. 
McKenzie (1962) then went on to determine whether vasoconstriction could 
be used as an index of relative potency of topically applied steroids. 
He assessed the vasoconstrictor activity of twenty topical steroids, 
finding that in the case of triamoinolone the formation of the acetonide 
greatly enhanced the percutaneous absorption. Acetates were better 
absorbed than the parent alcohol whereas phosphate salts were poorly 
absorbed. In 1964 McKenzie and Atkinson, used the vasoconstrictor assay 
in healthy human subjects to screen betamethasone and twenty-three of 
its esters and ortho-esters. Taking fluocinolone acetonide as the 
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standard steroid they found that the steroids tested had vasoconstrictor 
activities ranging from 0-1% to 40W,, of the standard. Concluding, that 
although the assay was of low precision it was of value in screening 
potential topically active steroids. 
Allowing for individual variation in skin sensitivity to steroids, 
and for the fact that in psoriasis, the relative importance of steroid 
transport and activity differ from that found in normal skin, they found 
good correlation between the degree of vasoconstriction and subsequent 
therapeutic efficacy in patients with psoriasis. 
Using the vasoconstrictor assay described by McKenzie, the topical 
potency of beclomethasone dipropionate has been assessed and compared with 
two of its metabolites and seven other steroids. 
Materials and Methods 
Alcoholic solutions of three concentrations, (0.0001%9 0-015% and 
0.01%) of the following steroids were prepared. Beclomethasone-17,21- 
dipropionate, beclomethasone-17-propionate, beclomethasonep triamoinolone 
acetonide, dexamethasone, dexamethasone isonicotinatel dexamethasone di- 
sodium Phosphate, 
_prednisolonel 
prednisone and cortisol. Fourteen 
healtby human volunteer subjects'were chosen for the experiment, the 
steroids being applied to the skin of the ventral aspect of the forearms. 
The technique of applying, and occluding the steroids to be tested 
is shown in the following three photographs: - 
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: 
FIGURE 16 
S 
I 
ýI 
The sites of application are dew cated by an eight millimetre 
square cut out of a plastic circle. This is lightly greased with 
siliconised white soft paraffin, and placed on the forearm, the greasy 
side against the skin (right forearm marked A). This assists in 
localising the steroid. 
A micropipette delivering 10 pl. of an alcoholic solution of the 
steroid to be tested is emptied into the square (left forearm Tmrked B). 
The siliconised white soft paraffin assists in restricting the steroid 
to the site of application. 
57 
S 
IS "" 
S S" 
SS 
I 
.4 
". I 
. 
""S 
-SS 
FIGURE 17 
As soon as the alcohol has 
evaporated, the plastic circle is 
carefully removed and the site 
occluded with a square of polythene, 
about one inch square (right fore- 
arm mn ked A). 
II. lb 
0 
FIGURE 18 
The polythene is kept in place 
by an adhesive tape* of low 
sensitising potential. The 
sites remain occluded for 
fifteen hours. 
* micropore surgical tape 1530 
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At the end of fifteen hours the sites axe uncovered, left for one 
hour, by which time the hydrated areas of skin have dried. They are 
then exanined and scored. 
Two observers score independently of each other using a scale 
from 0-3 where: - 
0= no change observed 
1= definite but slight skin pallor 
2- obvious pallor, at least one corner of the square 
dew cated by vasoconstriction 
3= two or more corners of the square clearly dew cated 
by vasoconstriction. 
Vasooonstriction of the skin does not photograph well. A high 
contrast colour photograph, gives an idea of the sort of response 
obtained (Figure 19). Only the higher scores are apparent. A is a 
typical response scoring 3, and Ba typical 2 score. 
FIGURE 19 
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We have given considerable attention to methods of estimating the 
results; and have examined various alternative procedures. Infra-red 
photography, both in colour and in black and white, proved to be too 
penetrating and did not pick out capillary vasoconstriction (Figure 20). 
FIGURE 20 
High contrast colour photography was also disappointing when com- 
pared with the scoring method, as only the higher scores were apparent. 
The only method which compares at all favourably with the two observer 
scoring method is to place the subject in a good light in a suitable 
corridor or long room. Each observer in turn, then moves steadily 
away from the subject until the vasoconstricted areas cease to be 
apparent. The distance from the observer to the subject is noted. 
The greater the degree of vasoconstriction the greater the distance it 
may be observed from. This method, however, is less convenient than 
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scoring which we use routinely. The correlation between the scoring 
of the two observers has been found to be remarkably consistent. 
OL= method differs from that described by McKenzie in two respects. 
We place the steroid under test onto a small dema cated area which is 
square instead of round, and we occlude each site separately rather than 
using a common covering over all the sites. 
Results and Discussion 
The full scoring results for each of the three concentrations used 
axe given. Tables 1-3 in the Appendixg pages 188 to 190. 
By plotting the percentage of the total possible score against the 
concentrations of the steroids used, dose response curves can be drawn: - 
score (as a %of 
the possible total) 
so 
E TRIAMCINOLONE 
ACETONIDE 
F BECLOMETHASONE 
17-PROPIONATE 
D BECLOMETHASONE 
17- 21-Dipropionate 
B DEXAMETHASONE 
ISONCOTINATE 
C DEXAMETHASONE 
G DEXAMETHASONE 
DISODIUM PHOSPHATE 
J BECLOMETHASONE 
A PREDNISONE 
I CDRTISOL 
H PREDNISOLONE 
0.00011.9-015% 0-17. 
(Concentration of Steroid) 
FIGURE 21 - Topical Potency of Ten Steroids determined by McKenzie's 
Vasoconstriction Test 
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The steroids tested fall into three groups* The first group, showing 
=xked topical potency at a concentration of 0-015%r contains triamoinolone 
acetonidet beclomethasone-17,21-dipropionate and beclomethasone-17- 
propionate, in that order of potency. These three steroids remain as 
the most topically potent when the concentration is increased further to 
0.1%op although the order is re-arranged. At both these concentrations, 
there is no significant difference between their topical potencies. The 
second group at a concentration of 0-015% contains the two eaters of 
dexamethasoneq and the third graup the remainder. There is a significant 
difference in potency between the first three steroids, and all the others 
(P > 0-05)- But no significant difference between the second and third 
groups. Beclomethasone has no topical potency in terms of this testj 
but its esters, the 17-ProPionate and the 17., 21-dipropionate each have 
marked topical potency, equal to that of triamcinolone acetonide. Thns 
esterification of the 17 and 21 positions or the formation of an acetonide 
does impart significant topical potency to these steroids. The first 
major difference in man between beclomethasone-17,21-dipropionate and 
the other steroids which have been administered by inhalation in 
bronchial asthma is that it has significant topical anti-infla tory 
potency. 
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CHAPTER IV 
The Absor ption, Metabolism and Excretion of Beclomethasone Dipropionate 
in Man, following Oral and Intravenous Administration 
Introduction 
Several reports describing the use of inhaled beclomethasone 
dipropionate in asthma suggested that failure of absorption or poor 
absorption of the drug might explain its apparent lack of systemic effects 
(Smith, Booth and Daveyt 1971; Morrow Brownt Storey and Georget 1972; 
Chatterjee, 1972; Pinesp 1973; and Hertheimer, 1973)- 
When amy medicinal aerosol is inhaled only a small portion of inhaled 
drug reaches the lungav the greater part being deposited in the mouth and 
oro-pharynx from where it is swallowed and may be absorbed during the passage 
through the gastro-intestinal tract (Dollery, Davies and Conollyr 1971)-, It 
was important, thereforejo to establish the fate of orally administered 
beclomethasone dipropionate in wn to see whether the selective effect. of 
this steroid depends on poor absorption or metabolic inactivation. As no 
chemical method for assaying this corticosteroid is available a radio 
chemical analysis had to be carried out. Beelomethasone-17,21-dipropionate 
was radio labelled with tritium on the 16 and 16a positions (Figure 22) 
having a specific activity of 50 1'Ci/Pg- 
5 
FIGURE 22 
CH20COC2Hr, 
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Patients and Methods 
This study was carried out in the Brompton Hospital, London, under 
the supervision of De. T. J. H. Clark. Six male patients, aged between 
twenty-three and sixty-one years (mean forty-seven) who were in hospital 
recovering from an exacerbation of their asthma were given radio labelled 
beclomethasone dipropionate with their full informed consent. The labelled 
beclomethasone dipropionate was adsorbed from chloroform solution onto 
lactose and given in a gelatin capsule to four subjects; i micronised 
aqueous suspension with a paxticle size identical to that of the aerosol 
used in the treatment of asthma was given to two other subjects. All six 
subjects, therefore, ingested 4 mg- (200 pCi) of beclomethasone 
dipropionate. 10 ml. venoue blood samples were collected from the patients 
at intervals from five minutes to twenty-four hours in the patients taking 
the capsules, and, at intervals up to forty-eight hours in those who took 
-the suspension. Urine was collected for three days in twelve hour samples 
and faeces for four days, merthiolate being added to the Urine containers 
and methanol to the faecal containers to prevent microbial activity before 
the samples were frozen (-15'C)- 
The determination of the concentrations of radio activity in the 
plasma, urine-and faecal samples, and also the chromatographic techniques 
used-for the isolation of beclomethasone dipropionate and its metabolites 
from the. urine and faeces were all carried out in the Biochemical 
Department of Allen and Hanbu: L7s Research Limited at Ware in Hertfordshire 
under the supervision of Dr. L. E. Martin. These methods have been 
fully described (Martins Tanner, Clark and Cochranes 1974) and they also 
appear in the Appendix 1, page E3 144 t0 15 4 An account of the in vitro 
metabolism of the drug 17 human faeces and lung slices is also given because 
this information is needed to interpret the results of this in-vivo study. 
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Results 
In Vitro Studies 
Incubation of Radio Idbelled Beclomethasone-17,21-Dipropionate with 
Human Lung Slices 
The results obtained from radioohromatograms of the alcohol extracts 
from the incubation of radio labelled beelomethasone-17921-dipropionate with 
chopped hiiman lung are given in Appendix Table 4 (Page 191)- The lung 
slices hydrolysed radio labelled beelomethasone-17921-dipropionatep the 
radio active metabolites having Rf values corresponding to radio labelled 
beclomethasone-17-Propionate, the major metabolite, and to radio labelled 
beclomethasone. No hydrolysis of radio labelled beclomethasone-17,21- 
dipropionate occurred in the control tubes. Conjugated polar metabolites 
were not found in the extractse 
Incubatian of Radio Iabelled Beclomethasone-17t2l-Dipropionate with Human 
Faeces 
Analysis of the radiochromatogTams of the extracts of the freeze-dried 
incubation mixture of radio labelled beclomethasone-17921-dipropionate with 
human faeces showed that radio labelled beclomethasone-17,21-dipropionate 
was hydrolysed. After six hours incubation 1.4% of the radio activity 
in the supernatent fraction and 10. Wo in the faecal, pellet were present as 
Unchanged drugp compared with 93-V in the control tube. The major metabolite, 
with an R. value correspondi33g to radio labelled beclomethasone-17-ProPionate, 
accounted for 89-5% of Erupernatent and 79-0 of the pellet radio activity. 
The metabolite with an Rf value corresponding to radio labelled 
beclomethasone accounted for 8.25% of the supernatent and 9-eo of the pellet 
radio activity. 
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In-Vivo Studies 
Plasma Radio ActivitZ Concentration after 4 mg. of Radio labelled 
Beelomethasone-17,21-Dipropionate 
The results (Appendix Table 5, page 192) show that the plasma levels 
of radio activity were higher and more sustained in the subjects who took 
t he suspension. The peak levels occurred at-about five hours in each 
group - 
Urinary and Paecal Excretion 
About lWo - 15% of the administered radio activity was excreted in 
the urine from both groups of subjects. Faecal recovery of radio activity 
varied from 3Wo to 6Vo, the position being complicated by the need to give 
laxatives to some individuals. - Detailed results are given in Appendix 
Table 6 (Page 193) 
Chromatographic Analysis of the Twelve Hour Urine Sample from Subject NK 
This urine sample contained 6.1% of the radio active dose. The 
methanolic fraction from the Amberlite XAD-2 column U-1. which contained 
4% of the dose when examined by thin layer chromatography did not contain 
radio labelled beelomethasone-17v2l-dipropionate or radio labelled 
beolomethasone-17-propionate. eo of the radio active dose administered 
was present as free metabolites U. 2., and eo. as conjugates, U-3- The results 
are illustrated overleaf. Thin layer chromatography of the free metabolite 
residue U. 2. showed that 55% of the applied radio activity was present as 
an unidentified peak with an Rf value of 0-40, 
Enzymatic hydrolysis of the conjugate fraction U-3- yielded fraction 
U-4. which after partition yielded 1.3ýo of the radio active dose as 
bydrolysable conjugates U-5., and O. Vo as unbydrolysable conjugates U. 6. 
The unhydrolysed metabolites U. 6'., when examined by thin layer chromatographic 
ana3, vsis, had a similar chromatographic pattern to that of the conjugate 
I. fraction U-3- The radio activity was present as overlapping peaks with lower 
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Rf values than the internal standards. Several radio labelled compounds 
were preBent on the thin layer radiochromatograms of the enzyme hydrolysable 
conjugates U-5-; they were not further investigated- 
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KGURE 23 - Thin layer radiochromatograms of the urine extracts from a 
capsule dosed subject (MK 0- 12 hours). (U 1. ) Methanol 
eluate from an, Amberlie XAD72 column. (U-2. 
ý 
Chloroform 
phase from partition of the eluate, free steroids. (U-3-) 
Aqueous phase from partition of the eluatep conjugated 
metabolites. (U-4-) Enzyme bydrolysate of conjugated 
metabolites eluted-with methanol from an Amberlite XAD-2 
column. (U-5-) Chloroform phase from partition of the 
hydrolysate,, hydrolysed conjugates. The positions of the 
three unlabelled reference compounds are also indicated. 
Ana4sis of the'Faeces 
9Wo to 1OWo of the radio activity in the faecal, samples was extracted 
into chloroform-methanol. The results of thin layer chromatographio 
BC 1F1 8P2 La 
Ui wo 
BC VI 5F2 
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analysis of the original chlorof orm-methanol extracts are given in 
AAimendix Table 7 (Page 194)- The suspension treated subjects excreted 
. rý 
less free steroids'and more polar conjugates than those who took capsules. 
Radiochromatograms of the faecal extracts and their partitioned 
fractionss for subjects KN (suspension) and GW (capsule), are compared 
in Figure below. 
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PIGUhE 24- Thin layer radiochromatograms of faecal extracts from a 
capsule dosed subject (GW 12 - 24 hours) and a suspension 
dosed subject (KN 84 - 96 hours). (A) Chloroform- 
methanol extract of faeces. (B) Aqueous phase from 
partition of the extracts, conjugated metabolites. (C) 
Chloroform phase from partition of the extractsq free 
steroids. The positions of the three unlabelled reference 
compounds are also indicated. 
The results obtained by high performance radiochromatographý of the 
faecal free steroid residue A from these subjects and by radio assay of the 
jC WiP2 BC BPI BP2 
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eluate agreed with the thin layer chromatography as shown for subject GW 
Figure 25 below. 
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FIGURE 25 EUgh performance radiochromatogram of the chloroform phase, 
free steroids, from the partition of the faecal extract from 
a capsule'dosed subject (GW 12 - 24 hours). The three 
absorbance peaks correspond to 5 Pg- of the unlabelled 
compaLmde. 
From the data in Appendix Tables 6 and 7 (pages 193 and 194) the 
percentage of the dose of radio activity which was excreted as 
beelometbasone-17,21-dipropionate, beclomethasone-17-propionate, 
beclomethasone and polar metabolites. was calculated for each sample. 
Discussion 
When an oral dose of radio labelled beelomethasone-17t2l-dipropionate 
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was given to six subjects the main route of excretion of the radio activity 
was the faeces. Radiochromatographic analysis of the faeces showed that 
beelomethasone-17#21-dipropionateg beclomethasone-17-ProPionate, 
beclomethasone and unidentified polar metabolites were present. 
- Beolomethas=e-17-ProPionate and beolomethasone could have been produced by. 
,. enzymic hydrolysis during the drug's passage through the gastro-intestinal 
tract. 
Polar metabolites of beclomethasone-17,21-dipropionate have not been 
observed to be formed by gat and faecal bacterial enzymes, but they do occur 
,, in the bile and faeces of rats and dogs given-the steroid intravenously. 
Therefore, the polar metabolites found in the human faeces probably arise 
from the biliary excretion of metabolites, of absorbed drug. 
Metabolites of the drug accounted for the small amount of radio 
activity excreted in the urine, these could have been formed in the liver 
and kidney. 
The plasma levels of radio activity were noticeably higher and more 
prolonged izi the subjeots who took the microfine suspension of beclomethasone- 
l7p2l-dipropionate than in those treated, with capsules of the drug. 
The administered dose of, radio activity was not completely cleared from 
the body during the period of hospitalisationt-but if it is assumed that 
the beelomethasone-17,21-dipropionatej beelomethasone-17-ProPionate and 
beclomethasone in the faeces was derived from unabsorbed drug then about 
9Wo of the given drug as a suspension was absorbed, and only 61%o to 7wo 
of that in the capsules. probable reason for this difference in 
absorption between the two formulations is thatIthe average particle size 
of the steroid was smaller in the suspension than the capsule, but the 
delayed release of, the drug from the capsule itself might have been an 
additional factor. 
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In view of these results it is clear that the selective effect of 
inhaled beelomethas=e-17921-dipropionate in asthma does not depend on poor 
absorption of the swallowed portion. of the drug. It could, however, depend 
upon the inactivation of beelomethasone-l7p2l-dipropionate in the liver. 
Since beclomethasone-17921-dipropionate was hydrolysed to 
beclomethasone-17-Propionatet and more slowly to beclomethasone, but not 
further metabolised by isolated human lung tissuep it seems probable that 
the therapeutic effect of inhaled beelomethasone-17921-dipropionate in 
asthma is derived from these substances. Beolomethasone-17,21- 
dipropionate and beelomethasone-17-ProPionate are probably more important 
than beclomethasone because they are present in greater quantity and each 
has a much greater anti-inflammntory effect on human skin. 
Clearance of Intravenous Beclomethasone Dipropionate 
Materials and Methods 
Beclomethasone dipropionate labelled with tritium on the 16 and 
16a positions was dissolved in 2 ml. of an aqueous Cremophor EL solution 
(Bee footnotev page 93)- 1 mg. of beclomethasone dipropionate (specific 
activity 100 4Ci) was injected intravenously over four minutes in one 
subject. Samples of venous blood were taken imm diately after the 
injection was completed, and at one minute, five minutes and thirty 
minutes afterwards; thereafter hourly for seven further hours, with a 
final sample twenty-four hours after the injection. 
The heparinised blood was centrifugedg the plasm separated and stored 
in the deep freeze. Urine and faeces were collected for seventy-two and 
ninety-six hours respectively according to the methods already described 
(page 63 )- 
The methods for determining the concentrations of radio activity'in 
the plasma, urine and faecal sampleal and the chromatographic techniques 
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used for the isolation of beclomethasone dipropionate and its metabolites 
are described in the Appendix (pages 148,152 and 153). The method of 
identifying the radio active material present in the plasma is also 
described in the Appendix (Page 154)- 
Results 
There was a rapid removal of radio activity from the plasma following 
the intravenous dose of 1 mg. of radio labelled beclomethasone dipropionate 
and then a slow clearance of the residual radio activity (Appendix Figure 1., 
page 160). The half life of the second phase was fifteen hours. Thin 
layer chromatographic examination of the ethanolic plasma extracts showed 
that for the first three hours the circulating radio activity was attributable 
to unchanged beclomethasone dipropionate (Appendix Figure 29 page 160). 
The concentration of radio activity in the subsequent plasma samples was 
too low to am lyse quantitatively. 
loo of the injected radio activity was slowly excreted in the urine 
during the seventy-two hours following the intravenous injection. (Appendix 
Figure 3, page 161). Thin layer chromatographic analysis of the urine 
samples (Appendix Figure 4, page 161) showed that all the excreted radio 
activity was attributable to free and conjugated polar metabolites of the 
steroid. Ihecal excretion was also slow. Only 64% of the dose of radio 
activity administered had been excreted during the ninety-six hours 
following the injection, (Appendix Figure 59 page 162). Thin layer 
chromatographic analysis of the chloroform methanol extract of the faeces 
showed that the excreted radio activity wan almost entirely due to free 
and conjugated polar metabolites (Appendix Figure 6, page 162). 
Discussion 
These studies show that the circulating radio activity for the first 
three hours following an Intravenous injection of beclomethasone dipropionate 
to man is attributable to beclomethasone dipropionate. After this time 
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polar metabolites are also present in the plasma. Thus the potent 
glucocorticoid effect on circulating plasma cortisol seen following 
intravenous beclomethasone dipropionate (Chapter Vs page 94) is due to 
beclomethasone dipropionate and not to any other steroid or active 
metabolite. About loo of the intravenous dose of radio activity was 
excreted in the urine, and this radio activity was due entirely to polart 
free and conjugated metabolites of the steroid. The main route of excretion 
was the faeces, this was slow, only 64% being excreted during the time the 
faeces were collected (ninety-six hours). Polar unidentified metabolites 
excreted via the bile accounting for the radio activity in the faeceso The 
pattern of excretion of beclomethasone dipropionate in the urine and faeces 
following intravenous administration of the drug is similar to that 
following its oral administration. 
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CHAPTER V 
The Effects of Various Doses and Rautes of Administration 
of Beclomethasone Dipropionate compared with Dexamethasone 
on ITypothalamic-Pituitary-Adrenal Function 
Introduction 
This Chapter describes several experiments, designed to find the 
effect of dose and route of administration of beclomethasone-17921- 
dipropionate, and two of its metabolitesp beclomethasone-17-proPionate and 
beclomethasoneq upon the Fqpothalamic-Pituitary-Adrenal (H. P. A. ) axis. In 
many of these studies beclomethasone dipropionate has been compared with 
dexamethasone or esters of dexam sone, so that some idea of the intrinsic 
systemic activity of beelomethasone-171,21-dipropionate can be established. 
lastly, the absolute systemic potency of beclomethasone dipropionate com- 
pared with dey-nmethasone was determined by measuring the effects of these 
two steroids on the H. P. A. axis after intravenous administration. 
Subjects and methods - General 
Twelve healthy male adult volunteersl aged between twenty-six years 
and thirty-nine years, agreed to form a panel of subjects, from which varying 
numbers were chosen to take part in the experiments which are described. 
Each subject was shown to have a no=nl suppression of H. P. A. function 
in a dexamethasone suppression testg that is 2 mge of dexamethasone (0-5 mg- 
six hourly) for two successive days (Liddle, 1960). 
All the inhaled doses of beelomethasone-17,21-dipropionate were 
givenby an Armstrong automatic breath actuated inhaler, and each subject 
was trained to be expert in its use. This was done to minimise dose 
variation due to the operation of pm aerosol and to ensure the beat chance 
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of the drug being carried on the airstream into the lungs. A photograph 
of this device and how it is used is fully described in the Appendix 
(pages 163 and 164)- 
Daily doses were given in equal amounts every six hoursp starting at 
midnight. Inhaled dexam sone-isonicotinate could not be given by the 
Armstrong deviceg because the aerosol can size and dimensions of the valve 
stem would not permit it. This compound was, therefore, given from the 
commercially available inh ler. 
Plasm corticosteroids were determined fluorimetrically (Spencer-Peet, 
Daly and Smith, 1965)- Plasma cortisol was determined by a modification 
of the competitive protein binding method described by Murphy (1967)# using 
(1923H) cortisol, specific activity 2 Ci/mol (Radiochemical Centre, 
Ame37sham), and human third trimester pregnancy serurn as a source of cortisOl 
binding globulin; dextran-coated charcoal was used to adsorb the unbound 
cortisol. Urinary 17-oxogenio steroids were determined by a modification 
of the method of GrV and his colleagues (1969) in whichp to ensure complete 
reducticing the sodium borobydride reduction was carried out at PH 8- 8-5 
instead Of PH 7- 
The majority of these assays were carried out in the Department of 
Biochemistryt Allen and Hanburys Research Limited, Ware# Hertfordshire, under 
the direction of Dr. L. E. Martin, a few, howeverg were done in 
Professor Gray's Department of Chemical Pathologyj King's College Hospital 
Medical Schoolp Londong S, E-5-t under the direction of Dr. Mollie Booth. 
The studies fall readily into two groups, depending on whether the 
effects of beelomethasone-17921-dipropionate on the H. P. A. axis were 
assessed by measuring the urinary 17-oxogenic steroid excretion rate, or 
the early morning plasma corticosteroid or cortisol levels. 
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Methods 
Studies where the effects on the H. P. A. axis were assessed by measuring 
the urinary 17-oxogenio steroid excretion rate 
All twelve subjects took part in this first group of experimentst 
and it was during these experiments that they each had the dexamethasone 
suppression test I have already mentioned. They each collected twenty- 
four hour urine samples for fourteen consecutive days, and six of them 
extended their collection of twenty-four hour urine samples for a further 
seven daysq enabling them to take additional inhaled doses of beclomethasone- 
17921-dipropionate. The effects of the following steroids were examined. 
1. Inhaled beclomethasone-17,21-dipropionate 
Doses from 200 pg. - 29000 pg. in increments of 200 pg. 
2. Oml dexamethasone 
mg. daily (0-ý mg- six hourly) for two days. 
3- Oral beclbmethasone-17,21-dipropionate 
1 mg., 2 mg-, 3 mg-, and 4 mg. daily. 
Oral beclomethasone-17-propionate and beclomethasone 
(two metabolites of beclomethasone-l7t2l-dipropionate) 
4 mg. daily. 
Inhaled dexazo tb sone-isonicotinate (Auxilosone - Thomae) 
At the lowest recommended therapeutic dose of lj250 Pg- 
daily. 
Oral dexamethasone or the test steroid were given on either the third 
and fourth days or the tenth and eleventh daysl the other days being controls. 
The doses mentioned were given in equal amounts at six hourly intervals for 
two days. The dosing schedule for each subject is given in the Appendix 
Mables (pages 195 to 213)- 
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Results 
Effects of dexamethasone and beclomethasone dipropionate on urinary_exeretion 
of 17-oxogenic steroids 
Detailed individual results are given in Appendix Tables 8- 26 
(Pages 195 to 213)9 Figures 261,27p 28 and 29 show the details and were 
drawn to highlight the effects of various treatments, Figure 26 shows 
that orally administered dexamethasane, 2 mg. /day for two days, caused 
clinically significant suppression of H. P. A. function in all twelve subjects 
tested. 
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FIGURE 26 - Urinary 17-Oxogenic Steroid Values (Twelve Norml Subjects) 
: following Oral D8xamthasone (2 mg. a day tor two days) 
Beclomethasone dil=opionate given for two days by inhalation in 
doses up to 2 mg. or by mouth in doses up to 4 mg. did not greatly affeot 
the 17-oxogenic steroid content of the urine although there was a tendency 
for lower values after higher doses of the drug (Figures 27 and 28 overleaf). 
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Ingestion of beclomethasone dipropionate does not greatly affect 
urinary 17-oxogenic steroid values because only a minor proportion of the 
drug appears as polar metabolites in the urine. If all the urinary 
metabolites derived from a4 mg. dose of beclomethasone dipropionate were 
assayed as 17-oxogenic steroid, the mqxi=3m addition to the twenty-four 
hour urine value would be 0-7 mg- (Harrisp Martin, Harrison and Jackv 1973)- 
The results outlined in Pigure 2? axe of interest when taken in 
conjunction with Figure 21 (Chapter IIIj, page 60 ). From Figure 21 the 
effects of eaterification at the 17 and 21 positions are seen to impaxt 
significant topical potency to the parent alcoholy beclomethasone, which 
does not itself possess topical potency. 
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Figure 29 shows an increase in effect an the H. P. A. axis as hydrolysis 
of the eater groups occur. The loss of the propionate eater group from the 
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21 position, to form beclomethasone-17-propionate, reveals that this steroid 
has a slightly greater effect on the H. P. A. axis than the 17,21-dipropionate, 
although neither cause a clinically significant suppression. Further 
hydrolysis removes the remaining ester group at the 17 position to form the 
alcohol, beclomethasone. This steroid at a dose of 4 mg. by mouth does 
cause adrenal suppression, similar to that produced by 2 mg. of dexa sone 
by mouth. Thus esterification of beclomethasone with propionic acid to 
form beclomethasone-17921-dipropionate in addition to creating a steroid 
with marked topical potencyp would also appear to involve some loss of 
systemic adrenal suppressing effect in this steroid. These first studies 
show that when beelomethasone-17921-dipropionate is given by mouth or by 
inhalation it is a weaker systemic corticosteroid than dexamethasone in 
Man. 
The second series of experiments more closely resemble the clinical 
situationg as they involve giving the steroids to be examined at fixed or 
steadily increasing doses over several weeks. In these experiments the 
effects on the H. P. A. axis are assessed by measuring the early morning 
Plasma cOrtisol or corticosteroid valueso 
Methods 
Studies where the effects on the H. P. A. axis were assessed by measuring 
early morning plasma cortisol or corticosteroid values 
The subjects were drawn from the original panel of twelve. Againg 
the inhaled doses of beelomethasone-17921-dipropionate were given by the 
Armstrong automatic devicel and all doses by any route were given in equally 
divided amounts over the twenty-four hours, beginning at midnight. Blood 
for plasma cortisol determinations was taken at 9.00 a. m. on every Monday, 
Wednesday and Friday during each study. The plasma cortisol values being 
available during the afternoon of the same dayog so that a subject could 
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be instructed to change or stop his dosage as soon as possible if the plasma 
cortisol values fell to levels indicating adrenal suppression. The 
following studies were carried out: - 
1. Two subjects inhaled 1 mg. beelomethascrne-17- 
propionate daily for one week. 
2. Two subjects inhaled 1 mg. beclomethasone daily for 
one week. 
Plasma corticosteroids were assayed by the fluorimetric method and 
by the competitive protein binding methods already referred tot in these 
two, and the following two studies, this was done to find out how well the 
two assay methods correlated with each other. 
3- Two subjects inhaled 1 mg. daily of beclomethasone-17P 
21-dipropionate for one month. 
Three subjects inhaled 1 mg. daily of beclomethasone-17t 
21-dipropionate for one week, and thereafter doubled their 
dose each week until a suppressing dose was determined. 
5- Four subjectog increasing oral doses of beclomethasone-179 
21-dipropionatee 
Four subjectog increasing intra-nasal doses of 
beclomethasone-179,21-dipropionate. 
Five subjects inhaled 1 mg. daily of beclomethasone-17P 
21-dipropionate for five weeks plus increasing intra- 
nasal doses of beelomethasone-17,21-dipropionate from 
the second to fifth weeks. 
8. Twelve subjects in four groups of three. Each group 
inhaling increasing doses of one of four commercially 
avail. ible steroid aerosols until a suppressing dose of 
each had been reached. 
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Three subjects inhaled increasing doses of dexamethasone- 
isonicotinate (Auxilosone - Thomae) aerosol to find the 
lowest suppressing dose. 
Intra-nasal doses were administered via a special adaptor, fitting over the 
valve stem of the aerosol can. A photograph showing this adaptor is in 
the Appendix (page 165)- 
Results 
Detailed individual results are given in the Appendix Tables 27 - 
38 (pages 214 to 225) and are expressed graphically in Figures 30 to 35- 
Figure 30 reveals no important effects on the H. P. A. axis in four subjects 
who inhaled two of the metabolites of beelomethasone-17,21-dipropionateI that 
is beclomethasane-17-Propionate and beclomethasone. 
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FIGURE 30 - Plasma Corticosteroid and Cortisol Concentrations in Four 
Normal Subjects after Inhaling Beclomethasone-17-Propionate 
or Beclomethasone (1 mg. per day for seven days of either 
drug) 
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The two assay methods gave comparable resultst although one samplev 
from subject M. T. 9 was spilt in the laboratory leaving insufficient ser= 
to carry out both assay methods in his case. 
The 9.00 a. m. plasma 11-hydroxy-corticosteroid and cortisol values 
found in two volmýteers before and during a twenty-eight day course of 
beclomethasone dipropionate, 1 mg. per day by inhalationj are given in 
Figure 31 below. 
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FIGURE 31 - 9.00'a. m. Plasma Cortisol Values in Two Healthy Subjects who 
each Inhaled 1 mg. of Beclomethasone Dipropionate Daily for 
One Month 
It is obvious that no major changes occurred during treatment- In 
the same wayl no change in 9.00 a. m. plasma cortisol level was found in 
three other volunteers after the same treatment for a week (Figure 32 
overleaf). Howevers one of these subjects showed a marked reduction in 
9.00 a9m* plasma cortisol level after a further week's treatment with 
beclomethasone dipropionate, 2 mg. per day by inhalation, and two of the 
three showed suppression after 4 mg- per day of the drug. 
"MCETWPUOTUA$S. 
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FIGURE 32 - 9.00 a. m. Plasma Cortisol Concentrations in Three Healthy Male 
Subjects following Inhalation of Beclomethasone Dipropionate 
In these first four studies the two assay methods gave similar values. 
Therefore, in the remaining studies plasma cortisol only was assayed. 
In four subjects following steadily increasing doses of beclomethasone- 
17,21-dipropionate by mouth, the plasma cortisol values fell in all subjects 
when the dose reached 4 mg- per day (Pigure 33 overleaf), reducing the dose 
to 3 mg- in one subject (D. M. ) permit sa slow rise in his plasma cortisol 
values; increasing the dose in the other three subjects to 8 mg. daily does 
not alter the degree of suppressiont neither is a dose dependent effect 
obvious. In no subject did plasma cortisol values fall sufficiently to 
become unmeasurable. 
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FIGURE 33 - 9.00 a. m. Plasma Cortisol Concentrations in 
Four Healthy Male 
Subjects following 0=1 Administration of Beclomethasone 
Dipropionate 
Those subjects who inhaled increasing doses intra-nasally showed 
little evidence of effect on the H. P. A. axis until doses of 8 mg. daily 
were reached (Figure 34 overleaf). The higher dose, by this route of 
administration, necessary to cause adrenal suppression might possibly 
be explained in terms of the efficient function of the nose in expelling 
particulate mattert in this case particles of beclomethasone-17,21- 
dipropionate. The simultaneous administration of this steroid into the 
lungs and nose was, carried out in five subjects and led to a reduction of 
plasm cortisol values, when the combined dose reached 3 mg- (i. e. 1 mg. 
daily by inhalation and 2 mg. daily intra-nasally) (Figure 35 crverleaf). 
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KGURE 35 - 9.00 a. m. Plasma Cortisol Concentrations in Five Healthy Male 
Subjects following the Inhalation of 1 mg. Beclomethasone 
Dipropionate Daily together with the Simultaneous Intra-Nasal 
Admi33istration of Increasing Doses of Beclomethasone Dipropionate 
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From Figure 35 it can be seen that further increasing the combined 
dose to 4 mg. and 5 mg. daily, resembled the result obtained after 
increasing the oral dose alone to 4 mg-, there was no further reduction in 
the plasma cortisol valuest neither was a dose dependent effect seen; 
similarly, there was no evidence of complete adrenal suppression (Harris, 
Martin, Harrison and Jack, 1974)- 
There are now (1974) two steroid aerosols oommercially available in 
Great Britain, beclomethasme-17,21-dipropionate as Becotide Inhaler and 
betamethasone-17-valerate as Bextasol Inhaler. In the United States of 
America, dexamethasone-sodium-phosphate is available as Respihaler Decadront 
and in Germany and Francep another dexamethasone ester, the lisonicotinate, 
is available as Auxilosone. I have compared the effects of these aerosols 
on the H. P. A. axis in human subjects, again using early morning plasma 
cortisol values as the index of adrenal function. 
The full plasma cortisol values and dosing schedules are given in the 
AAD endix Tables (pages 222 to 225 and are presented graphically in Figures vp 
36 and 37 (Pages 87 and 88). In Figure 36 beclomethasone-17021-dipropionate 
is-compared with dexamethasone-isonicotinate. The starting dose of 
beclomethasone-17,21-dipropionate by inhalation in this study being 1 mg., 
increasing by 1 mg. each week until an effect on the 9.00 a. m. plasma cortisol 
values was observed. In two out of three subjects this occurred when 3 mg- 
had been inhaled for two days, and agrees with the eaxlier study (Figure 32) 
where an effect on the adrenals was noted at doses between 2 mg. and 4 mg- 
The dose of dexamethasone-isonicotinate 19250 pg. daily (equivalent to 
960 pg. dexamethasone) was chosen from the manufacturer's literature as the 
lowest recommended clinical dose. This dose, within forty-eight hours 
caused a prompt fall in plasma cortisol values in all three subjects, the 
values soon returning to normal when the drug was stopped. 
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Becotide (Allen and Hanburys Limited) Auxilosone (Thomae) 
(Beclomethasone-17,21-Dipropionate) (Dexamethasone-21-Isonicotinate) 
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9.00 a. m. Plasma Cortisol Values in Healthy Subjects 
88 
Similar results were observed in three subjects who inhaled dexamethasone- 
sodium-phosphate (Figure 37below), again at the lowest recommended clinical 
dose, in this case 900 pg. daily (equivalent to 756 pg. dexamethasone). 
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Betamethasone-17-valerate, which is an analogue of beclomethasone-17, 
21-dipropionate, was also given by inhalation at a dose of 1 mg. The effect 
of this steroid ester on the 9.00 a. m. plasma cortisol values is identical with 
that of beelomethasone-17,21-dipropionate (Figure 37)v the plasma cortisol 
values fallingg and, thereforeq indicating an effect on the adrenals when a 
dose of 3 mg. a day was reached in two out of three subjects. 
An obvious effect on the plasma cortisol values was seen with both 
dexamethasone aerosols when the lowest recommended therapeutic dose was 
inhaled. Figure 38 below shows the smallest close of inhaled dexamethasone- 
isonicotinate which causes a fall in plasma cortisol, levels. 
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The full plasma cortisol values and the dosing schedules in the 
three subjects tested are recorded in the Appendix Table (page 226 ). An 
obvious effect on plasma cortisol excretion was noted (Figure 38) in two 
of the tl=ee subjects at a daily dose of 750 Pg- (equivalent to 568 pg. 
dexamethasone). 
From the studies described so far the doses of beclomethasone-173,21- 
dipropionate by various routes likely to cause adrenal suppression may be 
listed (Table 
TABLE 
Steroid Route Dose at which an effect on H. P. A. axis is obvious 
Beclomethasone-17P Inhalation 3.0 mg. 21-dipropionate 
Beclomethasone-179 Oral 4 0 mg 21-dipropionate . . 
Beclomethasone-17, 
21-dipropionate Intra-nasal 8.0 mg. 
Beclomethasone-17, Combined inhalation 4-0 mg- to 5-0 mg- 21-dipropionate and intra-nasal 
Betamethasone-17- 
valprate Inhalation 3-0 mgO 
Dexamethasone- Inhalation 0-750 mg-* 21-isonicotinate 
* Dquivalent to 0-568 mg. dexamethasone 
These studies also show that beclomethasone dipropionate has weaker 
systemic activity than dexamethasone in man when both steroids are administered 
by inhalation or by mouth. Dexamethasone, was between five and six times 
more potent by this route in its effects on the HoP. Ao axis than 
beclomethasone dipropionate. 
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The Effects of Intravenous Beclomethasone Dipropionate on the H. P. A. Axis 
These experiments were carried out to determine the absolute systemic 
potency of beclomethasone dipropionate compared with dexamethasone. The 
drugs being given intravenously to bypass inactivating mechanisms in the 
liver. 
The initial experiments were carried out on nyself 9 and consisted of 
two series of control measurements of plasma cortisol values and the effect of 
1 mg. of dexamethasone on plasma cortisol levels. The measurements were 
made at regular intervals (half hourly or hourly) from 9.00 a. m. for periods 
between six and seven hours. The detailed results are given in Table 
TABLE 4 
Plasma Cortisol Levels following 1 mg. Dexamethasone Intravenously 
compared with Two Series of Control Meam=ements (one Norml Subject) 
Plasma Cortisol Levels (pg-AOO ml-) 
Time (Hours) Control 
Dexamethasone 1 mg. 
2 
0 - 6. o 
1/2 7.8 11.2 5.6 
1 8.0 9.6 5-3 
1 Y2 6.3 - 3-8 
2 8.1 9.7 3-3 
2 Y2 8.1 - 2.8 
3 11-3 9.8 2.6 
3 Y2 13-9 - 1.8 
4 11-4 10-3 - 
4 Y2 13-5 - - 
5 16.1 9-9 1-4 
5 X2 14-0 - - 
6 16.3 9.9 - 
7 - 11.2 0-4 
24 - 5-8 
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Following 1 mg. of intravenous dexamethasone there is a steady fall in 
plasma cortisol levels over the seven hours during which they were measured. 
This agrees with findings in other studies involving normal subjeots fpl- 
lowing intravenous dexamethasone (Jamesj 1965) and demonstrates normal 
suppressibility of ny own H. P. A. axis. Beclomethasone dipropionate is 
insoluble in water, this led to problems in the following experiments when 
the effects of this steroid given intravenously on qj plasm cortisol levels 
were examined. A microfine suspension of three doses of beclomethasone 
dipropionate (100 Pg-t 500 Pg. and 1,000 pg. ) were Injected intravenously, 
the results are tabulated below. 
TABLE 
Plasma Cortisol Values following Three Dose loevels of 
Intravenous Beclomethascrne D4ýcopionate (One Norml Subject) 
Time (Hours) 
Plasma Cortisol Levels (pg. /100 mi. ) 
Following I. V. Beclomethasone Dipropionate 
Injection 
100 pg. 500 Pg- 11000 pg. 
0 7.2 9.0 14-0 
V2 6-3 7-0 10.8 
1 8.0 9.0 8.0 
11/2 13.2 10.0 8.2 
2 15.6 9.0 8.9 
2 Y2 13.2 9.0 6. o 
3 12.1 9.0 6. o 
3 V2 9-7 6. o 5-0 
4 7-5 5-0 4-0 
41/2 7*4 4-0 4-8 
5- 8.9 4-0 4-8 
51/2 8.0 - 3-0 
6- 8.0 5-0 4-0 
6 Y2 - - 7-0 
7 6. o 
7 Y2 5-0 
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The levels following the 100 pg. dose do not differ greatly from 
ny control values. Following the 500 Pg- and 1,000 pg* doses the plasma 
cortisol levels obtained are quite unlike those occurring after dexamethasone. 
Very little change is seen following either dose until about two and a half 
to three hours after the injections, when the levels begin to fall, but not 
very dramatically. Possible explanations for this could be that the drug 
particles were being taken up by cells of the reticulo-endothelial system, 
or that beclomethasone dipropionate was being bound to plasma proteins or 
metabolised to a more active compound. The latter possibility was checked 
by ny receiving beclomethasone dipropionate 1 mg. intravenously, the drug 
being labelled with tritium on the 16 and 16a positions. (The amount of 
radio-activity was 100 Aft/mg. ) This experiment has already been described 
(Chapter IV, pages 62 to 72 ) and showed conclusively that after seven 
hours metabolism of beclomethasone dipropionate had not occurred, thus'any 
observed effect on the H. P. A. axis following intravenous beclomethasone 
dipropionate is attributable to that steroid. and not to beclomethasone-17- 
propionate, beclomethasone or any other active metabolite. 
Obviously a meaningful comparison between the soluble dexamethasone 
and beclomethasone dipropionate would only be possible if a solution of 
beclomethasone dipropionate could be prepared. This was achieved by using 
Crem. ophor EL (BASFj Ger. )*. This substance is used to solubilise the 
steroidsp alphaxalone and alphaxalone acetate, which form the steroid 
anaesthetio "Althesin't produced by Glaxo Iaboratories. No effects on the 
H. P. A. axis attributable to Cremophor EL has been noted by workers-in these 
laboratories (personal communication, 1974)- 1 then received 1 mg. of 
this solution. A prompt and dramatic fall in the plasma cortisol values 
*a brand of polyethoxylated castor oil containing forty units of ethylene 
oxide to each triglyceride unit (Martindale, 1972). 
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occurring, the levels fallimg to zerop with a return to ny norml range 
within twenty-four hours. The experiment was repeated in two more normal 
subjects, who had previously had blood taken at the same time of day and 
at the same intervals for control purposest with the same result. 100 pg. 
was then given tb all three subjectat again, an effect was observed, the 
values now falling to levels just below I! normal". These results are given 
in Table 6. 
TABLE 6 
Plasma Cortisol Values in Three Normal Subjects following 
100 pg. and 1,000 pg. of Beclomethasone Dipropionate Intravenaus2y 
Plasma Cortisol Values pg. /100 ml. 
Time (Hours) 
After I. V. Subject D. H. Subject D. R. Subject D. J. 
Injection 
C* 
100 1VOOO C* 
I 100 1,000 C* 100 
19000 
pge PZO pgo pg4p pg* Pg* 
0 11.2 7.6 8-7 6.9 8.2 11-3 10.2 6.2 8-7 
1 9.6 7-9 2-3 5.2 9-4 9*2 10*2 6.8 1-4 
2 9-7 6.8 0 9.2 6.2 5.2 10-3 4-0 2-7 
3 9-8 4-0 0 10.3 9-3 4-7 12.0 3-5 0 
4 10-3 '5.2 0 10.4 5-3 0-5 1290 5-4 0 
5 9.9 6.1 0 7-9 3-8 0 13.2 4-1 0 
6 9.9 6.9 0 7.3 8.5 0 7-7 5.2 0 
7 10.0 6.8 1-7 7-4 6-5 0 10.1 4-8 0 
24 11-3 8.2 5-7 9.3 8-3 12.0 1 - I-. I 
C* = Control 
Thust when possible inactivating mechanisms in the liver axe bypassed 
by giving beclomethasone dipropionate intravenously this steroid is found 
to be of the same order of potency as dexamethasone. These findings will 
be discussed in the concluding Chapter of this Thesis. 
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CHAPTER VI, 
The Systemic Effects of Beclomethasone-17,21-Dipropionatet cqmpared with 
Several Other Corticosteroids on Circulating White Blood Cells and Fasting 
Blood Sugax 
Introduction 
The efficacy of synthetic corticosteroids for use in man, and their 
biological properties must ultimately be assessed in man. Corticosteroids 
in therapeutics are used mainly as anti-infla tory agents. This paxticular 
activity is unimportant as part of the normal physiological effects of 
corticosteroids, although it is considered paxt of their overall gluco- 
corticoid function. Tests for glucocorticoid function in animals include 
assessment of liver glycogen deposition and inhibitory effects on the thymus 
and adrenal glands. Of these, only the effects on the adrenal gland are 
applicable to man, and these effects as far as beclomethasone-17,21- 
dipropionate is concerned have been fully investigated (Chapter Vy pages'73 
to 94)- As the structure of the naturally occurring adrenal cortical 
hormones became more extensively modified by the steroid chemists, an 
increasing disparity between the effects observed in animals and man became 
apparent (Soffer and Orr, 1958)- Considerable species differences may 
occur, possibly as a result of differing metabolic handling of the steroid 
from animal to animal. Two additional tests may be usefuldn assessing 
corticosteroids in mn. They are the effects on circulating white blood 
cells, and the hyperglycaemic effect which is a metabolic phenomenon,, and 
from which the description of corticosteroid activity - "glucocorticoid" - 
is derived. As far as the white cells are concerned, the eosinopenic 
effect is the one usually measured. Circulating eosinophils axe extremely 
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sensitive to corticosteroids. A purified pig pituitaxy adrenocortico- 
trophic hormone preparation was produced by the Armour Idboratories of 
Chicago in 1948P in sufficient quantity for use in human subjects. This 
provided Thorn (1948) and his colleagues with an opportunity to directly 
stimu2ate the human adrenal cortex. They predicted, correctlyt that 
patients with classical Addison's disease would fail to show a normal 
response. They also demonstrated that in subjects with an intact adrenal 
cortex, a prompt fall in circulating eosinophils occurred, reaching its maximum 
at about four hours, patients with Addison's disease failed to show this 
response. This response plus the effect on the urinary excretion rate of 
uric acid, which is raised following the administration of adrenocortico- 
trophio hormone only if the adrenal cortex is intactp was made use of as a 
clinical test for adrenal insufficiency (Thornq Forshamq Garnet Prunty and 
Hillst 1948)- 
Bloodl sputum and tissue eosinophilia occurs in bronchial asthma. 
I Schwartz 1973) routinely monitors the total eosinophil counts in his 
I 
asthmatic patients. By doing this he is able to predict which patients 
will be relatively steroid resistant in that they require higher than 
average* daily doses of prednisone to keep thoe symptom free. i 
He finds that in resistant patients the fall in circulating eosinophils 
in response to prednisone is approximately half that observed in those 
patients who respond readily (falls of 7Vo and 3Wo respectively). In an 
effort to understand these findings, cortisol turnover studies were carried 
out in four patients using tritium labelled cortisol and cortisol half 
life determinations carried out. The responsive group showing a mean half 
* Walsh and Grant (1966), found in sixty-five asthmatic patients that an 
average dai3, y dose of 10 mg. of prednisone was effective. 
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life of one hundred and twenty-eight minutes and the resistant group one of 
eighty-six minutes. Thus a decrease in biological potency of hydrocortisone 
is associated with its rapid clearance from the plasma in some patients, 
the sensitivity of eosinophils to circulating cortisol is also seen as a 
reduction in the degree of eosinopenia associated with lower cortisol levels 
(Schwartz, Lowell and Melby, 1968). 
Ringler (1964) and her colleagues, found that eosinopenic and 
hyperglycaemic assays of synthetic corticosteroids correlated closely with 
an anti-infla tory efficacy in patients with rheumatoid arthritis. 
Although the thymolytic and liver glycogen potencies determined in the rat 
failed . to correspond with their eosinopenio, hyperglycaemic and anti- 
inflammatory potencies measured in mm. This emphasises the need to 
examine parameters of corticosteroid function in mant as animal tests cannot 
be relied upon to predict the effects of corticosteroids in non. Similar 
findings were reported by West (1958)- 
In addition to their effects on eosinophils, corticosteroids also 
effect the neutrophil leucocytes and the lymphocytes. In man, and ami ls 
with an intact adrenal cortext a single injection of pituitary adreno- 
corticotrophin hormone (A. C. T. H. ) evokes a leucocyte response (Wintrobe, 1967)- 
Dougherty and White (1944) showed that A. C. T. H. injected into various ma-mm-lo 
produced a lymphopenia. Similar responses have been shown in man, indicating 
that a single intra-muscifla in I jection of A. C. T. H. results in an increase in 
neutrophil leucocytes and a reduction in lymphocytes in the circulating blood 
(Daughadays Williams and Daland, 1948)- 
More recently Chai and Gilbert (1973) confirmed these findings in 
children receiving alternate dav steroid therapy. The response of the 
white cells to corticosteroids being dramatic during the days on which 
prednisone was giveng the cells returning to normal on the days off. 
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This chapter describes experiments to assess the effect of 
beelomethasone-17,21-dipropionate on circulating white cells and fasting 
blood sugarl comparison with other synthetic corticosteroids are made. 
Methods ' 
An identical design of experiment was chosen to examine both effects. 
The experiment was designed following statistical advice, in order to obtain 
significant results, and at the same time to reduce the number of blood 
samples and periods of fasting to a minimum. Twelve healthy human 
subjects were chosen for each experimentq six male and six female; their 
age range for the white cell study being: - I 
Males - twenty-one to twenty-six yeaxs 
and 
Pemales - twenty-one to thirty-one years, 
and for the hyperglycaemia, study the age range was: - 
Males - twenty-one to forty-three years 
Females - nineteen to twenty-nine years. 
They were divided into four groups of three, and the following 
corticosteroids given as single doses. Dexamethasone 2 mg. by mouth as a 
positive controlq a placebo tablet by mouth as a negative control. All 
twelve subjects received dexamethasone and the placebo. In addition 
prednisone by mouth (5 mg- and 10 mg. ), beelomethas=e-17,21-dipropionate 
by inhalation (500 pg. and 2 mg. ) and beelomethasone-17921-dipropionate by 
mouth (1 mg- and 4 mg-) were given as single doses making six further. 
"treatments". Each subject taking four steroids out of the possible six. 
The following Table 7 indicates the dosing regime. 
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TABLE 
Dosing Regime - White Cell and Fasting Blood Glucose Studies 
Subj ect A B c D E F G H Number 
1 x x x x x x 
2 x x x x x x 
3 x x x x x x 
4 x x x x x x 
5 x x x x x x 
6 x x x x x x 
7 x x x x x x 
a x x x x x x 
9 x x x x x x 
10 x x x x x x 
11 x x x x 
t I 
x x 
12 x x 
I 
x 
a -- 
x X x x 
A- Oral dexamethasone 2 mg. 
Placebo 
C- Oral prednisone 5 mg- 
D- Oral prednisone 10 mg. * 
E- Oral beclomethasone dipropionate 1 mg. 
F- Oral beolomethasone dipropionate 4 mg. 
G- Inhaled beclomethasone dipropionate 500 Pg- 
H- Inhaled beclomethasone dipropionate 2 mg. 
In the fasting blood glucose study the 10 mg. dose of oral prednisone 
was increased to 20 mg. .- 
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In the white cell study, blood was taken at 9.00 a. m. and the dose 
of steroid given immediately afterwaxds, the subject returning five hours 
later at 2.00 p. m. for a further blood sample. A total and differential 
white cell countg and an absolute eosinophil count in addition, for greater 
accuracy, was carried out on each sample. The method employed for the 
eosinophil, count is described in the Appendix (page 1,5)- The counts were 
begun as soon as the blood samples were received in the laboratory (about 
fifteen minutes after collection). 
For the blood glucose study the subjects fasted from 8.00 p. m* took 
the appropriate dose of steroid or placebo at a quarter to midnight, and 
reported for a blood sample to be taken nine hours later (8-45 a. m. ). 
Blood for this study being taken into fluoride oxalate containers, 
and the glucose level examined as soon as possible after collection, using 
the method described by Werner, Rey and Weilinger (1970)- 
No untoward effects were noted in amy subject during any experiment. 
Results 
The full neutrophil leucocyte and lymphocyte counts, the absolute 
eosinophil count results and the fasting blood sugar values are given in full 
in the Appendix Tables 41 to 52# pages 228 to 240- 
Because each subject did not receive every steroid, simple averages 
cannot be used. Instead, mathematically adjusted true means had to be 
calculated. The tables and graphs which follow have been prepared from 
these mean figures. 
White Blood Cell Study 
Total Count 
The mean total white cell counts before and after a single dose of 
steroid are given in Appendix Table 46, page 234- The count was increased 
in every subject five hours after taking a steroid (the mean increase being 
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19601). This contrasts with the findings of Chai (1973) who f ound little 
change in the total count in children following the use of steroids. The 
increase following placebo is probably explained as a circadian effect, as 
the afternoon white cell count in normal subjects is higher than the early 
morning countf the so called "afternoon tide" (Whitby and Britton, 1969).. 
Apart from the increase following 1 mg. of beclomethasone-17,21- 
dipropionate by mouth which is not statistically different from placebot the 
increases following the other steroids are significantly different from 
placebol but not from each other. Neither is a dose response relationship 
seen. 
Distribution of White Cells 
The distribution of neutrophils and 2yMhocytes before and after a 
single dose of steroid are seen below (Figure 39 
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TIGM 39 - The Distribution of NeutrophilS and'Lymphocytes in Twelve 
Healthy Subjects Before and-After Dosing with'Varibus Corticosteroids. 
(Bach point is the'mean of three-subjects, counts. )* 
102 
The haphazard distribution of these cells before the steroids were 
given is replaced by their separation following every steroid but not the 
placebo. This is due to the leucocytosis and lymphopenia which occurs in 
subjects with normal adrenal function following the administration of 
corticosteroids. The greatest response follows oral dexamethasone (2 mg. ) 
and oral prednisone (10 mg. ) and the smallest occurs after oral beclomethasone- 
17,21-dipropionate (1 mg. ). This change is not significantly different 
from the placebo result, whereas those following dexamethasone, and prednisone 
(10 mg. ) are. So also are the responses following 5 mg- of prednisone by 
mouths 4 mg. beelomethasone-17,21-dipropionate by mouth and both the inhaled 
doses of beclomethas=e-l7p2l-dipropionate (500 pg. and 2 mg. )p although 
they are not significantly different from each other. The eosinopenia 
following these corticosteroids is apparent from Figure 40 below and from 
Appendix Table 44t page 231- 
CONTPOX 3nW Smp 10mp %"q 4-P 04"W 2OW 
a" em am NVAftif 
ONAMM"m p1mm"N WOOMMANK NCIOMIKUM 
. 
234a611a1234a07a 
FIGURE 40 The Absolute Eosinophil Count in Twelve Healthy Subjects Before 
and After Dosing with , 
Various Corticosteroids- 
(Each point'is the mean of the three subjects' caunts. ) 
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Again, oral dexamethasone and prednisone (2 mg. and 10 mg. 
respectively) cause the greatest fall in circulating eosinophils, and oral 
beclomethasone-17,21-dipropionate (1 mg. ) the smallest, with no significant 
difference from placebo. Oral prednisone (5 mg-)t and oral beclomethasone- 
17,21-dipropionate (4 mg. ) and Inhaled beelomethasone-17,21-dipropionate 
(2 mg. ) all caused a similar eosinopenia whereas the fall following 0-5 mg- 
of inhaled beclomethasone-17,21-dipropionate is somewhat less, although there 
is no significant difference between the eosinopenia caused by these latter 
four corticosteroids. A dose response relationship is apparent between the 
steroids given and their effects on the distribution of the neutrophilst 
lymphocytes and eosinophils. 
Having found that an inhaled dose of 500 P9. of beclomethasone 
dipropionate led to a significant eosinopeniat I felt it was important to 
establish whether lower inhaled doses would cause an eosinopenia. Using 
three of the original twelve subjects and the routine described on page 100 
inhaled doses of 100 pgo 200 P9-P 300 Pg- and 400 Pg- were given. The 
full absolute eosinophil counts are recorded in Appendix Table 45 , page 232 
The results expressed as percentage falls in the eosinophil count are shown 
in Appendix Table 54, page 242. 
An eosinopenia, is seen following doses of 200 P9-P 300 pg. and 400 pg- 
There is also a 21.4% fall following the placebo. Analysing the results 
as a ratio between the afternoon and morning counts, the mean ratio (Appendix 
Table 55P page 243) is significantly less than 1.0 being 0-71 so the mean 
afternoon count is 29% less than the morning count. This is highly 
significant (P < 0.001). Howevert as the difference between the morning 
and afternoon control counts is 21. e. no individual mean is statistically 
different from control. The relative change is related to the dose, but 
the doses used were not large enough to produce a significant change at any 
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one level. Thus at doses between 200 pg. and 400 pg. an eosinopenia 
is seen which is neither significant nor related to the dose of 
beclomethasone dipropionate. 
Fasting Blood Glucose Study 
A significant increase in fasting blood glucose occurs only after 
dexamethasone (2 mg. by mouth) and prednisone (in this study 20 mg. by mouth) 
(Appendix Table 50, page 238) The other steroids causing no significant 
changes from the control (placebo) value, neither is the small apparently 
dose related difference seen in the table significant. 
Discussion 
These studies confirm that the circulating white blood cells are 
a sensitive index of corticosteroid activity in man. Fasting blood glucose 
values are increased only by dexamethasoneq a corticosteroid with a potent 
glucoco. rticoid function, about five times more potent than prednisone 
(Chapter III Page 48) as an anti-inflammatory agent in mn, and by a 
large dose (20 mg. ) of prednisone. Thus at these doses no separation of 
anti-infla tory from other glucocorticoid effects is apparent in these 
steroids. The lack of effect on fasting blood glucose, following a low 
dose of prednisone (5 mg-) and the doses of beclomethasone-17,21- 
dipropionate given both by mouth and by inhalation are interesting. The 
low dose of prednisone, which is small for anti-infl tory purposes, 
probably explains its insignificant glueocorticoid effectl although adrenal 
. inhibition has been recorded with this steroid 
(Hicklin and Wells, 1968) 
at this dose. The daily therapeutic dose of beclomethasone-l7y2l- 
dipropionate by inhalation is around 0-4 mg- (Introduction, page 24)- 
The pituitary-adrenal suppressing dose by mouth is 4 mg. and by inhalation 
3 mg. 9 no effect was observed at doses of 4 mg. by mouth and 2 mg. by 
inhalation of this steroid on fasting blood glucose. Thus in terms of 
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overall glucocorticoid functiong separation of activity in Man is seen 
with this steroid, wide differences between the anti-inflanmatory dose 
and the pituitary-adrenal suppressing dose, and the doses likely to lead 
to changes in fasting blood sugar are observed. The effects on circulating 
white blood cells are also interesting particularly in relation to the role 
of the eosinophil in asthma. At a dose of 05 mg, by inhalation which is 
within the therapeutic dose range, beelomethasone-17921-dipropionate led to 
a 45% fall in the circulating eosinophils. Similarly inhaled doses 
between-200 pg. and 400 pg. also led to an eosinopenia following each dosep 
although these were not significantly different from the control value. 
At doses above 500 Pg- this effect is dose related, as a four-fold increase 
in the inhaled dose to 2 mg., led to a 72-5% fall in circulating eosinophils, 
which is not significantly different from the 8Wo fall observed after 10 mg, 
of prednisone by mouth. This potent effect on eosinophils my be a further 
separation of activity within the glucocorticoid function of this steroid. 
An eosinophilia'is associated with immune reactions, paxticulaxly in bronchial 
asthma, where eosinophils axe also present in the sputum and tissue of the 
bronchi. Their precise functional role is still not well understood-, 
neither is the mechanism whereby corticosteroids induce an eosinopenia. 
Endogenous corticosteroids exert an effect on circulating eosinophils', and 
the pituitary and adrenal glands have a controlling function on the 
production and distribution of white blood cells. There is a well maxked 
diurnal-variation in-the circulating eosinophil count which is highest at 
i 
midnight and lowest in the early morning, this is the opposite of the plasma 
cortisol diurnal variations, thus when the circulating cortisol levels are 
high the eosinophil count is low and vice versa, Changes in the white 
cell count (neut 
I 
rophil leucocytosis, lylphopenia and eosinopenia) following 
exercise and shock of various types have been explained in terms of increased 
secretion of oortisol as a response to stress applied to the 
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Hypothalamic-Pituitaxy-Adrenal (H. P. A. ) axis (Whitby and Britton, 1969). 
Several hypotheses have been suggested to explain the corticosteroid 
-induced eosinopenia, including direct destruction of eosinophils in the 
bloodr inhibition of eosinophil nyelopoiesis, distributional changes within 
the blood depots, and. migration into the tissues and fixation of eosinophils 
at sites of functional demand. These hypotheses have. been investigated by 
Essellier and hie colleagues (1954)-who concluded that corticosteroid induced 
eosinopenia depended on inhibiting the release of mature eosinophils from 
the bone marrow and upon their increased destruction by cells of the 
reticulo-endothelial system. Other workers believe the eosinopenia is due 
to a decrease in circulating histamine, which occurs after corticosteroids 
have been administered (Archer, 1957; Porter, Young and Mitchell, 1970)- 
Histamine acts as a stimilus to the eosinophil, the-cells accumulating 
locally in tissues in response to the local liberation of histamine, as a 
result of an antigen-antibody reaction involving the tissue mast cells, with 
which they are thus functionally linked, This eosinophilotaxisp and the 
identification of an eosinophil chemotactic factor has also attracted much 
attention. This work has been well reviewed by Honsinger,, Silverstein and 
Van Aradel (1972). . The conclusion being that eosinophilia, is the con- 
sequence of an antigen-antibody interaction and that the eosinophil does not 
mediate antibody production. -It is possible that a certain type of anti- 
body response is necessary to induce eosinophilotaxis as not all antigen- 
antibody complexes do so. Both Litt (1968) and W (1970) have found that 
eosinophilia correlated with passive cutaneous anaphylaxis producing anti- 
body in the guinea pig, but not with precipitating antibody. In patients 
with penicillin allergy,, 'eosinophilia was shown to correlate with reaginio, 
probably IgEt antibody but not with penicillin haemagglutinating antibody 
(IgG, IgM) (Zolov and, Levine, 1969).., -Eosinophilia is much more common in 
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atopic disease, such as asthma, mediated by reaginiop IgE antibody than 
in immine disease mediated by non-reaginic antibody. 
Evidence that a product of the large thymus-dependent lymphocyte is 
required for the development of eosinophilia'in the Trichinella infested 
rat was presented by Basten'and Beeson (1970)- Passive transfer of thoracic 
duct lymphocytes after enteric inoculation resulted in eosinophilial whereas 
passive transfer of lymphocytes from thymus,, spleen and peripheral lymph 
nodes did not. Thymectozy or treatment with specific antisera against 
thoracic duct lymphocytes led to a suppression of the eosinophil response 
in the. infested animal whereas antisera against lymphocytes from peripheral 
nodes did not. These eosinophilotactic mechanisms help to explain the 
tissue eosinophilia, which occurs after an antigen-antibody reaction, but the 
increase in circulating eo sinophils which occurs during the ensuing twenty- 
four hours has Yet to be explained, presumably some eosinophil releasing 
factor or substance stimulating eosinophilopoesis has to, be postulated. 
This cell appears to'have'a unique function in the inflammatory process 
although its precise role is not clear. Their congregation at tissue 
sites where antigen-antibody reactions are occurring together with their 
functional linkage with'tissue mast cells. suggests they have a function 
of, 'ýnopping up" the contentsq particularly histamiriep liberated from mast 
cells which occurs as the result of the antigen-antibody reaction. Thus 
the eosinophil may hav e an important function in maintaining homeotasis in 
the host. Corticosteroids in normal physiology, -are also considered to 
be prime agents in maintaining homeotasis, and there is an obvious inter- 
relationship between these hormones and the circulating eosinophils. 
Undoubtedly corticosteroids are valuable therapeutic agents in asthma. . 
If 
the tissue eosinophil too, has an important part to play in minimising the 
injurious consequences which follow mast cell disruption, then the action 
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of corticosteroids in causing an eosinopenia, of the circulating eosinophils 
might be regarded as a paradoxt as any reduction in these cells would negate 
their useful function. Sodium cromoglycate is thought to act by preventing 
the mast cell mediated antigen-antibody reaction. It is, therefore, not 
surprising that when this drug is used there is no effect on circulating 
or tissue eosinophils (Manners and Ezeoke, 1973)- An explanation may be 
that as there is no discharge of mast cell contents there is nothing for the 
eosinophil. to do. Corticosteroids diminish the circulating eosinophilat 
this has been explained as diminished production from the bone ma=ow coupled 
with their increased destruction. Alternative explanations nay be that 
corticosteroids hasten in some way, probably involving eosinophilotactic 
factor, the passage of eosinophils to those tissues in the body where 
antigen-antibody reactions are likely to occur, for example the skin, lungs 
and gat. This would explain the eosinopenia, and would remove the paradox 
that as both corticosteroids and eosinophils appear to be working for the 
cause, that is to reduce the injurious consequences of the antigen- 
antibody reaction, their reduction by corticosteroids would be harmful. A, 
simpler explanationt however, may be that as circulating white cells are 
Intrinsically very sensitive to glucocorticoid steroids, enough beclomethasone 
dipropionate is absorbed from the lungs to affect their numbers. 
Dexamethasone as I have already mentioned has about five times the anti- 
infla tory potency of prednisonet but its eosinopenic potency is seven 
times that of prednisone (Briggs and Brothertont 1970)- 
However, the possibility that the observed effects of beclomethasone 
dipropionate on circulating white cellsl particularly eosinophils might in 
some way be part of the anti-inflammatory action of beclomethasone 
dipropionate cannot be entirely excluded. They might, for example represent 
a useful shift from the blood of these cells to sites of functional demmd 
in the tissues. Alternatively following a useful local anti-infla tory 
log 
effect, the need for these cells might be reduced. 
Further work is clearly necessary to explain this phenomenon. It 
is possible that examination of the cellular content of sputum, nasal 
secretions or even biopsy material from the lungs or nasal cavities might 
be of assistance in Ostablishing the mechanism whereby beclomethasone 
dipropionate affects white blood cells. 
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CHAPTER VII 
A Review of the Literature concerning the Use of Inhaled 
Beclomethasone Dipropionate in Bronchial Asthma 
Beclomethasone dipropionate has been shown (Chapter III, pages 53 
to 61) to possess considerable topical potency when applied to the skin. 
Its local anti-inflanmatory potency following direct administration, by 
inhalation, onto the bronchial mucous membrane can only be assessed by 
observing its clinical effect in controlling the symptoms of bronchial 
asthmae Thereforeg its anti-infla tory effects are now assessed by 
reviewing the published literature. 
I have, in the Introduction, (pages 24 to 25 ) already refe=ed to 
the earliest publications (Smith, Booth and Davey, 1971; Morrow Browns 
Storey and Georgel 1972; Gregg, 1972; Granto Crompton# Malones Choo-Yangt 
1972; and Clarko 1972). Although these early studies may be criticised 
in terms of design or control, they indicated that inhaled beclomethasone 
dipropionate appeared to be exerting a useful anti-infla tory effect and 
that this was being achieved without an important effect on the Hypothalamic- 
Pituitary-Adrenal (H. P. A. ) axis. In a disease as capricious as asthma 
where there may be a large placebo response effect it was important to 
carry out a blind controlled study. Such a study was carried out in the 
General Hospital at Bury in Iancashire (Ialt Harris, Mhalla, Singhal and 
Butler, 1972). This was a double-blind crossover trial of prednisolone 
and beclomethasone dipropionate aerosol in thirty-eight steroid-dependent 
patients with reversible airways obstruction. The patients were allocated 
at random to two groupst one group receiving beclomethasone dipropionate, 
100 pg. three times a dayp plus placebo prednisolone tablets for one month, 
i 
ill 
followed by prednisolone tablets (2 mg. in the morning and 5 mg. at night) 
and a placebo be, clomethasone dipropionate aerosol for a further month. 
The other group receiving these treatments in the reverse order. Finally, 
to confirm that the patients needed corticosteroids to control their 
symptomsall active treatment was discontinued in the third month, this 
final period being blind only so far as the patients were concerned. Each 
patient was seen on entering the trial and at the end of each monthp when 
the forced expiratory volume in one second, vital capacity and peak 
expiratory flow rate were measured. Blood was also taken at the same 
time (between 10.00 a. m. and 12 noon) for plasma 11-hydroxycorticosteroid 
estimation by the method described by Mattingly (1962). Each patient 
was provided with a Wright Peak Flow Meter and 'readings were taken and 
recorded each morningt afternoon and evening. They also noted the 
number of times they used their bronchodilator aerosols each day. They 
were able to contact any one of three of the triallistsq at any time if 
they felt unwell, 
In this trial, respiratory function was as well maintained during 
the month on. beclomethasone dipropionate as it was when the patients were 
receiving prednisolone. Morning plasma 11-hydroxYcorticosteroid levels 
increased in every patient during the month on beclomethasone dipropionate. 
There were no significant differences in the patient's preference for 
either treatment nor in their bronchodilator usage. During the third 
month there was a prompt fall in respiratory function, and an increased 
use of bronchodilator drugs in over half the patients during the first 
two weeks of this periodo and no patient completed this third month 
without having to return to corticosteroids. This study indicated that 
300 Pg- of beclomethasone dipropionate could control asthma as well as 
7-0 mg- prednisolone by mouth and that beclomethasone dipropionate appeared 
to have little, if any, effect on the H. P. A. axis. Choo-L? mg and his 
112 
colleagues (1972) in a small controlled trial involving seven patients 
compared beclomethasone dipropionate at 2.0 ing. a day with preanisolone 
(20 mg. daily) and their placebos. They chose this large dose of 
beclomethasone, dipropionate because they were unconvinced from a 
preliminary studys that a lower dose (400 pg. daily) would control asthma. 
Six out of seven patients had an increased forced expiratory volume in one 
second following their transfer from placebo to beclomethasone 
dipropionateq this was increased significantly in only one patient after 
the further transfer to oral Prednisolone. In one patient no significant 
change in respiratory function occurred with either corticosteroid sug- 
gesting the possibility of chronic bronchitis rather than bronchial asthma 
as a diagnosis. Four out of seven patients showed pituitary-adrenal 
suppression on 2 mg. beclomethasone dipropionate a day, which agrees broadly 
with ny own findings in normal subjects, particularly as it has been shown 
that the H. P. A. axis in patients with bronchial asthma is more sensitive 
to exogenoas cortioosteroids than in the normal subject (Robson and 
Kilborn, 1965). This trial may be criticised in view of the s 11 number 
Of Patients and the shortness (five or seven days) of the treatment periods 
80 that "carry over" effects of either treatments cannot be excluded. 
An UnControlled study (Chatterjee, Ross, Carroll, Harris and Butler, 
1972) in which it was possible to discontinue oral steroids in twenty- 
eight out of thirty-nine patients within twenty-eight days confirms the 
findings of the controlled study of Ial and his colleagues. Respiratory 
function was well maintained on beclomethasone dipropionate, and a return 
of adrenal responsiveness, noted by increased plasma cortisol levels, con- 
firmed by tetracosactrin stimilation tests occurred. Of the eleven 
remaining patients, nine were able to reduce their doses of oral cortico- 
steroids, In December, 1972, an amnotation in the Ioncet concluded that 
beclomethasone dipropionate was useful in mild asthmatic patients requiring 
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no more than 10 mg. prednisone daily to control their symptoms. In such 
patients beclomethasone dipropionate could be relied upon to enable oral 
prednisone to be withdrawn. This was not the case in more severely ill 
patients although the concurrent administration of beclomethasone dipropionate 
had a steroid sparing effect in that it generally allowed a reduction in the 
dose of oral corticosteroids, possibly enabling some increase in adrenal 
responsiveness. These conclusions were challenged in a letter (James, 
1973) to the Iancet, in which the author pointed out that it was meaning- 
less to try and equate the dose of a topically applied drug with a systemic 
one, it was further stated that the efficiency with which beolomethasone 
dipropionate was inhaled was of the greatest importance, and that in 
his experience provided beclomethasone dipropionate reached the bronchial 
mucous membrane adequately then it iss, in his experience, the equivalent 
of whatever oral dose of prednisone the patient previously needed. The 
importance of an inhaled drug getting to its site of action is obviously 
imPortantr and may explain the disappointing results in fifteen asthmatic 
patients with hypersecretion of mucus which Herxheimer experienced (1973)- 
It is likely that an excess of bronchial mucus would coat the mucous 
membranes, thus'creating a barrier preventing beclomethasone dipropionate 
from reaching its site of action. 
Of sixteen steroid-dependent asthmatic patients studied by Maberly 
and his colleagues (1973), six were able to discontinue oral corticosteroid 
therapy and in four a significant reduction of the oral dose was possible. 
The six patients who were able to Stop oral corticosteroids showed 
progressive recovery of adrenal function and within two months five out 
of six had a normal response to tetracosactrin stimui tion. 
A further double-blind crossover study (Gaddie, Reidt Skinner, Petrie, 
Sinclair and Palmer, 1973) involving fifteen patients, 'with moderately 
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severe chronic bronchial asthma who were not receiving oral corticosteroids, 
showed a significant improvement in respiratory function with no reduction 
of plasma cortisol levels in every patient. The daily dose of inhaled 
beclomethasone dipropionate in this trial was 400 Pg- 
In JulY9 19739 Pines described his experiences with a large series of 
patients, one hundred, his observations were based on between ten and twenty 
months of continuous treatment. His findings closely resembled those of 
other workers. Twenty-one of twenty-five patients who had previously 
received little steroid were satisfactorily improved. Pifty-nine of 
seventy-five steroid-dependent patients were maintained equally well by 
iýnhaled beclomethasone dipropionate, forty-seven of them were able to stop 
taking all systemic steroids, and the remaining twelve had substantial 
reductions in their oral steroid dosage. A mean daily requirement of 
prednisolone before the trial of 8.9 mg. daily being reduced to 2.9 Mg. 
There was no evidence of adrenocortical depression due to beclomethasone 
dipropionate. In sixteen patients the treatment failed, this was due 
eitherto persistently depressed adrenal function, or because of only 
Partially reversible airways. obstruction. 
A further paper by Morrow Brown andý'Storey was published in Julyt 
1973- This time dealing with the'response of children aged between two 
and a half and sixteen yearal to beclomethasone dipropionate over periods up 
to twenty months. Thirty-one children with chronic perennial allergic 
asthma were studied, sixteen had been steroid-dependent for up to eleven 
years. Fifteen were successfully weaned off oral corticosteroids, the 
sixteenth child could not be maintained on beclomethasone dipropionate., - 
Fifteen other childrent with worsening asthma not adequately controlled 
by bronchodilator drugs or sodium cromoglycatep were all adequately treated. 
No adrenal suppression occurred, although four patients developed oral or 
faucial monilial infection. Loss of weight, resumption of growth and the 
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disappearance of Cushingoid features were observed and considered to be 
evidence of lack of systemic steroid effect. 
Gaddie and his colleagues (1973) having ca=ied out the double-blind 
crossover trial I have already described (page 113)v then proceededt in the 
same fifteen patients, to examine whether increasing the dose above 400 pg. 
a day would result in a greater therapeutic response, and at the same time 
to examine the lowest dose at which adrenal suppression occurs. The daily 
dose of 400 pg. was increased by increments of 400 pg. every twenty-eight 
days up to a daily dose of 1,600 pg. No dose dependent improvement in 
respiratory function was noted in this studyl and some impairment of adrenal 
response to a tetracosactrin test was noted at 19600 pg. daily. The 
failure to observe a therapeutic dose response effect in this study is 
interesting, as a dose response effect was observed so far as adrenal 
function was concerned. And dose response effects were observed in the 
studies described in Chapters V and VI (pages 73 to 109)- A further 
studys not yet publishedt which was carried out by Dr. T. J. H. Clark- 
(1973) has produced a clear therapeutic dose, response relationship andt 
therefore, conflicts with the findings of these workers. No reasons axe 
advanced, by, these authors to explain their, findings. 
The predictable variation -in plasma cortisol level in the normal subject 
during the course of, the twenty-four hour day-night cycle is well established 
(Blissr Sanberg., Nelson and Eik-Nes, 1953; Gemzell, 1954; and Engel, 
Helmreich, Hertoghe and Booth, 1955)- Several methods of assessing adrenal 
function have been employed in the studies so far described, early morning 
plasma cortisol determinations, tetracosactrin stimulation tests and the 
response to insulin challenge. Buisseret (1973) in seven asthmatic 
patientsp whose symptoms were controlled on a daily dose of 400 pg- of 
beclomethasone dipropionate, examined the effects of this dose on the adrenal 
cortex. Plasma 11-hydroxycorticosteroid, determinations being made at 
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thirty minute intervals throughout a twenty-four hour period. No chamge 
from the normal diurnal pattern occurred. 
Between August and October, 1973, the results of four controlled 
trials were published, three of them involving children (Smith, Booth and 
Davey; Dickson, Hall, Ellis and Horrocks; Godfrey and Konig; and 
Morrisan Smith). A total of eighty-four children and twenty adults were 
studied for periods of four weeks. The therapeutic response in every 
study was goodp symptoms being controlled as effectively as they had been 
on oral corticosteroids, and no evidence of adrenal suppression was noted, 
and, apart from one case of oral fungal infection, no side effects were 
noted. The majority of patients were able to discontinue oral cortic6- 
steroids entirely, or to significantly reduce their daily dose. The daily 
dose of beclomethasone dipropionate was again 400 pg- Several other points 
emerge from these studies, although no side effects were noted, Dickson 
and his colleagues comment that caution in long-term use is necessary until 
it is established that no harmful local effect occurs. This is echoed by 
Dr. R. S- Jones in his annotation in the Archives of Disease in Childhood 
(1973)9 and in the papers of Morrison Smith, and Godfrey and Konig. The. 
appearance Of Oral fungal, infection-is again noted.; Every author comments 
on the advantages of beclomethasone'dipropionate in treating asthma, 
particularly in children. Dr. Jones commenting thatý-'Ithe-long-term 
treatment of children with oral steroid is no longer desirable because 
better alternatives are now available". The need for longer-ýterm controlled 
studies. to establish whether the beneficial effects were maintained was 
also mentioned (Godfrey and Konig)* Such a study (Cameronp Cooperp Crompton, 
Hoare and Granto 1973) involving ten patients in a double-blind study 
extending over six months, showed that substantial reductions in oral 
corticosteroid requirements could be achieved by substitution with 
beclomethasone dipropionatep although only in a minority of patients could 
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oral corticosteroids be completely withdrawn (two out of ten patients). 
It was only in these two patients that the response to tetracosactrin 
stimulation returned to normal. These authors conclude by saying that 
any reduction in oral corticosteroids is to the patient's advantage and 
that beclomethasone dipropionate "can be regarded as a valuable addition 
to the measures at present available for the treatment of chronic asthma". 
In this study and in many of the others, the need to exercise caution when 
reducing the dose of oral corticosteroids upon the substitution of 
beclomethasone dipropionate is emphasised. It may take weeks or even 
months (Malone, Drever, Grant and Percy-Robb, 1972) for a normal response 
of the H. P. A. axis to stress to return after oral corticosteroids have been 
withdrawnp and that, in the event of infection, trauma, surgery or other 
stressful conditions, until a normal response is verified by suitable tests 
of adienal function then an immediate return to oral corticosteroids is 
essential. Having once started to treat a patient with corticosteroids 
it may be difficult or even impossible to discontinue them. Inhaled 
beclomethasone dipropionate has increased the chances of successfully 
withdrawing corticosteroids, and six letters, written'to the British Medical 
Journal between February and November, 1973, emphasise that patients 
following transfer to inhaled beclomethasone dipropionate from systemic 
corticosteroids may be at special risk until the adrenal glands axe 
functioning normally. Batten and his colleagues (1973) reported two cases, 
in one, worsening asthma was ignored, the patient being reluctant to return 
to prednisolone tablets which she had been warned to take under just these 
circumstancesp because she was fearful that steroid side effects would return. 
This patient had normal adrenal function. The other patient developed a 
cold, his adrenal response to tetracosactrin was grossly reduced and he 
was admitted in adrenal failureq having failed to take the prednisolone 
tablets-with which he had been provided. Thus worsening asthma may require 
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oral corticosteroids in a patient previously well controlled on 
beclomethasone dipropionate, and the effects of stress with no adrenal 
reserve are seen. A similar patient was described by Cayton and Howard 
(1973)t this patient's asthma was well controlled by beclomethasone 
dipropionate and oral prednisone, the dose of the latter having been 
reduced over one month from 15 mg- to 7-5 mg. daily. His adrenal response 
to tetracosactrin was abnormal. He developed an obscure viral illnesst 
his prednisone was not increased and within hours he was dead. Right lower 
lobe pneumonia and small atrophic adrenal glands being noted at necropsy. 
Robson (1973) commented that physicians must recognise the risk of adrenal 
failure in patients transferred to beclomethasone dipropionate, and that 
the response of those patients to tetracosactrin identified those at risk 
with reasonable assurance. Yqles and Daly (1973) agreed that a 
tetracosactrin test was useful but pointed out that an insulin hypoglycaemia 
test was the only adequate way of testing the integrity of the whole Of 
the H. P. A. axis. Cooke and his co-authors (1973) considered that a very 
slow reduction (1 mg. per month) of oral prednisone was essential when a 
patient was being transferred to inhaled beclomethasone dipropionate, using 
this routine they have noted only one patient with symptoms of adreno- 
cortical hyp6-function in over one hundred patients. They too felt that 
the tetracosactrin test only tested the response of the adrenals, and not 
that of the H. P. A. axis to stresss andl therefore, might not be entirely 
reliable in forecasting a patient's response to, infection or trauma. The 
last of these letters (Dalgleish and Leon,, 1973)o agrees with Cooke and 
his colleagues in advocating a slow withdrawal of systemic steroids, 
having by this means avoided any episodes of severe illness in their 
patients. They also observed that beclomethasone dipropionate was more 
easily substituted for systemic steroids in those patients whose asthma 
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was well controlled by systemic steroids, finding that it was extremely 
difficult or even impossible to substitute beclomethasone dipropionate 
in patients whose symptoms were inadequately controlled by oral cortico- 
steroids. 
Conclusions 
These studies show that beclomethasone dipropionate administered by 
inhalation directly on to the bronchial mucous membrane is an effective 
anti-inflamnatory steroid at doses between 300 pg. and 600 pg. daily. In 
contrast with the earlier studies carried out with other corticosteroids, 
a useful anti-inflamnatory effect has been achieved without effects on the 
H. P. A. axis, and the opinions of the earliest workers with beclomethasone 
dipropionate referred to in rW Introduction (pages 24 to 25 ) have been 
borne out by larger controlled studies. These latter studies too, axe 
in contrast with those studies reported between 1951 and 1971 in that 
many of them are properly controlled, and objective measurements of 
respiratory and adrenal function have been made in every study. Several 
other observations are worthy of note. Clinicians have found it essential 
that patients should use their aerosols efficiently or insufficient drug 
enters the bronchi, similarly excess mucus in the bronchi will prevent the 
drug from reaching its site of action. This mucus must be cleared up by 
a course of oral corticosteroids before the aerosol is introduced. Concern 
aver potentially toxic long-term effects of corticosteroids on the 
bronchial mucous membrane was expressed by some authorst oral candidiasis 
has been notedq and the failure of the H. P. A. axis to response to stress 
in recently transferred patients had already been commented upon. Apart 
from oral candidiasis the only other side effects encountered were un- 
masking of allergic rhinitis and eczema, in patients previously maintained 
aa systemic corticosteroids. Symptoms suggestive of adrenal insufficiency, 
such as nausea, malaise and muscular weakness were also noted during the 
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transfer of patients from oral steroids to inhaled beolomethasone 
dipropionate. 
The questions of local toxicity and candida infections of the mouth 
are discussed in the next Chapter. 
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CHAPTER VIII 
An Account of the Animal and Human Studies which have been caxried out 
to Assess the Toxicity of Beclomethasone-17,21-Dipropionate on the 
Tissues of the Respirato; y Tract. Including a Discussion of the 
Problem of Oro-Pharyngeal Infection with Candida Albicans complicating 
Treatment with this Steroid. 
Severalauthors of papers about beclomethasone dipropionate have 
expressed concern over possible deleterious local effects of this drug 
on the lung tissues. This is a reasonable attitude following the 
introduction of any new drug, however, in this instance the uneasiness is 
increased because the drug involved is a corticosteroid with enhanced topical 
potency being directly applied to the bronchial mucous membrane. 
-Systemic corticosteroids 
taken for long periods can induce skin changes, 
and similar changes are seen when topically potent corticosteroids axe 
applied to the skin. The purpose of this chapter is to describe the problems 
associated with topical corticosteroids, to examine the results of studies 
involving animals exposed to enormous amounts of beclomethasone dipropionate 
by inhalation, and, to assess what clinical evidence there is concerning 
harmful local effects following the inhalation of this drug. 
Side Effects associated with Potent Topical Corticosteroids 
Unwanted side effects from topically administered drugs are just as 
likely to occur as they are following other routes of administration. This 
is especially true of corticosteroids, particula ly those fluorinated in the 
nine alpha (9a) position, applied under occlusion. In an extensive 
literature the commonest effects are thinning or atrophy of the skin (Baker, 
1968; Kalish, 1973; Goette, 1973) which is usually reversible within two 
or three months after stopping treatment. Atrophy is often associated with 
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striae (Mearaq 1964) which do not disappear when treatment ceases. 
Telangiectasia is also a common accompaniment (Stevanovic, 1972; Sneddon, 
1969). The likelihood of skin infections is increasedt and minor trauma 
will lead to splitting and bruising of the thin atrophic skin. Barry (1973) 
writing in the Medical Journal of Australia, has identified patients who are 
afraid to stop using their cream or ointments because of the uncomfortable 
rebound inflarmntion which follows their withdrawal. He regards them as 
examples of addiction to a topically applied drug, both skin and patient 
becoming "hooked". If enough of a potent topical corticosteroid is applied 
to the skin, significant absorption will occur leading to adrenal axis 
suppression (Scoggins, 1962; Scoggins and Klimang 1965; and James, Munro 
and Feiwelp 1967)- 
SimiLtr skin changes are observed in patients receiving long-term 
systemic corticosteroids, atrophy and striae'are a feature of Cushing's 
syndrome both iatrogenic and spontaneous. 
Wound healing my be delayed and the proper formation of granulation 
tissue impaired in patients receiving very large doses of corticosteroids. 
Topical steroids have in fact been advocated during wound healing to prevent 
excess scar formation (Berliners Williamst Taylor and Nabors, 1967)- 
These changes in the skin are brought about by the effect of 
glucocorticoid steroids on connective tissue. It has been suggested that 
they exert an inhibitory effect on fibroblast activity in turn leading to 
a reduction in the production of collagen (Asboe-Hansen, 1959)- 
-Stevanovio (1972) suggests that the atrophy may be due to a quantitative 
decrease in the-ground substance, by a steroid induced restriction of its 
formation. He describes empty spaces around blood vessels and collagen 
bundles in histological sections., and argues that diminished supportive 
tissue will not permit collagen or blood vessels to develop. Furthermore 
as the grbund substance is the medium through which essential nutrients 
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are transportedl then these too must be in short supply and will lead to 
deficiences in the function of the cells of the dermis. There is a decrease 
in the amount of tissue hexosamine, this is an essential component of muco- 
polysaccharides, its lack inhibits the synthesis Of chondroitin sulphuric 
acid in regenerating connective tissue (Asboe-Hansent 1959)- It is con- 
ceivable that a steroid applied topically to-the lungs might induce similar 
changes, it is for this reason that concern over possible long-te=. hazards 
has been expressed. 
Animal Studies 
Long-Term Toxicological Study of Inhaled Beolomethasone Diproplonate in 
Rats and Dogs 
I am indebted to Dr. Desmond Poynterg Head of the Department of 
Pathology, Allen and Hanburys Research Limited, Ware, Hertfordshire, for 
the details of his toxicological studies, and also for the photographs 
in the Appendix (pages 166 to 183). 
Long-term toxicological studies, using inhaled beclomethasone 
dipropionate have been carried out in albino rats (CFY strain)t and 
beagle dogs. Results are available on rats which were dosed daily by 
injection for ninety-five weeks. The maxiim, Tn, dose these animals received 
by inhalation was forty times the human daily therapeutic dose (400 Pg-)t 
and in addition one hundred times this dose was given by mouth for eighty- 
two of the ninety-five weeks. No evidence of steroid side effects were 
seen, and no abnormal findings in any part of the respiratory system, 
either macroscopically or microscopically were discovered. There axe 
problems associated with the toxicity testing of inhaled drugs in animals. 
These have been assessed by Dr. Poynter (1973)- He described the methods 
used to dose rats and dogs (these are described and illustrated in the 
Appendix, page a 166 to 167) and proof of the efficacy of these methods was 
provided, and is worth mentioning here. The animals used for inhaled drug 
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toxicity have to be patiently trained in the procedures used, this is 
particularly important in teratology, because the stresses of the experiments 
in untrained animals can lead to resorption of the foetuses or the production 
of abnormal offspring. Therefore, the results of such experiments have to 
be interpreted with caution. Similarly, in the dog, an anxiety state is 
easily caused by the stresses of these experiments, and frequently this 
presents as convulsions. So again the interpretation of the results could 
be difficult. If the animal has been properly trained the amount of inhaled 
drug reaching the lungs is significantly increased, which further underlines 
the importance of training. 
In order to demonstrate the efficacy of the methods in trained 
animals, tritiated beclomethasone dipropionate was administered to dogs, 
and the concentration of drug in the lungs of the freshly killed animal 
measured. Following a dose of twenty inhalations of 50 Pg- per actuation 
the concentration of the steroid in the dog lung was found to be 1 pg. per 
gr=, with 2 pg. -3 Pg- per gran being present in alveolar tissue adjacent' 
to the major bronchi. Assuming twenty-five percent of an inhaled drug 
in mm enters the lung, and that the lung weight is 1,500 grams., following 
a dose of 100 pg. the lung concentrations would be about 17 nanograms per 
gr=. Thus the concentration achieved in the dog study are much higher 
than those likely to occur in man. 
At this stage it is relevant to point out that a considerable dif- 
ference of response to beclomethasone dipropionate exists between species 
and the rat is the least susceptible (personal communication, Pharmacology 
Department, Glaxo Iaboratories, 1974)- The dogg however, is much more 
susceptible to this steroid, more so than man, and so it may be considered 
that the toxicological experiments in the dog are more meaningful than those 
carried out in the rat. 
Profýnmd steroid side effects were noted in the dog after nine months 
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treatment at high level dosing. This comprised 2 mg. daily by inhalationt 
with an oral supplement of 400 pg. lKg. daily (twenty times the daily 
therapeutic dose of 400 Pg- in mam). Regular monitoring of plasma cortisol 
levels and the response to Synaothen challenge soon revealed suppression of 
the pituitary-adrenal axis. The dogs also developed overt signs of 
hypercorticism resembling Cushing's syndrome in mn (see Appendixt page 168). 
At post mortem complete adrenal atrophy was observed (Appendixg page 169) 
and changes associated with CushingIs syndrome noted. However, no abnormal 
changes in any tissue of the respiratory tract were seen (Appendixt pages 170 
to 173). There is a paucity of literature on the pulmonary effects of 
corticosteroids in man, presumably because such effects axe absent. No lung 
changes ha; ve been recorded in patients with Cushing's syndrome either 
spontaneously occurring or as the result of the prolonged administration of 
corticosteroids at high dosage. David and his colleagues (1970) in their 
extensive review of the clinical consequences of corticosteroids refer only 
to reports of spontaneous pneumothorax occurring in patients with tuberculosis 
(Lindholmg 1967; and Armstrong and Xitchell, 1960) and mediastinal widening 
in two patients due to an increase in the epicardial fat deposits, as part 
of the same metabolic alteration which increases other central fat depots. 
These changes resolved when corticosteroids were withdrawn (Bodman and 
Condemil 1967)- One author (Berkheiser, 1963) noted alveolar 
epithelialisation and epidermal metaplasia at autopsy in thelungs-of a 
patient who had received high doses of corticosteroids, but since no other 
cases are reported the significance of such a finding is doubtful. Thus 
there is no experimental evidence that inhaled beclomethasone dipropionate 
leads to deleterious effects on lung tissues. It is also of interest that 
lung changes in patients who have received large doses of corticosteroids 
appear to be exceedin 
ý 
eq whereas skin changes occur frequently. A 
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Human Studies 
Histological Evidence from Patients receiving Inhaled Beclomethasone 
Dipropionate 
Dr. E. Andersson of Sygelinset, Fakse, Denm 
Ia, 
mentioned at a 
meeting that he had carried out biopsies of the bronchial mucous membrane 
in some of his patients who had received. beclomethasone dipropionate for 
at least six months. Knowing of ny interest in this corticosteroid he 
kindly sent me the clinical details of twelve patients together with the 
histological preparations and his local pathologist's report (these details 
are included in the Appendix, pages174 to 187). Dr. Poynter examined the 
slides without reference to the reports and his comments, together with 
six micro-photographs are included in the Appendix (pages 174 to 187) - 
The lungs of these twelve patients following six months treatment 
with inhaled beclomethasone dipropionate revealed no damage which cc d Ul 
be attributed to the drug. Pathological changesq thickening of the 
basement membrane and infiltration with eosinophils characteristic of 
bronchial asthma were seen, and in one area of one biopsy squamous meta- 
plasia was seen, the significance of which is not known. 
Survey into possible Clinical Effects of Long-Term Treatment with 
Beclomethasone Dipropionate compared with Oral Corticosteroids 
Introduction 
Inhaling a corticosteroid might lead to deleterious effects within 
the respiratory passages, but it is only possible to speculate how such 
changes might present clinically. It is possible that resistance to 
infection might be reduced,. and that if an infection occurred it might 
respond more slowly to treatment with anti-biotics, The symptoms of 
bronchial asthma might be less well controlled in the long-term than when 
the patient was receiving oral corticosteroids. If the inhaled drug led 
to epithelial and connective tissue thinning within the lungs this might 
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present as haemoptysis due to unsupported blood vessels rupturing. 
Methods 
To examine these possibilities I organised a survey with the co- 
operation of four physicians each of whom had experience of treating 
patients with beclomethasone dipropionate (they are acknowledged 
later in the thesiss page 256). Patients who had received beclomethasone 
dipropionate by inhalation as their only corticosteroid treatment for one 
year were chosen and their clinical control for that year was compaxed with 
a previous year when they were receiving oral corticosteroids. These two 
years do not follow each other exactlyt they are separated by a period of 
time varying from four weeks to four months. This corresponds to the 
period of time during which a patient is being transferred from oral cortico- 
steroids to inhaled beclomethasone dipropionate which varies considerably 
from patient to patient. The two years are remarkably comparable so far as 
weather conditions are concerned, no extreme conditions such as persistent 
fog or intense cold being recorded in either year. In both years the 
incidence of influenza was similar, and the pollen counts during the summer 
months were comparable both as far as the years were concerned and from area 
to area. The dosage of oral corticosteroids lay between 5 mg. and 20 mg. 
of prednisone or its equivalent. The dose range of beclomethasone 
dipropionate was between 200 pg. and 600 pg. daily. A total of 211 patients 
were surveyed. The following information being obtained from the patients' 
records for both periods: - 
1. Frequency of bacterial infection of the lungs. 
2. Duration of anti-biotic treatment when instituted for 
such infections. 
3- Frequency of oral candidiasis*. 
Judged clinically by symptoms and the appearance of obvious thrush on 
examination. 
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Prequency of hospital admissions for worsening asthma. 
Evidence of worsening asthma which caused the patients 
to either increase their dose of oral corticosteroids or 
to take oral corticosteroids with which they had been 
provided in addition to beolomethasone dipropionate, or 
to come upto out-patients before their next appointment. 
Incidence of haemoptysis. 
Results 
Table 8 below records the number of incidents which were noted 
The total of course includes several patients who experience more than 
one incident during the survey. 
TABLE 8 
Incidents in year patients received: - 
Incidents 
a) Oral b) Inhaled Beclomethasone 
Corticosteroids Dipropionate 
Bacterial infection of 188 168 respiratory tract 
Fungal infection of 
mouth (as defined - 0 
footnote, page 127) 
Severe attacks of asthma 
necessitating ad- 58 25 
mission to hospital 
Other episodes of asthma, 
NOT requiring hospital 172 84 
admission 
Haemoptysis 0 0 
Prom this table it is seen that 4emoptysis does not appear to be a 
complication of corticosteroid therapy, by either the oral or inhaled routes. 
No episodes of haemoptysis being recorded. Oral candidiasis on the other 
hand only occurred when the patients were being treated with beclomethasone 
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dipropionate. This has already been noted as a complication of 
beclomethasone dipropionate in the literature and will be discussed in 
more detail later in this chapter. Although more episodes of bacterial 
respiratory infection occurred when'the patients were receiving oral 
corticosteroids than when they were maintained on beclomethasone 
dipropionate the difference is not significant. However, the treatment 
of bronchial asthma with beclomethasone dipropionate does not increase the 
incidence of bacterial infection, neither, if such an infection occurst 
does it take longer to respond to anti-biotic therapy. (Average duration 
of anti-biotic therapy in both groups - five days). 
The control of asthma in the terms defined (points four and five, 
page 128) is significantly better in those patients being treated with 
beclomethasone dipropionate (P < 0-005)- Fewer severe attacks of asthma 
occurring in these patients. 
The number of patients related to incidents is given in Tableg 
where it should be noted that the "as mamy incidents" column refers also 
to no incidents, for example in the fungal infection line under "as many 
incidents" the figure 205 is given. This refers to 205 patients, none of 
whom had fungal infection of the mouth in either of the years surveyed, the 
figure 211 opposite haemotpysis similarly refers to the total number of 
patients, none of whom had a haemoptysis during either year. 
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TABLE 
Incident 
Patients treated with 
Beclomethasone Dipropionate 
More As Nany Fewer 
Incidents Incidents Incidents 
Bacterial infection of 52 98 61 
respiratory tract 
Fungal infection of 205 0* mouth 
Severe attacks of asthma 
necessitating ad- 12 -159 40** 
mission to hospital 
Other episodes of asthma, 
NOT requiring hospital 28 128 55' 
admission 
Haemoptysis 0 211 0 
* There were significantly (P < 0-05) more patients with more fungal in- 
fections of the mouth during treatment with beclomethasone dipropionate. 
** There were significantly fewer (P < 0-005) patients with more asthmatic 
attacks during treatment with beclomethasone dipropionate. 
Conclusion 
These resultst whilst confirming that oral candidiasis might complicate 
treatment with beclomethasone dipropionate (the incidence in this survey 
being 2, Wo) also show that the control of asthma is significantly greater 
when the patients are treated with beclomethasone dipropionate. There is 
a lower, although not significant incidence, of respiratory infections 
caused by bacteria, during treatment with beclomethasone dipropionate. Such 
infections when they occurred responded as rapidly to treatment as they did 
in the group receiving oral steroids. It may, therefore, be concluded from 
this investigation that inhaled beclomethasone dipropionate does not increase 
the likelihood of lung infection by any local deleterious effect on the 
tissues of the respiratory tract. 
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The findings of this survey, together with those of the animal 
studies and the histological studies from patientsp indicate that at present 
there is no experimental or clinical evidence to suggest that inhaled 
beclomethasone dipropionate is exerting any local toxic effect on the lung 
tissues. Although this possibility cannot be excluded, pulmonaxy changes 
following corticosteroid therapy are very rare indeed. Similarlyj in 
Cushing's syndrome, where circulating cortisol levels are very high, lung 
changes have not been recorded, whilst skin changes are prominent, and an 
important feature of this syndrome; these facts raise the possibility that 
the epithelial and connective tissues of the lungs may in some way be 
resistant to the glucocorticoid effects of steroids. Certainly the connective 
tissue of the skin is greatly. affected in'Cushing's syndrome, by oral 
corticosteroids and particularly by fluorinated potent topical steroids when 
placed on the skin to treat various disorders, under occlusive plastic 
dressings. It is beyond the scope of this thesis to discuss all these 
phenomena in detail, but it is unlikely. that the effects of beclomethasone 
dipropionate are qualitatively different on the skins compared with the 
lung. The concentration of the drug when applied to the skin varies between 
0.025% and 0-5%, it persists in the skin for long periods and to assist 
penetration it is placed under occlusion. Although no complications have been 
recorded following its use on the skin, it is prescribed less frequently 
than other topical steroids, and so this may. not be significant. However, 
when the drug is. inhaled the amount entering the lung is much smaller than 
that applied to the skin, the drug is not occludedt and the lung is a much 
. more efficent metabolic organ than 
the skin. In Chapter IVt page 64, 
its rapid hydrolysis to beclomethasone monopropionate and thence its slightly 
slower further hydrolysis to the alcohol beclomethasone has been mentioned, 
its clearance from the lung is rapids about one hour. Thist together with 
the small doses involved may explain its lack of toxicity on lung tissue. 
I 
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A further explanation may be that if the ratio of elastic to fibrous tissue 
in the connective tissue of the lung is higher than that of the skin, then 
possibly the inhibitory glucocorticoid effect on fibroblast activity is 
more important in the skin than in the lung. 
Oro-Pharyngeal Candidiasis complicating Treatment with Beclomethasone 
Dipropionate 
From the literature and in conversation with many physicians there 
is no doubt that oral, and occasionallyp laryngeal candidiasis occurs in 
patients treated with beclomethasone dipropionate. This appears to be 
commoner in patients transferred from oral corticosteroids. The majority 
respond rapidly to appropriate local anti-fungal treatment, only rarely, 
because of frequent recurrences of candidiasis is it necessary to stop 
treatment with beclomethasone dipropionate. No cases of tracheal or 
bronchial candidiasis in beclomethasone dipropionate treated patients have 
so far been recorded. 
The preliminary results from a long-term study, presently in progress 
at the Brompton Hospitalt London, show a marked relationship between the 
dose of beclomethasone dipropionate and the incidence of positive throat 
swabs for candida albicans (Brompton Hospital/'Medical Research Council 
Collaborative Trialq 1974)- At a dose of 800 pg. per day the incidence 
of oro-phaxyngeal candidiasis is 7Vwhereas at a dose of 400 Pg- per day, 
this figure drops to 45%- Pines (1974) in a letter to the British Medical 
Journal states that at doses of 200 pg. to 300 pg. daily oro-pharyngeal 
candidiasie is rare in his experiencep maintaining that this complication 
might be avoided if: - 
1. The dose is left as low ap possible, 
and 
2. The patient is carefully taught how to use the 
aerosol to avoid depositing most of the drug in the 
mouth and throat. 
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Several physicians at a symposium on beclomethasone dipropionate (held in 
May, 1974 in London) observed that rinsing the mouth with water a few 
minutes after each inhalation does much to prevent thrush developing. A 
further observation from the long-term study I have already mentioned, is 
that the presence of candida, precipitins in the blood, indicating a previous 
infection with candida albicans, undoubtedly increases a patient's chances 
, of 
developing oro-pharyngeal candidiasis as a complication of treatment with 
beclomethasone dipropionate. A previous vaginal infection, therefore, might 
explain why eleven out of sixteen patients who developed this complication in 
a series of one hundred and twenty patients (McAllen, Kochanowski and Shaw, 
1974) were women. Similarly, eight of the twelve patients with oro-pharyngeal 
thrush reported to the Adverse, Reactions Section of the Committee on Safety 
of Medicines between October, 1972 and May, 1974 were also women (personal 
communication - Dr. M, F. Cuthbertj Principal Medical Officer, Committee on 
Safety of Medicines) and ten patients out of a total of thirteen who developed 
candidiasis in a'series of one hundred patients were also women (Kennedys 
1974)- Thus previous vaginal candidiasis and the development of circulating 
precipitins appears to be a predisposing factor. 
Prom the survey mentioned in this chapter the incidence of oral 
candidiasis was 2. W.. From the literature and. other sources including the 
survey the incidence in 1., 621 patients was 5-05%, The candidiasis being 
diagnosed clinically (the full details appear in Appendix Table 57 v page 
249- 
Candida albicans exists as a commensal in the. mouth of many normal 
people. Table 10 below, prepared from the literature, illustrates this. 
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TABLE 10, 
Candida Albicans in the Mouth 
Authors T; ype of Case 
Number 
of Cases 
Percentage of 
Candida Albicans 
Stenderap and 
Pedersen (1962) Hospital patients 625 53-0 
Mackenzie (1961) Throat swabs from 79 3400 hospital. patients 
Healthy adults 112 16.9 
Fox and 
Ainsworth (1958) Dental patients 188 28.0 
Figures, sent to me by Dr. L. J. R. Milne and Dr. G. K. Crompton from 
Edinburgh, 1974, Table 11, reveal a similar percentage of positive throat 
swabs in control subjects. The incidence is increased in patients receiving 
beclomethasone dipropionate, and to a lesser extent in those treated with 
prednisone. 
TABLE 11 
Survey to Investigate the Incidence of Oro-lýýeal Thrush 
in Patients attending a Chest Clinic - Figures obtAined over Six Months 
(Milne and Crompton Edinburgh, 1974) 
Treatment Patients (Total 936) 
+VE Culture SI ore Throat 
Sore Throat Plus 
+VE. Culture 
Number % Number % Number % 
A 283 77 27.2 6 2.1 2 0-7 
B 177''' 73 41.2* 14 7-9* 10 5.6* 
C 333 136 40-8* 29 8-7* 18 5-4* 
D 143 47 32.9 0-7 1 '0- 7 
Significantly different from control (P < 0.01) 
A- Not receiving corticosteroids 
B- Beclomethasone dipropionate 
C- Beclomethasone dipropionate-plus prednisolone 
D Prednisolone. 
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It is not known why treatment with beclomethasone dipropionate should 
be complicated by oral thrush or lead to an increase in the population of 
candida albicans existing in the mouth as a commensal. The factors which 
predispose to oral candidiasis are worth examin as they may enable the 
identification of possible additional aetiological factors, and, thereby 
identify those patients most likely to develop thrush as a complication of 
beclomethasone dipropionate therapy. 
The association of high levels of circulating candida precipitins and 
the development of oral thrush in patients receiving beclomethasone 
dipropionate has already been referred to (Brompton Hospital/Medical ]Research 
Council Collaborative Trial, 1974 - page 132 ). Lehner and Ward (1970) make 
the same observation in patients receiving local corticosteroid treatment for 
oral herpetitiform ulcers. They also noted that candidiasis only complicated 
local treatment with a steroid of enhanced topical potency, in this instance 
betamethasone-17-valerate; betamethasone disodium phosphate and hydrocortisone 
hemisuccinate treated patients did not develop this complication. These 
latter corticosteroids do not possess particular: ff topical potency. In 
addition they are water soluble, whereas both betamethasone-17-valerate and 
beclomethasone dipropionate are relatively insoluble in water, it is, there- 
fore, possible that a soluble steroid applied locally is rapidly diluted by the 
saliva so that the local concentration of drug is low. This would not apply 
to an insoluble steroid. Similarly, a steroid with marked topical potency, 
either a-17 eater or an acetonide, has, as I have already mentioned, powerful 
vasoconstriction properties, this too, in the mouth might delay, its removal 
from its site of application. This might explain how thrush may complicate 
the local application of a topical steroid, but the interaction between - 
candida and corticosteroids remains unknown, andlso other predisposing-factors 
must be looked for. Artifical teeth and a high carbQbvdrate diet have been 
cited (Dolbyq 1972), The state of oral hygiene may be an important factor 
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concerning the presence or absence of candida. albicans in the mouth. In a 
series involving dental patients of various kinds and also dental students, 
the incidence in dental students of positive candida throat swabs was only 
four percent (Johnston, Chick, Johnston and Jarvist 1967)- This section of 
the population are probably the most highly motivated concerning oral hygienel 
and certainly care in this direction greatly reduces the incidence of oral 
candidiasis, compared with the population at large. Patients with denture 
stomatitis axe also subject to oral thrush, and the incidence is increased in 
those patients who do not remove their dentures at night (Ritchie, Gletcher, 
Main and Prophet, 1961). Other authors have noted the association between 
dentures and oral thrush (Cawsonj 1965)- The association between oral thrush 
and serious illnessl such as malignant disease, blood dyscrasiasp various 
endocrine disorders, particula ly diabetes mellitus has been well documented 
(Winner and Hurley, 1964). These authors also comment that, with the 
possible exception of the new-borng it is virtually impossible to reproduce 
oral thrush in the mouths of the healthy. However, if the buccal mucous 
membrane becomes damaged the disease becomes reproducible. Thus local 
damage is a predisposing factor. 
In order to evaluate the aetiological factors involved in the production 
of oral thrush in patients inhaling beclomethasone dipropionate, particular 
attention should be paid to the state of oral hygiene and the incidence of 
artifical teeth in these patients including orthodphtic appliances in childreng 
in additionj the presence of other disease, recent treatment with. anti-biotics 
and the dose of beclomethasone dipropionate used will have to be carefully 
noted. Also it would seem worthwhile to check that the patients are using, 
their aerosols correctlyj and not depositing most of the dose into the mouth 
and throat. In this way, it may be possible, by identifying and where 
possible correcting predisposing factors, to reduce the incidence of this 
complication. 
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Finallyp after five years of clinical trial,, and eighteen months 
following the appearance of the drug on the w et, no evidence of pulmonary 
invasion with candida albicans has been seen. This would appear unlikely, 
it has been stated that columnar epithelium has a natural resistance to 
infection with candida albicans (Plummert 1966). This is in contrast to 
the apparent predilection of this organism for stratified epithelium. The 
same author also points out that the presence of pulmonary candidiasis in 
patients dying of serious illnesss complication by systemic widespread 
candidiasis is exceedingly rare at post-mortem. It may be that the uterus 
too enjoys a similar resistance. In spite of the frequency of vaginal 
candidiasis there are no reports in the literature of uterine invasion and 
consequent infection by this organism. 
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CHAPTER IX 
General Discussion and Conclusions 
The results presented in this thesis leave no doubt that there is 
a clear separation between the inhaled dose of beclomethasone-17,21- 
dipropionate required to control bronchial asthma (around 400 pg. daily) 
and that needed to reduce 9,00 aam. plasma cortisol levels or urinary 
17-oxogenic steroid output (2 mg. -3 mg. daily). No such separation of 
dose occurs with the dexamethasone esters (21-isonicotinate or 21-phosphate) 
when they axe given by inhalation, nor for that matter with the other 
glucocorticoid steroids such as hydrocortisone and prednisone previously 
used by inhalation in asthma. Thus when beclomethasone-17,21-dipropionate 
is inhaled a local selective anti-infla tory effect is achieved. 
The major difference between beclometbasone-17921-dipropionate and all 
the other steroids previously tried by inhalation in bronchial asthma is 
that beclomethasone-17921-dipropionate has exceptional anti-infla tory 
activity on body surfaces. This enables very small doses to exert a useful 
anti-inflammatory effect on the mucous membrane of the bronchial tree 
following inhalation. 
This contrasts with the earlier work involving inhaled corticosteroids, 
where the doses needed were as great or even greater than those required for 
oral administration. Thus no separation of anti-inflammatory from other 
glucocorticoid effects was achieved and no benefit for the patient gained. 
These corticosteroidsq hydrocortisone, prednisone and dexamethasoner are 
potent glucocortiocid steroids by any route of administration. The 
swallowed portion of any drug administered by inhalation is important as 
the part swallowed is far greater than that which is inhaled ry (Dolle 9 Davies 
and Conolly, 1971) and undoubtedly contributes to the production of 
I 
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glucocorticoid. effects. The fate of orally administered beclomethasone- 
17,21-dipropionate is also a factor in the selective action of the inhaled 
drug, because when beclomethasone-17,21-dipropionate (4 mg-) was given by 
mouth to Tynm as a microfine suspension, over qWo of the drug was absorbed 
and most of it was excreted via the bile in the faeces as inactive polar 
metabolites (Martin, Tanner, Clark and Cochrane, 1974)- 
The swallowed portion of beclomethasone dipropionate in ordinary 
inhaled doses is unlikelyl therefore, to contribute to any observed effects 
on the Hypothalamic-Pituitary-Adrenal (H. P. A. ) axis. This conclusion is 
consistent with the finding that the drug given'by the inhaled route affects 
H. P. A. function at a lower dose than that required after oral administration. 
The effects on the H. P. A. axis are, thereforep probably attributable to drug 
absorbed from the lungs. - This was checked by giving the drug intravenously 
to assess its absolute glucocorticoid activity by bypassing inactivating 
systems in the liver. As I have said on page 94, it was found to be about 
as potent as dexamethasone by this route. - High topical activity relative to 
systemic activity when inhaled, together with metabolic inactivation of the 
swallowed portion of-beclomethasone dipropionate appear, therefore, to be 
the reasons why this corticosteroid controls bronchial asthma in most 
patients without causing important glucocorticoid side effects. 
Although therapeutic inhaled doses of beclomethasone dipropionate do 
not affect H. P. A. function,, a significant effect on circulating white 
blood cells was found, ' The simplest explanation is that circulating white 
cells are intrinsically, very sensitive to glucocorticoid steroids and that 
enough beclomethasone-dipropionate is'absorbed. from the lungs to affect 
their numbers. On the other hand, these, cells are involved in inflamnatory 
and allergic'processes in the tissues and so the observed corticosteroid 
induced leucocytosis and eosinopenia. might iii some way be part of the anti- 
inflanwtory action of beolomethasone dipropionate. They might, for 
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example, represent a shift from the blood of these cells to sites of 
functional demamd in the tissues. Alternatively following an effective 
local anti-infla tory effect, the need for these cells might be reduced. 
Purther work is clearly necessary to explain this phenomenon. It is possible 
that examination of the cellular content of sputum, nasal secretions or even 
biopsy material from the lungs or nasal cavities might be of assistance in 
establishing the mechanism whereby beclomethasone dipropionate affects white 
blood cells. 
Problems Associated with the Use of Inhaled Corticosteroids 
Since the introduction of beclomethasone-17,21-dipropionate in 
October, 19729 an anologue, betamethasone-17-valerate (Bextasol - Glaxo 
laboratories) has already been made available. This steroid has similar 
properties to beelomethasone-17,21-dipropionate (McAllen, Kochanowski and 
Shaw, 1974; Friedman and Prears, 1974)- A recent report from the United 
States (Williams, Kane and Shim,, 1974) suggests that inhaled triamoinolone 
acetanide might also be of value in the treatment of bronchial asthma. 
No doubt other preparations will come along. The development of these 
inhaled corticosteroids has enabled many, patients with asthma, previously 
dependent on systemic steroids for their well-being, to enjoy either a 
significant reduction in, the dose of their steroids or to stop them . 
completely. Many patientsp especially children, requiring corticosteroid 
therapy for the first time have been controlled by the use of 
beclomethasorle-17,21-dipropionate alone, thus avoiding the risks associated 
with traditional steroid therapy. , For these reasons, inhaled 
beclomethasone-17921-dipropionate-probably represents a useful addition to 
the. drugs available for the, treatment. of-bronchial asthma. 
The important problems associated with the use of inhaled cortico- 
steroids cang I thinkg. be divided into three broad areas. The first is 
a potential problem, and is concerned with the long-term effects on lung 
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tissues. So farg there is no animal or human evidence to suggest that 
beclomethasone-17#21-dipropionate is exerting any local toxic effects. 
. Similarly# there is no evidence in man that bacterial infection of the 
lungs is more likely to occur or be more difficult to control in patients 
treated with this steroid. However# these effects cannot be excluded, and 
no opportunity either at post mortem or following surgeryp to examine the 
lung tissues of patients who have regularly received beclomethasone-17, 
21-dipropionate over long periods should be missed. The second problem 
which =y occur has already been reported and discussed in this thesis 
(Pages 117 to 118). 1 refer to the danger of adrenal suppression, or even 
atrophy, in the previously steroid-dependent patient transferred to 
beclomethaeone-17#21-dipropionate. This group of patients are at special 
risk in the event of a stressful situation until their adrenal function has 
been shown to have recovered. Until that time they must be warned to take 
Oral corticosteroids and to seek help prompt3, Y should they develop an 
, infectiong be involved in an accident or undergo surgery. No recent 
reports have appeared in the medical press and it is to be hoped that this 
potentially dangerous situation is now recognised. 
The third problem is being reported regularly. This is the problem 
of oro-pharyngeal or laryngeal candidiasis complicating treatment with 
beelomethasone-17,21-dipropionate. I have referred to this at length 
(Pages132 to 137) and outlined possible factors, such as dental health or 
previous infection which may predispose a patient to this complication. 
These factorep and also evidence of a dose response relationship in the 
Production of local candidiasis formed a prominent part of the preliminary 
report (August, 1974) of the Brompton Hospital/Medical Research Council 
Collaborative Trial of Beolomethasone-17921-Dipropionate in 33ronchial 
Asthma, This report showed that the incidence of Oro-phaxyngeal candidiasis 
was greatly increased when the dose was doubled. Their conclusions are 
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worth repeating here: - "Our present knowledge suggests that the advantage 
gained by the patient when the oral corticosteroid. dosage is reduced probably 
exceeds the disadvantages of oral candidiasis, in that this is not an 
invariable occurrence, rarely causes symptoms, is controlled by therapyt 
and so far has only been reported as a superficial colonisation". 
The risks of superficial colonisation. of the mouth and throat may be 
minimised by using the lowest dose of beelomethasone-17,21-dipropionate 
which controls the patientst symptoms. It also seems preferable to begin 
with a low dose which may be increased if necessary3, rather than by reducing 
from a high loading dose (McAllen - personal communication, 1974)- 
Conclusion 
Beelomethasone-17921-dipropionate appears to have been accepted as a 
useful addition to the drugs available for the treatment of bronchial asthma. 
Its use so far has not been associated with many complications or obvious 
evidence of local or systemic toxicity in mam, but amy opportunity which 
occurs to examine lung tissues in patients treated with this steroid should 
be taken. 
A corticosteroid intended for use by inhalation should possess high 
topical activity, so that the doses needed to control asthma would be too 
small to exert other glucocorticoid effects. Thus a selective anti- 
inflammatory action within the lungs can be achieved. This must be 
associated with an absence of local toxic effects on the tissues of the 
respiratory tract. Beelomethasone-17921-dipropionate goes far towards 
fulfilling these criteria, however, an absolute separation of anti- 
inflammatory activity from all the other activities within the glucocorticoid 
profile would still appear to be a worthwhile goal for medicinal steroid 
chemists, 
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PHARMACEUTICAL FORMATION OF BECLOMETEASOVE DIPROPIONATE FOR ABSORPTION 
AND EXCRETION STUDIES DESCRIBED IN CHAPTER IV 
Capsule 
Beclomethasone-17921-dipropionate-16,16a-3H (radio labelled 
beclomethascne dipropionate), labelled with tritium m the 16 and 16a 
positions (50 ['Ci/mg. ), was prepaxed. 
0.25 ml- of a chloroform solution containing 4 Ing. radio labelled 
beclomethasone dipropionatel 200 [iCip was pipetted onto 215 mg- of 60 mesh 
lactose contained in the lower half of a gelatine capsule, the solvent 
allowed to evaporate, and the top placed on the capsule. 
b) Suspension 
A microfine aqueous suspension of radio labelled beclomethasone 
dipropionatet with an average particle size less than 5 Pt was prepared 
using Tween 80 as a wetting agent and hydroxymethylcellulose as a suspending 
agent for the drug. Radiochemical analysis of the suspension showed that 
4 mg- of radio labelled beclomethasone dipropionatet 200 pCi, were contained 
in a 16-4 ml- of suspension. 
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IN VITRO STUDIES DESCR IN CHAPTER IV 
a) Incubation of Radio Iabelled Beclomethasone Dipropionate with Human 
Lm Slices - Method 
Half a grm of chopped fresh human lung was added to each of three 
tubes containing 10 ml. Ringer phosphate buffer pH 6.8 together with 30 ng. 
radio labelled beclomethasone dipropionate in 0.1 ml. ethanol. These tubesl 
and a substrate control containing no lung tissue were incubated at 37' for 
five, fifteen or sixty minutes* A second control, containing lung slices, 
was immediately placed in boiling water to destroy tissue enzymes and then 
incubated for sixty minutes. 10 ml. ethanol were added to each tube to 
stop enzymic reactiong the mixture was shaken and then centrifuged at 
2p5OO g. minutes. The supernatent was removed, the residue washed with 
10 ml. ethanol and the mixture re-centrifuged., The washings were combined 
with the supernatents and evaporated to dryness. The residues were 
extracted with 1 ml. ethanol and examined by thin layer chromatography 
(TLC). 
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IN VITRO STUDIES DESCRIBED IN CHAPTER IV 
b) Incubation of Radio labelled Beclomethasone Dipropionate with Human 
Paeces - Method 
Five grams of human faeces were shaken with 15 ml- 0.2 M phosphate 
buffer PH 7-4- 0-47 Mg- radio labelled beclomethasone dipropionate in 
0.2 ml. ethanol was added and the mixture, with a faeces free substrate 
control, were incubated at 370 in a shaking water bath. After six hours 
the faecal suspension was centrifuged (2,500 9- minutes) and the supermtent 
-removed and frozen. This sample, the faecal pellet and the substrate 
control solution were freeze-dried. The supernatent and control residues 
were extracted with 3 ml. ethanol which was concentrated to 0.2 ml. and 
analysed by TLC. The freeze-dried faecal pellet was extracted with 15 ml- 
methanol-chloroform, (1: 1 v/v). 3 ml- of the extract were evaporated to 
dryness, the residue resuspended in 0.2 ml. methanol and analysed by TLC. 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Absorption Studies in Patients taking Oral Radio Iabelled Beclomethasone 
Dipropionate - Methods 
Each'of four subjects swallowed a capsule containing 4 mg., 200 gCiq 
radio labelled beolomethasone dipropionate and two subjects each drank the 
same dose of steroid as a micronised suspension. 
10 Ml. samples of venous blood were collected at intervals from one 
'to tuenty-four hours, see Appendix - Table 5, from the patients who took 
the capsulesp and at intervals up to forty-eight hours from those who took 
the suspension. The heparinised blood was centrifuged, the plasma separated, 
and a known volume freeze-dried. 
Urine samples were collected for three days after taking the radio- 
active drug. 1 ml. of lWo methiolate solution was added to each as an 
antibacterial agent, and the samples were stored at 40C- 
The faecal samples were collected for four days after giving the drug. 
Each sample was immediately placed in methanol to inhibit the action of 
faecal micro-organisms. Samples were prepared for analysis by evaporating 
the methanol and freeze-drying the residues. The freeze-dried product was 
ground into a homogenous powder and stored at 40C- 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Radiochemical Analyses for Absorption Studies in Patients tak#g Oral 
Radio labelled Beclomethasone Dipropionate 
a) Plasm 
The total weight of the freeze-dried residue of a known volume of 
plasma was determined and a 50 mg- sample combusted in a Packard Trit-jim 
Oxidiser. The'water formed was collected . into 10 ml. of I)ray's 
scintillation cocktailq and the radio-activity determined with a Packard 
3320 Liquid Scintillation Spectrometer using the external standard channels 
ratio technique. 
b) Urine 
A 0.25 ml. aliquot of each urine was added to 10 ml. of Diotol 
solution (Martin and Harrison, 1968)9 and the radio-activity measured as 
described for plasm. 
C) Faeces 
0-5 to 1.0 g. samples of the freeze-dried faecal powders were 
combusted in plastic bags filled with oxygen using a modification of 
the method described by G. N. Gapta in 1968; in which the'platinum irridium 
-combustion apparatus was replaced with a'nichrome spiral mounted on a'small 
, piece of aluminium, sheet. The plastic. bag and combustion apparatus were 
discarded after each analysis*' 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Methods of Extraction and- Bydrolysis of the Urinar Metabolites from the 7 
Twelve Hour Urine Sample from Subject M. K. who received Oral Radio Idbel-led 
Beclomethasone Dipropicnate 
The twelve hour urine sample from the capsule treated subjecty M. K., 
was further analysed as follows: - 
100 ml. of urine was passed down an Amberlite XAD-2 columa, 2-5 x 
15 cm. 9-which was then washed with water, 450 ml., and eluted with methanol, 
375 ml- The washings and eluate were collected in 25 ml- fractions. 
Fractions-1 to 6 of the methanol eluate were combined and evaporated to 
dryness to yield residue U. 1. 
The conjugated and free steroids present in this residue were 
separated by partition in the water-methanol-chloroform system (Polchp Lees 
and Sloane Stanleyt 1957)- The lower chloroform phase, containing free 
steroids, was evaporated to dryness to give residue U. 2. The upper 
aqueous phase, containing conjugated metabolitest was evaporated to dryness 
and the residuep. U-3-, redissolved in 30 ml- 0-5 N sodium acetate buffer 
(PH 5-4)- 
The activities of the P-glucuronidase and arylsulphatase in the- 
preparation used to hydrolyse the conjugates were checked by incubating, 
for sixteen hours, 0.01 ml. of enzyme solution with 1 ml. samples of 
buffered conjugate solution containing either sodium phenolphthalein-p-. 
glucuronide or potassium phenolphthalein disulphate. The hydrolysis of 
these two substrates was not inhibited by the urine extract. 1-04 I-U- 
P-glucuronidase and 0-52 I. U. arylsulphatase in 0.2 ml. water were added 
to 20.0 ml. of the buffered conjugate solution and the mixture incubated 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Methods of Extraction and Hydrolysis of the Urinary Metabolites from the 
Twelve Hour Urine Sample from Subject M. K. who received Oral Radio labelled 
Beclomethasone Dipropionate 
caumm 
at 37'C for sixteen hours. The hydrolysate'was passed down an Amberlite' 
XAD-2 columap 2-5 x 15 cm-, which was washed with 300 ml- water, and eluted 
with 200 ml. methanol. The washings and eluate were collected in 25 ml. 
fractions. 0.25 ml. aliquots of these fractions were radio-assayed as 
described for urine. The first three methanol fractions were combined 
and evaporated to dryness to give residue U-4- The free steroids and the 
... conjugate present In this residue were separated by partition in the water- 
methanol-chloroform system mentioned above. The lower chloroform phase 
was evaporated to dryness to give residue U-5. and the upper aqueous residue 
U. 
Each of the residues U. 1. to U. 6. was dissolved in 10 ml. methanol and 
the radio-activity of 0.1 to 0-5 ml. aliquots determined as described for 
urine. A2 ml. aliquot was evaporated to dryness and the residue re- 
dissolved in 0-05 or 0.1 ml. methanol for analysis by TLC. 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Method of Analysis of Faecal Samples from Subjects following Oral Radio 
Iabelled Beclomethasone Dipropionate 
The nature of the radio-active substances present in the freeze- 
dried faecal powders which contained more than W,, of the administered 
radio-activity was studied. 1 g. of each was extracted with 3x 10 ml- 
of a chloroform methanol 1: 1 v/v mixture-and the radio-activity of a 0-5 ml. 
aliquot was determined as described for urine. A2 ml. aliquot of each 
extract was evaporated to 0.1 ml. under a stream of nitrogen and the 
concentrated i3olution analysed by TLC. 
The free and conjugated metabolites of radio labelled beclomethasone 
dipropionate present in the methanol-chloroform extracts of faecal samples 
collected from f orty-eight to sixty hours from M. N. p eighty-four to ninety- 
six hours from K. N. and twelve to twenty-four hours from G. W. were 
separated by solvent partition (Folch, Lees and, Sloane Stanleyj 1957)- . The 
chloroform and aqueous phases were separated and rotary evaporated. The 
residues were dissolved in 10 ml. methanol to give solution A containing 
free metabolitep and solution B containing conjugates. A 0.25 ml. aliquot 
of each solution was added to 10 ml. Diotol for radio-assay. 1 ml .. of 
each methanol solution was evaporated to dryness under a nitrogen stream 
at 450C the residue dissolved in 0-05 ml- methanol, and examined by TLC. 
i 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Methods used in carrying out Thin layer Chromatography (TWT Of Lung, Urine 
and Faecal Extracts from Subjects taking Oral Radio labe . lled Beclomethasone 
Dipropionate 
10 to 40 41- of each extract was applied as a streak, together with 
10 pl. of an internal standard solution containing 5 mg-/ml- of 
beclomethasone diPropionate, beclomethasone monopropionate and beclomethasone, 
to a 20 x 2-5 cm- Str'P Of Polygr= S" G/UV254 (Camlabs Cambridge) silica 
gel TLC plate which was then developed twice to a height of 17-5 cm- with 
a' 
4: 1 v/v benzene-methanol mixture solvent system. The plates were 
examined using an ultraviolet lamp (254 nm) and the internal standards were 
detected as dark "spots" against the fluorescent background of the plate. 
., 
Thýe radio-activity an the plates was determined using a Panax RTLS-1A thin 
layer scanner, or by cutting the chromatographic strip into'18 x1 cm. 
pieces, each-of which was cut in half and both pieces placed in 4 ml. Diotol 
solution and the radio-activity determined by liquid scintillation counting. 
The radio-activity (cpm) present per cm. of the chromatogram, was plotted 
against the distance from the origin, to give a histogram of the distribution 
of radio-activity on the TLC plate. 
From the relationship between the Rf of the internal standards, as 
detected under ultraviolet light, and that of the radio-activity it was 
possible to-identify tentatively radio labelled beclomethasone dipropionate, 
radio labelled beclomethasone monopropionate and radio labelled 
beclomethasone. 
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IN VIVO STUDIES DESCRIBED IN CHAPTER TV 
Method of carrying out High Performance Liquid Chromatogýra hy (EPLC) of the 
Faecal Extracts from Subjects taking Oral Radio Labelled Beclomethasone 
Dipropionate 
HPLC was used to confirm the presence of radio labelled beclomethasone., 
radio labelled beclomethasone monopropionate and radio labelled beclomethasone 
dipropionate in the residue A from the paxtitioned faecal extracts. 9 41. 
of each of the methanol solutions of residue, A were mixed in a Hamilton 
syringe with 1 pl. of the internal standard and the mixture was injected 
into a Da Pont 820 liquid chromatograph equipped with a1 metre ODS 
Permaphase column maintained at 40OC- The steroids were eluated using a 
linear gradient of isopropanol into water from 1% to 40 formed at a rate 
of 1% per minute, which, under a pressure of 1,200 psi, gave a flow rate 
of 1.2 ml. /minute. An ultraviolet (254 nm) flow through detector (8 a. ) 
set at 0.16 AUFS (Absorbance units full scale), monitored the eluant which 
was collected at thirty second intervals into Diotol (12 ml. ). The radio- 
activity in each fraction was determined. 
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IN VIVO STUDIES DESCRIBED IN CHAPTER IV 
Method for the Identification of Radio Active Material in Human Plasma 
1 ml. of plasma was added to 2 ml. of ethanol and the mixture 
stirred on a Rotamixer for twenty seconds. The suspension was then allowed 
to stand at room temperature for a further ten minutes to allow the protein 
to precipitate. The tube was centrifuged at three thousand revolutions per 
minute for ten minutesq the supernatent removed and resuspended in 2 ml. 
ethanol. This suspension was stirred as described previously and re- 
centrifuged. The supernatents from the two washings were combined. 0.1 Mi. 
of a solution containing 1 mg. /ml. of each of the following steroids, 
beclomethasone, beclomethasone-17-propionate, beclomethasone-21-propionate 
and beelomethasone-17,21-dipropionate in ethanol was added to the combined 
supernatents as an internal standard and the solution evaporated under a 
current of nitrogen and at a temperature of 45'C until the volume was about 
0.2 ml. 
The radio activity in 50 111- of the solution was determined by 
liquid scintillation counting. 20 4. of the solution was applied as a 
.2 cm. band on a Polygram Silica Gel/ultraviolet22,4* The sheet was placed 
in a chromtography tank and developed for one hour with a mixture of 
methanol thirty parts, dichloromethane 470 1PXts- The steroids added as 
an internal standard were located by ultraviolet light and the sheet was 
cut into strips 0-5 mm. by 2*cm. Each strip was placed in a 
scintillation vial containing 5 ml- of NE260 and the radio activity determined 
by liquid scintillation counting. 
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NLTHOD OP CARRYING OUT AN ABSOLUTE EOSINOPHIL COUNT 
Diluent 
0,2 g. Bosin (water and alcohol solution) 
10 ml. Acetone 
Make up to 100 ml. with distilled water 
Filter and store in the fridge for no more than two weeks. 
Method 
Add 0-4 ml- of bloodt 0-38 ml. diluting fluid in an LPC tube flick 
to mix for fifteen seconds. Load both sides of a counting chamber (with 
separate capillary tubes). Allow to settle and stain for exactly fifteen 
minutes. Count all nine ruled areas using X10. The eosinophils stain 
daxk pink, the neutrophils a lighter pink. 
Perform at least six counts on each specimen with at least three 
different dilutions. 
Calculation 
Let X be the mean number in the ruled area, multiply by 11.67 to 
find the number per microlitre. 
Normal range 40 - 440 although higher values may occur in atopic 
individuals. 
156 
BRIEF DETAILS OF REPELTED DOSE STUDIES OF BECLOMETHASONE DEPROPIONATE IN 
THE RAT (Pathology Department, Allen and Hanburys Research Limited, Waxe, 
Hertfordshire) 
Test Species - Albino rat (CFY strain) 
Fifteen male and fifteen female per group 
Duration of Study - Twenty-two months 
Route of Administration - By inhalation, daily intermittent exposures. In 
addition, some animals also received oral dosage of 
the test material. 
Experimental Design: - 
Dosing of beclomethasone, dipropionate byinhalation was carried out 
daily as follows: - 
Group 1- High dose. Received 40 x the estimated human daily dose. 
Group 2- Medium dose. Received 20 x the estimated human daily dose. 
Group 3- Low dose* Received 10 x the estimated human daily dose* 
Group 4- Vehicle control. Animals dosed with aerosol vehicle only 
at the level used for animals in Group 1. 
Group 5- Chamber control. These animals were subjected to the same 
handling and chamber schedules as other groups but were not 
dosed in any way. 
Exposure of animals to the above schedule was carried out daily for 
twenty-six weeks. In addition, to the above procedure, some of the animals 
were treated by oral dosing for the final thirteen weeks of the study. 
Oral dosing was carried out to assess the effect of swallowing beclomethasone 
dipropionate assuming that this may possibly occur to some extent in man, 
after normal. direct self-achninistration of the drug from an aerosol pack. 
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13RIEF DETAILS OF REPEATED DOSE STUDIES OF BECLOMEMS014E DIPROPIONATE IN 
TEE RAT (Pathology Department, Allen and Hanburys Research Limiteds Warej 
Hertfordshire) 
CONTINUED 
Oral dosing was ca=ied out as follows: - 
Group 1- High dose. Animals received orally 100 x the estimated 
inhaled human dose. 
Group 2- Medium dose. Animals received orallY 30 x the estimated 
inhaled human dose. 
GrouP 3- Low dose. Animals received orally 10 x the estimated 
inhaled human dose. 
Group 4- Vehicle control. Animals received orally suspension 
medium at a volume equal to that given to animals in 
Group 1. 
GrouP 5- Chamber control. No oral treatment. 
Treatment given to animals in the various groups was therefore: - 
GI roup 
Total number 
of animals 
Animals dosed by 
inhalation only 
Animals dosed by 
inhalation + 
oral dosing 
No dosing 
15 male + 
15 femle 8 male 8 female 7 male 7 female 
2 15 mle + 15 female 8 male 8 female 7 male 7 female 
3 15 male + 15 female 8 male 8 female 7 male 7 female 
4 15 male + 15 female 8 male 8 female 7 male 7 female 
5 15 male + 15 female 15 male 15 female 
II 
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BRIEF DETAILS OF REPEATED DOSE STUDIES OF BECLOMLTHASONE DIPROPIONATE IN 
THE RAT (Pathology Departments Allen and Hanburys Research Limited, Ware, 
Hertfordshire) 
CONTINUED 
No mcroscopic abnormlities were seen that were considered to be 
related to the test compound. Similarly, on histological examination 
no abnormalities were seen that could be related to the test compound. 
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BRIEF DMAILS OF REPFATED DOSE STUDIES OF BECLOMETHASONE DIPROPIONATE IN 
THE DOG (Pathology Departmentp Allen and Hanburys Research Limited, Ware, 
Hertfordshire) 
Dosage Schedule - twice daily for twelve months 
Breed - Beagle 
ViiTn'hpT- nf A-nirn-nIr! -- 
Male Female Dose Level 
33 10 x 100 pg. burst twice a day 
332x 50 pg. burst twice a day 
33 10 x bursts of placebo aerosol twice a day 
Formulation (per can): - 
100'yg.. /b=_st 50 Pg-Aurst 
Beclomethasone dipropionate 19-95 mg. * 9.98 mg. * 
Oleic acid 2*00 mg. * 1.00 Mg. * 
Arctaa 11 5.02 g. 5-02 g. 
Arcton 12 12.94 9- 12.94 9- 
plus, 5% overage 
Total volume 13.2 Mi. 
Number of bursts per can 180 
Route 
Pulmonary 
Pulmonary 
Pulmonary 
Control 
2.00 Mgo* 
5-02 9. 
12.94 9- 
This experiment was terminated at the end of nine months because 
of frank Cushingoid changes observed in these animals. No changes in 
the respiratory tract attributable to beclomethasone diprbpionate was 
observed. 
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FIGURE 1- Plasm Radio-Activity following the Intravenous Administration 
of 1 mg. of Tritiated Beclomethasone Dipropionate to Man 
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FIGURE 2- Thin Iayer Radiochromatogram, of Ethanolio Extraot of Human 
Plasma after 1 mg, of Tritiated Beolomethasone Dipropion%te, 
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FIGURE 3- Urinary Excretion of Radio-Activity by Man after 1 mg. of 
Tritiated Beclomethasone Dipropionate Intravenously 
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FIGURE 4- Thin layer Cbromatogram of Urine Extract after I mg. 'of 
Tri#ated Beolomethasone Dipropionate Intravenously 
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FIGURE 5- Faecal Excretion of Radio-Activity by Man after 1 mg. of 
Tritiated Beclomethasone Dipropionate Intravenously 
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FIGURE 6- Thin Iayer Chromatog-ram of Faecal Extract after 1 Mg. of 
Tritiated Beclomethasone Dipropionate Intravenously 
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FIGURE 7- The Armstrong Breath Actuated Inhalation Device 
The diagram and the mode of action are described overleaf (page 164). 
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FIGURE 8-A Sectional Drawing of the Armstrong Breath Actuated Inhalation 
Device (in discharge position) to explain its Mode of Action 
To cook the device the Cocking Strap (1) is pulled downwards to extend 
the Actuating Spring (2) and engage the Triqger Notch (3) of the Actuating 
Unit (4) in the lower end of the TTigger (5)- 
The sequence of events in using the device are: - 
The subject places the mouth piece in the mouth closing his lips around 
it. As he inspiresp air enters the device via the Air Inlet (6) which 
causes the Pivoted Vane (7) to be moved inwards against the force exerted by 
the Leaf Spring (8). A oint is reached (determined by the rate of air 
flow) when the Trigger 
M 
is disengaged from the Notch (3) allowing the 
Actuating Unit (4) to be sharply moved upward by the Actuating Spring (2)y 
depressing the valve of the Aerosol Can (9) and releasing the medicament via 
the Sprayhead (10). 
16' 
FIGURE 9- An adaptor to enable intra-nasal inhalations to be administered 
shown fitting over the valve stem of an aerosol can which has 
been removed from the conventional inhaler. The dose is 
discharged when the can is depressed on to the valve stem. 
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FIGURE 10- Rat Inhalation Apparatus (Pathology Department, Allen and Hanburys 
Research Limited, Ware, Hertfordshire) 
The apparatus consists of a central chamber in which the contents of 
aerosol cans may be discharged. Around the circumference of this chamber 
are placed perspex cylinders in which the rats axe held. They have been 
trained to place their snouts into the central chamber and therefore to inhale 
the gas in there. Dose levels may be adjusted by varying the time of 
exposure and by placing varying numbers of aerosol cans, up to a total of six, 
in the head of the apparatus which fires automatically. A constantly 
rotating fan provides even dispersal and a constant flow of fresh air is 
provided to the chamber at the rate of five litres per minute. 
The animals are thoroughly trained and become accustomed to the 
apparatus before any proper test is carried out, thus any exceptionally 
nervous animals may be excluded from the experiment and the testing procedure 
becomes less stressful for the remaining animals. 
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FIGURE 11 - The Expansion Chamber Assembly Use of Administering Aerosols 
to Dogs (Pathology Department, Allen and Hanburys Research 
Limited, Ware, Hertfordshire) 
This apparatus consists of an inhaler containing an aerosol can, seen 
in the photograph in the handler's left hand. Air which might enter 
between the can and the inhaler is excluded by a latex sleeve. The aerosol 
is discharged into an expansion chamber made of perspex in which there is 
a thin latex cuff. There is a soft rubber tube entering the dog's mouth, 
this is long enough to press the soft palate upwards thus occluding the 
naso-pharynx, leaving the dog no alternative but to breathe through its 
mouth. The dog's respiratory movements are reflected in the movements of 
the thin latex sleeve, full inflation corresponding with maximum expiration. 
The aerosol is discharged as the dog begins to inspire. 
After five bursts have been given from the aerosol can the inhaler is 
then disconnected to permit the dog to breathe fresh air. 
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'IP'L 
BEACrLE 
The Beagle in Figure 12is showing signs similar to those seen in 
Cushing's Syndrome in man. There is shortening of the snout together 
with fattening of the face and an obvious Irbuffaloll hump on the back of 
the neck. There has been some loss of hair, and although it is not 
apparent in the photograph eczema of the paws was also noted. The legs 
are thinner and bowed when compared with the control dog and another 
prominent feature is the large distended abdomen. Part of the distended 
abdomen was undoubtedly due to an enlarged liver because of increased 
glycogen deposition. The liver weight in the treated dog being 500 9. 
compared with 300 9. in the control dog. 
FIGURE 12- Beagle showing signs of 
Hypercorticism as a result 
of Prolonged High Dosage 
Treatment with 
Beclomethasone Dipropionate 
FIGURE 13 - Control Beagle 
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FIGURE 14 - Section of the Adrenal 
Gland from the Dog with 
Hypercorticism (Figure 6) 
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FIGURE 15 - An Adrenal Gland from a 
Normal Untreated Dog as 
a Control 
Capsule 
Zona Glomerulosa 
Zona Fasciculata 
Zona Reticularis 
Figure 14 shows complete adrenal cortical atrophy when compared with the 
normal adrenal. The capsule and zona glomeralosa are normal whereas the 
zona fasciculata has almost completely disappeared. Thus only the zona 
reticularis separates the zona glomerulosa from the medulla. 
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FIGURE 16 - Section of Bronchi and Adjacent Alveolar Tissue from Dog 
(Figure 12) 
Haematoxylin and Eosin Stain 
No histological abnormality is present. 
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FIGURE 17 - Higher Power View of Figure 16 showing the Bronchial Mucous 
Membrane 
Haematoxylin and Eosin 
No histological abnormality is present. Normal cilia and goblet 
cells axe present. 
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FIGURE 18 - Section of Bronchi and Adjacent Alveolar Tissue from the Dog 
Stained with Verhoeff's Stain for Elastic Tissue and Van 
Gieson's Stain for Collagen Tissue 
The elastic and collagen tissues are normal in amount and distribution. 
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FIGURE 19 - Section of Bronchi and Adjacent Connective and Alveolar Tissue 
from the Dog 
Stained with Van Gieson's Stain for Collagen 
No abnormlity is seen in any tissue. 
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Patient Number - 141209-0663 
Brief Clinical Details supplied by Dr. E. Andersson 
"Sixty-three year old non, suffering from bronchitis with attacks of 
dyspnoea during ten years. He has been treated with prednisone in periods 
during the last two to three years. For six months he has been treated 
with Becotide with good effect, he has only had a few slight attacks after 
starting treatment. The patient is allergic to dust and feather. " 
Bronchoscopy Report 
"Normal conditions are found everywhere. " 
Microscopy Report - Numbers 3758 and 3755/73 (Figures 20 and 21, overleaf - 
Page 175) - 
"Norml epithelium cells who have preserved the cilia, no 
pathological ce-11 infiltrations. " 
Comment by Dr. D. Poynter 
"Good biopsy material, regular epithelium with cilia and goblet 
cells. Muscle fine. Normal picture. " 
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FIGURE 21 - Section of Bronchial Mucous Membrane and Underlying Connective 
Tissue (Van Gieson's Stain for Collagen Tissue) 
Comment: - Normal respiratory epithelium with a normal sub-epithelial 
stroma. Van Gieson's stain shows ample collagenous tissue. 
lop 
FIGM 20 - Section of Bronchial Mucous Membrane and Underlying Connective 
Tissue (Haemato3qrlin and Eosin) 
/a 
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Patient Number - 140355-0961 
Brief Clinical Details supplied ýy Dr. 
_E. 
Andersson 
"This is a fifteen year old boy suffering from asthma since his 
second year. He is allergic to dust and dog's hair. The late years he 
has been chronically weak and has been emaciated with frequent attacks of 
asthma. After starting a Becotide treatment he has been absolutely wellp 
and has had no attacks. " 
Bronchoscopy Report - after six months' treatment 
"The mucous membrane is dry, there is a sparse secretionp on the 
left side abnormal discharge of the bronchial tubes of the superior lung 
is found. " 
Microscopy Report, - Number 2669/73 
"Normal bronchial epithelium with normal looking cilia. Normal 
microscopy.,, 
Conment ýy Iý. D. 
_ 
Poyxvkcx 
"The epithelial cells appear norml, cilia obvious, several 
eosinophils present. " 
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Patient Number - 171030-0352 
Brief Clinical Details supplied by Dr. E. Andersson 
Woman, forty-two years old, suffering from asthma for twenty years. 
Is allergic to dust, animal hair, and feather. Frequent attacks. The 
patient has received steroids in certain periods. She has been without 
wjmptoms after the start of a Becotide treatment. " 
Bronchoscopy Report - after six months, treatment 
"A norml state is found. " 
Microscopy Report - N=be: c 3954/73 
"Norml epithelium with distinct cilia. The basement membrane 
seems slightly thickened. Submudous tissues are somewhat oedematic 
with only a few lymphocytes and no eosinophilic granulocytes. Normal 
muscles. 11 
Oomment by Dr. D. Poynter 
17V specimens showed an almost complete artefactual stripping of 
epithelium. The basement membrane is thick and there is some sub-epithelial 
oedema and haemorrhage. The haemorrhage is fresh and in ny opinion related 
to the biopsy. There are some small round cells in the muscle layer. A 
few epithelial cells ma ing a secondary air passage were seen deep in the 
section and these had a normal appearance. " 
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Patient Number 231022-0518 
Brief Clinical Details supplied by Dr. E. Andersson 
"Fifty year old woman suffering from asthma during eighteen years. 
The patient is allergic to dust and feather and has had frequent asthma 
attacks. She has been put on a Becotide treatment with a good effect* 
Howeverp she has had a few, slight attacks. " 
Bronchoscopy Report - after six months, treatment 
"The primary bronchus look anemic, but the mucous membrane is 
normal, in some areas coated with a thickl white secretion. " 
Microscopy, Report - Number 4080/73 
"Normal cells, the tissue preparation is bad. No coherent tissues. " 
Comment by Dr. D. Poynter 
"Some thick tenacious basophilic mucus was present with many 
infla tory cells. The epithelial cells were normal with abundant 
dilia. The collagen seems norml. 11 
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Patient Number - 050717-0431 
Brief Clinical Details supplied by Dr. E.. Andersson 
Iftn, fifty-six years old, suffering from serious asthma during 
two years,, treated with prednisone, 5 mg- twice a day3, but now put on a 
Becotide treatment with good effect. He has been entirely out of symptoms 
the last months. " 
Bronchoscopy Report after six months' treatment 
Microscopy Report - Number 4274/73 (Figures 22- and 23, overleaf - page 180). 
"Normal bronchial epithelium, and the cilia are preserved. The 
basement membrane seems to be slightly thickened, no inflanwtory in- 
filtrations. " 
Comment by Dr. D. Poynter 
"A normal looking epithelial. layer, cilia normal, goblet cells 
normal. There is some. oedematous thickening of the basement membrane 
region. There is plenty of normal collagen. " 
FIGURE 22 
FIGURE 23 
180 
181 
Patient Number - 280128-0490 
Brief Clinical Detailssupplied by Dr. E. Andersson 
'Woman, forty-five years old, suffering from asthma bronchiale, with 
serious attacks during two years. The patient is allergic to dust, feather, 
and mould fungus. She has been treated with Becotide during six months, 
and she has had no attacks in this period. " 
Bronchoscopy Report - after six months, treatment 
"Normal conditions. " 
Microscopy__Report - Number 4459/73 
"Bronchial epithelium cells with normal nuclei, no suspect cells, 
and tissue flakes containing smooth muscles and fibrous connective tissue. 
Cell formation shows normal conaitions. " 
Comment by Dr. D. Poynter 
"The few epithelial cells seen appear normal and there is ample 
collagen present. There are some squames and mamy exfoliated epithelial 
cells with clear brush borders. The exfoliation is most likely the result 
of the biopsy procedure. There is ample mucus rich in eosinophils and 
small round cells. " 
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Patient Number - 231107-0663 
Brief Clinical Details supplied PZ Dr. E. Andersson 
"Sixty-five year old man suffering from asthma bronchiale during six 
years. He is allergic to house dust. During the last year he has 
suffered from exacerbating asthma with attacks daily. For six months he 
has been treated with Becotide, and his asthmatic symptoms have disappeared 
completely. He has only a slight cough in the morning and function 
dyspnoea. 11 
Bronchoscopy Re2ort 
""Normal state. 11 
Microscopy Report - Number 4716/73 (Figures 24 and 25, overleaf - page 183). 
"Border of inf Ia tory cells, predominantly lymphocytes and 
eosinophilic granulocytes. Bronchial biopsy with unspecified in- 
flammation. Slight metaplastic epithelium. " 
Comment by_Dr. D. Poynter 
"The epithelium shows squamous metaplasia with eosinophils migrating 
through this layer. There is abundant sub-epithelial collagen containing 
patches of inflammatory cells which are mainly lymphocytes. Mucus is 
abundant and this contains eosinophils. " 
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0,0* 
FIGURE 25 - Higher Power View. Squamous Epithelial Changes with Migration of 
Eosinophils through this Layer 
FIGURE 24 Bronchial Biopsy showing some Squamous Metaplasia 
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Patient Nmber - 210318-0557 
Brief Clinical Details supplied by Dr. E. Andersson 
'7bnl aged fifty-four years, suffering from asthma bronchiale for 
twelve years, gradually aggravating. He is allergic to dust and animal 
hair. His asthma is better after six months' treatment with Becotide# and 
a Ventolin Inhaler is not needed. " 
Brmchosco]py Report 
"No 1 macous membrane, trivial secretion. " 
Microscopy Report Number 4583/73 
"Norml conditions". 
Coment by Dr. D. Poynter 
"Nothing remarkable seen. " 
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Patient Number - 040623-0546 
Brief Clinical Details supplied by IhO E. Andersson 
"Fifty year old rinn suffering from asthma bronchiale during eight 
yearap allergic to house dust. Treated with Becotide in six months. The 
patient has had no real attacks after starting this treatment. " 
Bronchoscopy Report 
"The impression is given that the muco-as membrane is slightly atrophic 
everywhere. " 
Microscopy Report - Number 4326/73 
"Slight hyperplastic respiration epithelium tissue without nucleus 
being atypic. Only accompanied by a very sparce stroma, and no certain 
inflammatory infiltrations. " 
Comment by, Dr. D. Poynter 
"Possibility some slight hyperplasia of epithelium, but within normal 
range, well preserved cilia. " 
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Patient Number - 110112-0429 
Brief Clinical Details supplied by Dr! E. Andersson 
'7bn, aged sixty-one yearsq suffering from asthma since his youth. 
Iately he has complained of exacerbation with frequent attacks and function 
dyspnoea. Ile is allergic to house dust. Howeverv after six months' 
treatment with Becotide he has only had a few, slight attacks of asthma, 
which has been aborted with a Ventolin Inhaler. " 
Bronchoscopy Report 
"No comment made. 11 
Microscopy Report - Number 3869/73 
"A normal mucous membrane, not atrophic, in spite of a bad tissue 
preparation, but giving the impression that the cells are normal with 
normal cilia. " 
Comment by Dr. D. Poynter 
"Plenty of macus and eosinophils. Normal respiratory expithelial 
cells with normal cilia and goblet cells. " 
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Patient Number - 140602-0521 
Brief Clinical Details supplied by Dr. E. Andersson 
IMn, seventy-one years old, suffering from asthma bronchiale during 
nine years* He is allergic to dustt animal hair, and feather. He has 
started a Becotide treatment, but he has still had attacks of asthma and 
function dyspnoea. 11 
Bronchoscopy Report - after six months' treatment 
"Nonnl conditions. " 
Microscopy_Report - Number 3890/73 
"Norml looking and not atypic cells. " 
Coment by Dr. D. Poynter 
"A regular respiratory epithelial layer with normal cilia. " 
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APPENDIX - TABLE 1 
McKenzie Vasoconstriction Test Scores 
Alcohol Solutions of the Steroids 
listed below at a Concentration of 0.0001% 
Steroid A B c D E F G 
Observer A B A B A B A B A B A B A B A B A B A B 
Subjeot 
1 
10 - 
0 0- 0 0- 0 0- 2 0- 1 1- 1 0- 0 0- 0 0- 0 2- 0 
2 !l 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 
3 !0 0 0 0 0 2 0 0 1 0 0 0 0 0 0 0 1 1 0 0 
4 0 1 0 0 0 1 1 1 0 0 1 1 0 0 0 0 0 1 0 0 
5 0 1 0 0 0 0 1 1 0 3 0 0 0 0 0 0 1 2 0 0 
6 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
8 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 
9 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
'10 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 
11 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 
12 0- 0 0- 0 2- 0 0- 0 0- 0 0- 0 0- 0 0- 0 1- 1 0- 0 
13 0- 0 0- 0 0- 2 0- 0 0- 1 0- 0 0- 0 1- 2 0- 0 1- 0 
14 0- 0 0- 0 0- 0 0- 0 0- 0 0- 0 1- 1 0- 1 0- 0 0- 0 
Total 4 3 8 8 6 7 2 7 8 3 
af 4-8 3.6 9- 5 9- 5 7-1 1 8.3 1 2-4 8-3 9- 5 1 3.6 j 
Prednisone 
B= Dexamethasone Isonicotiriate 
C= Dexanethasone 
D= Beclomethasone Dipropionate 
E= Triamcinolone Acetonide 
F= Beclo. methasone Monopropionate 
G= Dexam sone di-sodium Phosphate 
Prednisolone 
I= cortisol 
J= Beclomethasone Alcohol 
* Percentage of possible maximum score 
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APPENDIX - TABLE 2 
McKenzie Vasoconstriction Test Scores 
Alcohol Solutions of the Steroids 
listed below at a Concentration of 0.015ýo 
Steroid A B C D E p G H I J 
Observer A B A B A B A B A B A B A B A B A B A B 
Subject 
1 0 1 1 1 1 3 1 2 1 1 0 1 1 0 0 1 2 1 
2 3 0 1 0 2 2 1 1 2 2 1 0 0 0 1 2 0 0 
3 0 0 1 1 0 0 3 3 1 2 2 2 1 0 1 0 1 2 1 1 
4 0 0 1 1 0 0 2 1 1 1 1 2 0 0 0 0 0 0 1 1 
5 0 0 2 1 1 0 3 3 3 2 3 3 0 0 0 0 0 0 2 1 
6 1 0 0 1 0 0 2 3 1 1 1 1 0 0 0 0 0 0 1 1 
7 0 0 1 2 0 0 2 0 0 3 1 2 0 0 0 0 0 0 0 1 
8 0 2 0 -. 1 0 0 0 0 1 2 0 2 0 0 0 0 0 0 0 1 
9 0 0 1 1 0 1 3 3 1 3 2 3 0 0 0 0 0 0 0 0 
10 0 0 0 1 0 0 1 2 1 2 1 2 0 0 0 0 0 0 0 0 
11 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 
12 0 0 1 3 0 0 2 2 2 3 3 2 0 0 0- 0 0 0 1 1 
13 0 0 1 1 0 0 1 1 2 2 2 1 0 0 0- 0 0 0 1 1 
14 1- 1 0- ,0 1- 0 3- 3 0- 0 1- 2 0- 0 0- 0 0- 0' 2- 0 
Total 11 23 5 52 35 45 3 2 7 20 
1 %* 1 13-1 127-4 1 6.0 161.9 146-4 153.6 1 3.6 1 2- 4 8-3 23.8 
Prednisone 
B= Dexamethasone Isonicotinate 
C= Dexamethasone 
D= Beclomethasone Dipropionate 
E= Triamoinolone Acetcrnide 
P= Beclomethasone Monopropionate 
G= Dexamethasone di-sodium Phosphate 
H= Prednisolone 
I= Cortisol 
J= Beclomethasone Alcohol 
* Percentage of possible maxiimun score 
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APPENDIX - TABLE 
McKenzie Vasoconstriction Test Scores 
Alcohol Solutions of the Steroids 
listed below at a Concentration of 0.1ýo 
Steroid A B C D E F G 
_H 
I J 
Observer A B A B A B A B A B A B A B A B A B A. B 
Subject 
i 0- 0 0- 1 0- 2 1- 1 3- 3 0- 2 0- 0 0- 0 0 -0 0- 1 
2 0 -, 0 1- 1 1- 1 3- 3 2- 3 3- 2 1- 1 1- 1 0 -0 0- 0 
3 0 0 0 0 0 0 1 1 1 1 1 2 0 0 0 0 1 0 0 2 
4 0 0 1 3 0 0 2 2 1 3 0 3 0 1 0 0 0 0 0 0 
5 0 0 1 1 1 1 3 1 3 3 3 3 1 1 0 0 1 0 0 1 
6 1 1 1 1 1 1 2 1 2 1 1 2 0 0 0 0 0 0 1 1 
7 0 0 1 0 0 0 2 2 2 3 1 3 0 1 0 0 0 1 0 0 
8 0 0 1 0 0 0 0 0 0 2 2 1 0 1 0 0 0 0 0 0 
9 1 1 2 2 2 1 1 1 1 1 0 1 2 1 0 0 1 0 1 1 
10 0- 0 0- 1 0- 0 3- 3 3- 3 3- 3 0- 0 0- 0 0 - 0' 0- 0 
11 1 1 3 2 1 0 0 2 3 3 0 2 1 1 0 0 1 0 1 0 
12 1 2 1 1 2 2 1 2 2 3 1 2 1 1 0 0 0 0 0 1 
13 0 0 1 1 1 1 0 3 1 2 1 1 1 1 0 0 0 2 0 1 
14 0 0 0 1 1 2 0 2 1 3 1 2 1 1 0 0 0 0 0 0 
Total 9 28 21 43 59 46 18 2 7 11 
%* 
-- 
1 10-71 1 33- 33 1 25.0 151.2 1 70.2 1 54-8 121-4 1 2-4 1 8-3 1 13-1 
Prednisone 
B- Dexamethasone Isonicotinate 
C= Dexamethasone 
D= Beclomethasane Dipropionate 
E- Triamcinolone Acetonide 
F- Beclomethasone Monopropionate 
G= Dexamethasone di-sodium Phosphate 
H= Prednisolone 
I- cortisol 
i- Beclomethasone Alcohol 
* percentage of possible m im= score 
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APPENDIX - TABLE 
In Vitro Metabolism of 30 ng- of Radio labelled Beclomethasone-11,21- 
Dipropionate in the 16 and 16a Positions by 0.5 g_. Hum= Lung Slices 
I cub tion 
% Total Activity 
n a 
Time Tube Radio Iabelled Radio Idbellea Radio Iabelled (Minutes) Beclomethasone- Beclomethasone- Beclomethasone 
Total 
I 
17,21-Dipropionate 17-Propionate 
Con- 
60 trol 100 0 0 100 No 
Lung 
Con- 
60 trol 100 0 0 100 Boiled 
Lung 
5 Test 67-4 26-4 6.2 100 
15 Test 12-7 83-5 3.7 99.9 
60 Test 0 86.9 13-1 100 
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APPEM)Ix - TABLE 
Plasma Drug Radio Activity Expccessed as Radio Labelled Beclomethasone- 
17,21-Dipropionate in the 16 and 16a Positions after an Oral Dose of 
mg. of Radio Labelled Beclomethasone-17,21-Dipropionate 
Time 
Capsule Group 
ng. /ml. 
Suspension 
Group 
ng. /ml. 
B. D. M. K. G. W. M. N. J. S. K. N. 
1 hour 1-4 2.0 1.2 3.8 9.2 7-7 
3 hours 6.3 9-3 7.6 15.2 19-4 10.8 
5 hours 10.2 11-3 9.6 13-8 19.9 20.1 
7 hours 4-8 10.1 13-3 10.8 17-9 10-4 
9 hours 4-4 6.2 9.0 12.9 15.4 9.2 
12 hours 4.2 5-0 8.2 8.6 -- -- 
24 hours 0-4 le2 1-5 -- 6.2 3-3 
48 hours -- -- 1 1-9- 1 3-81 
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APPENDIX - TABLE 6 
Excretion of Radio Activity in the Urine and Faeces 
Expressed as a Percentage of Administered Dose 
Time in Hours 
t -- Totals Subjec 
12 24 36 48 60 72 
1 84 96 
Urine 6.8' 2-4 1-3 o. 6 0.3 0.2 -- -- 11.6 
B. D, 
Capsule Faeces -- 23.9 -- 
17-0 -- 3.6 5.4 0.4 50-3 
Total 6.8 26.3 1.3 17.6 0-3 3-8 5-4 0.4 61.9 
Urine 6.1 2-4 1.6 0.8 0-4 0-3 -- -- 11.6 
M. K. Faeces -- -- -- -- -- 63-7 -- -- 63.7 Capsule 
Total 6.1 2-4 1.6 0.8 0-4 64-0 0 0 75-3 
Urine 4-5 3-9 2.3 1.3 0-5 0-3 -- -- 12.8 
G. W. Faeces -- 20.8 -- 35.9 
1 
-- 3.4 3-5 1.6 65.2 Capsule 
Total 4-5 24-7 2-3 37.2 0-5 3-7 3.5 1.6 78-0 
Urine 4.4 3.2 1.9 1.6 1.1 0-7 -- -- 12.9 
M. N. 
Capsule Faeces -- 1-7 -- -- 57-4 -- 
7-5 -- 66.6 
Total 4-4 4-9 1.9 1.6 58-5 0-7 7-5 0 79-5 
J. S. Urine 9-5 3.2 1-4 0-7 o. 6 0-4 -- -- 
15-8 
Suspen- Faeces -- -- 36.8 6.1 -- -- 2-3 0.4 45.6 
sion Total 9-5 3.2 38.2 6.8 0.6 0.4 2.3 0.4 61-4 
KeNe Urine 5-1 2.1 1-4 0-8 0-4 005 -- -- 10-3 
SusPen- Faeces 0 -- -- -- 4.5 -- -- 32.0 36-5 
sion Total 5.1 2.1 1-4 0-8 4.9 0.5 0 32.0 46.8 
a 
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APPENDIX - TABLE 
Thin Iayer Chromatogýra4ic Analysis of Faecal Extracts 
Containing over 8%oof the Administered Radio Activity 
% of Activity Present Faecal 
Sam le on the Chromatogram, T t t Subject p rea men Time in 
Hours Polar Metabolites B B-17-P B-17,21-32 
B. D. 12 - 24 24.2 2.0 48-1 21.8 
B. D. 36 - 48 45-7 3-0 14-1 32.0 
M. K. 60 - 72 46.9 5-5 39-5 2.0 Capsule 
G. W. 12 - 24 35-7 2.6 39-0 19.9 
G. W. 36 - 48 28.2 5.6 30.6 35.4 
M. N. 48 - 60 35-3 12*8 35.6 9.2 
J. S. 24 - 36 74o2 6.6 13-3 3-4 Suspension 
K, N. 84 - 96 64-7 14-8 13.6 
Beclomethasone 
B-17-P = Beclomethasone-17-Propionate 
B-17p2l-DP = Beclomethasone-17,21-Dipropionate 
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APPENDIX - TABLE 8 
Urinar7 17-Oxogenic Steroid Excretion Values 
Subject L. L. 
Day Dose Urine 17-Oxogenic Steroid mg-/24 hours 
] 
of Drug and 
Trial Route Individual Mean 
1 20.8 20-4 19.9 
2 18.6 18-4 1992 
3 Dexamethasone 2 mg. 
/day 12.0 12.0 Oral 11.9 
4 Dexanethasone 2 mg. 
/day 5-8 5.6 Oral 5-4 
5 9.6 9.8 10.0 
6 22-5 22-3 22.1 
7 19-5 19.8 20.0 
8 22.8 23-1 23-4 
9 24-4 24-1 23-8 
10 Beclomethasone dipropionate 200 pg. 
/day 
Inhaled 
19.6 
19.8 19-7 
11 Beclomethasone dipropionate, 200 jig. 
/day 
Inhaled 
21.0 
20.0 20-5 
12 20-7 20.9 21.1 
13 2394 23-4, 23-4 
14 22-5 22-4 22.2 
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APPENDIX - TABLE 
Urinary 17-Ozogenic Steroid Excretion Values 
Subject A. 0. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 
21.0 20*2 
19.3 
2 
18.0 18.0 
17-9 
3 Dexamethasone 
2 mg. /day 
Oral 
9-7 
10.1 9.9 
4 Dexamethasone 2 mg. 
/day 
Oral 
8.2 
7-9 
8.1 
5 
6-5 6-5 6-5 
6 14-4 14-9 15-4 
7 
20o2 
19-. 6 
19.9 
a 
18.8 
la. 6 
18-7 
9 17-5 17-7 17-8 
10 Beclomethasone dipropionate 400 P-9-/daY 18.2 17-7 Inhaled 17.2 
11 Beclomethasone dipropionate 400 Pg-/daY Inhaled 
18-4 
18.6 18-5 
12 19.9 19.6 19-3 
13 20.6 21-3 
k 
22.0 
14 20-7 20.1 19-5 
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APPENDIX - TABLE 10 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject D. M. 
Dose Urine 
17-Oxogenic 
Day Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 
15-3 
16.1 15-7 
13-5 12.6 2 11-7 
3 Beclomethasone dipropionate 
600 pg. /day 
Inhaled 
10.6 
8.8 9-7 
4 Beclomethasone dipropionate 
600 pg. /dav 
Inhaled 
13-4 
11-7 12.6 
5 
14.6 
8 1 14.2. 3- 
6 
16.2 15-8' 15-3 
13.6 14.0 7 14-4 
8 
18.3 16.3 18-3 
9 16.8 16.8 16.8 
10 Dexamethasone--' 2 mg. 
/day 
Oral 
-- 
17.8 17-8 
11 De xamethasone' 
2 mg. /day 
Oral 
11.1 
10.6 10.9 
12 
6-3 
6.9 6.6 
13' 
10-4 9.2 8.0 
14 
16.8 
16. a 
16.8 
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APPENDIX - TABLE 11 
Urinary 17-Ozogenic Steroid Excretion Values 
Subject H. M. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg. /24 hours 
Of Drug and 
Trial Route Individual Mean 
15.1 14.8 14.5 
17-1 16.4 2 15-7 
3 Dexamethasone 
2 mg. /day 
oral 
14-8 
13.7 
14.3 
4 Dexamethasone 
2 mg. /day 
Oral 
9.2 
9.2 
9.2 
7-0 7-1 5 7-1 
6 
12.5 11.8 
11.1 
15-9 15-9 7 15-9 
8 
17.2 17,2 
17.2 
9 
15-1 15-0 
14-9 
10 Beclomethasone dipropionate 
800 pg. /day 
Inhaled 
13.7 
13-9 13-8 
11 Beclomethasone' dipropionate 
Boo pg. /day 
Inhaled 
15.4 
16.0 15-7 
12 
16.0 
16. s 16-4 
13 
16.3 
17.0 16-7 
14 
16.4 16.2 15.9 
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APPENDIX - TABLE 12 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject N. P. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 13.6 13-7 13-8 
2 
16.2 16.2 16.2 
1,000 pg. 1 15-1 
3 Beclomethasone dipropionate day 13-9 14-5 Inhaled 
19000 pg. 1 10-7 
4 Beclomethasone dipropionate day 10-5 10.6 Inhaled 
5 
12-3 12.6 12.8 
6 18-7 18-7 18-7 
7 15-3 14.8 
1 
. 14-3 
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APPENDIX - TABLE 13 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject A. 0. 
Day Dose Urine 
17-Oxogenic 
Steroid mg-/24 hours of Drug and 
Trial Raute Individual Mean 
1 19-7 20.2 20-7 
2 
17-9 18.9 19.9 
19200 pg. / 15.6 
3 Beclomethasone dipropionate day 18.7 17.2 Inhaled 
19200 pg. / 14-1 
4 Beclomethasone dipropionate day 14-1 14-1 Inhaled 
5 
15.6 15-7 15-8 
6 20.8 21.1 21-4 
7 23.5 23-5 23-4 
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APPENDIX - TABLE 14 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject D. M. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg. /24 hours 
of Drug and 
Trial Route Individual Mean 
14-1 13.4 12-7 
2 
13-8 12.8 
11-7 
19400 Pg-/ 10.0 
3 Beclomethasone dipropionate day 9.8 9.9 Inhaled 
1P400 Pg. / 9.1 4- Beclomethasone dipropionate day 8.9 9.0 Inhaled 
5 9.1 9.0 8.9 
6 12.8 12.8 12o8 
7 12-5 13o6 
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APPENDIX - TABLE 15 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject L. L. 
Day Dose- 
Urine 17-Oxogenic 
Steroid mg. /24 hours of Drug and 
Trial Route Individual Mean 
1 15.2 15-1 15.0 
2 22.1 21-7 21-3 
1,600 pg. / 14-4 
3 Beclomethasone dipropionate day 14-4 14-4 Inhaled 
4 Beclomethasone dipropionate 
1,600 pg. / 
day 
15-8 
15-4 15.6 
Inhaled 
5 
17-4 17.2 17-0 
6 18-5 19.1 19.6 
7 
19.1 19.6 
20.0 
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APPENDIX - TABLE 16 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject H. M. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and ' Trial Route Individual Mean 
1 18.6 18.2 17-8 
2 
14.6 14.6 14.6 
11800 pg. 1 15.2 
3 Beclomethasone dipropionate day 15-0 15-1 Inhaled 
' 
11800 pg. 1 10.6 
4 Be clomethasone dipropionate day 1000 10-3 
Inhaled 
5 
12.1 12-4 12o7 
6 12.6 llo2 908 
15-1 15-0 14-8 
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APPENDIX - TABLE 17 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject M. T. 
Day Dose 
Urilie 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 14-7 14-3 13-8 
2 19.8 18.6 
19.2 
29000 pg. / 12.3 
3 Beclomethasone dipropionate day 12.6 12-5 Inhaled 
29000 pg. / 12*0 
4 Beclomethasone dipropionate day 12.6 12*3 Inhaled 
5 18.9 16.9 17.9' 
6 17-8 17-5 17.2 
7 15-6 16. o 16-4 
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APPENDIX - TABLE 18 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject D. B. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg. /24 hours 
of Drug and 
Trial Route Individual Mean 
1 15-0 15-4 15-8 
2 
13.5 13-4 13.3 
3 Dexamethasone 2 mg. 
/day 
Oral 
7.7 
7-9 7-8 
4 Dexamethasone 2 mg. 
/day 
Oral 
6.4 
5-7 6.1 
5 
9.4 
9.6 9-5 
6 12.6 12-5 12.4 
7 
14-1 14.6 15-1 
8 
14.7 
14-1 14-4 
9 15-1 14-7 14.3 
10 Beclomethasone dipropionate 1 mg. /day. Oral 
16.0 
17.2 16.6 
11 BeclOmethasone dipropionate 1 mg. /day Oral 
12.7 
12-5 12.6 
12 13.9 12-7 13-3 
13 13.5 13.8 14.1 
14 15.3 15.4 15.4 
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APPENDIX - T-AME 19 
Urimaxy 17-Oxogenic Steroid Excretion Values 
Subject N. P. 
Bose Urine 17-OxOgenic Day Steroid mg. /24 hours 
of Drug and 
Trial Route Individual Mean 
1 11-4 12.3 13.2 
2 
12-3 
12.6 12.5 
3 Dexamethasone 
2 mg. /day 10.1 9.8 
Oral 9-4 
4 Dexamethasone 
2 mg. /day 
Oral 
5-4 
5.6 5.5 
5 
4-8 5-0 5.2 
6 
7-5 6.6 
5-7 
7 
9-7 
10.1 9.9 
17.6 
16.8 17.2 
9 
12.1 12-5 
12.9 
10 Beclomethasone dipropionate 2 mg. 
/day 
Oral 
14-8 
14-3 
14.6 
11 Beclomethasone dipropionate 2 mg. 
/day 
Oral 
9-5 
9ý5 9.5 
12 13.9 13-5 13.1 
13 13-4 12.6 13-0 
14 
1 1 18*2 18.2 
1 
18.2 
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APPENDIX - TABLE 20 
Urinary 17-Oxogenic-Steroid Excretion Values 
Subject K. P. 
Day Dose Urine 17-Oxogenio Steroid mg. /24 hours of Drug and 
Trial Route Individual Mean 
1 15.9 15-7 15-5 
2 17.2 17-7 18.2 
3 Beclomethasone dipropionate 3 mg. 
/day 
Oral 
16.8 
17-0 16.9 
4 Beolomethasone dipropionate 3 mg-/daY Oral 
11.9 
12-5 12.2 
5 19.9 16-5 18*2 
6 17-3 17-3 17.2 
7 20-5 20-5 20-4 
23-9 23-0 22*0 
9 17-9 17-7 17-8 
10 Dexam sone 
2 mg. /day 16.9 17.2 Oral 17-5 
11 Dexamethasone 2 mgo/dav 6.9 7*2 Oral 7-4 
12 5-8 5-5 5*2 
13 13-8 
12.6 14.2 
14 15*2 15-1 15-0 
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APPENDIX - TABLE 21 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject M. T. 
Urine 17-Oxogenic 
Day Dose Steroid mg. /24 hours 
of Drug and 
Trial Route Individual Mean 
1. 17.2 16.9 16.6 
2 
19.2 19.0 18-7 
3 Beclomethasone dipropionate 4 rDg-/dav Oral 
17-8 
17.6 17-7 
4 Beclomethasone dipropionate 
4 mg-/&v 
Oral 
13.2 
13.4 13-3 
5 
13.2 13-1 1299 
6 
18.8 18.1 17-4 
7 
18.8 
18.6 18-7 
8 
15-3 
16.1 15-7 
9 
18-3 18*2 18.1 
10 Dexamethasone 2 mg. 
/day 14-9 14.2 
Oral 13-5 
11 Dexamethasone 2 mg. 
/day 9.6 9-7 
oral 9.8 
12 a. 6 9*2 9.8 
13 11-4 11-4 11-4 
14 13-5 13.9 L- 14-3 
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APPENDIX - TABLE 22 
Uriraxx 17-Oxogenic Steroid lbicretion Values 
Subject H. D. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 
11.6 11.8 12.0 
2 
13-0 12-5 12.0 
3 
12.6 12.2 11.8 
4 Beclomethasone 4 mg. 
/daY 10-5 10-7 
Oral 10.8 
5 Beclomethasone 4 mg. 
/day 
Oral 
5-9 
5-9 5-9 
6 10-4 10-3 10.2 
7 
7-8 8.1 8-4 
8 
11-4 12-4 
13-4 
9 9.2 9.0 8-7 
10 Dexamethasone 2 mg. 
/day 8-4 8.2 Oral &0 
11 Dexamethasone 2 mg, 
/day 
. 6.1 6.1 Oral 6.1 
12 5*2 5.6 5-4 
13 7.0 6.8 
. 
6.6 
14 10.0 9-7 9-4 
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APPENDIX - TABLE 23 
Urinaxy 17-Oxogenic Steroid Excretion Values 
Subjeot G. H. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg. /24 hours 
of Drug and 
Trial Route Individual Mean 
1 Incomplete Sample 
2 13-8 14-1 14-3 
3 
13-7 13-8 13-9 
4 Dexamethasone 2 mg. 
/day 
Oral 
10.5 
11-3 1009 
5 Dexamethasone 2 mg. 
/day 
Oral 
5-8 
5-0 5-9 
6 6. o 6. o 6. o 
7 
7-3 
6.9 7-1 
12*8 13-3 13-7 
9 14*2 14-7 15.2 
10 Bec lomethasone monopropionate 4 mg. 
/daY 
Oral 
15.4 
15-0 15.2 
11 Beclomethasone monopropionate 4 mg. 
/day 
Oral 
11.1 
11-3 11*2 
12 12-4 12.6 12.8 
13 16-5 164o3 16-4 
14 21-7 21.9 22,1 
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APPENDIX - TABLE 24 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject D. M. 
Day Dose 
Urine 17-Oxogenic 
Steroid mg-/24 hours 
of Drug and 
Trial Route Individual Mean 
1 15.0 15-0 15.0 
2 
14.6 14-9 15,2 
3 
19.0 19.2 
19-4 
4 Beclomethasone monopropionate 
4 Mg. /daY 
Oral 
12.9 
12-3 12.6 
5 
F 
Beclomethasone monopropionate 
4 mg. /daY 
Oral 
9-5 
9-5 
9-5 
6 
7-8 7*'5 7*2 
7 
12.3 12-5 
12-7 
14.8 14.6 
14.4 
9 
12.9 13.2 13-5 
10 Dexamethasone 2 mg. /day Oral 
17-9 
17 -l 
17.5 
11 Dexamethasone, 2 mg. /day 8-3 8-7 Oral 9.1 
12 8.2 7-8 7-4 
13 13-7 13-7 13-7 
14 
L- 
18.6 
16.0 17-3 
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APPENDIX - TABLE 25 
Urinaxy 17-Oxogenic Steroid Excretion Values 
Subject T. C. 
Urine 17-Oxogenic 
Day Dose Steroid mgo/24 hours Drug and 
Trial Route Individual Mean 
1 
18-7 18.2 17-7 
2 
22-7 22-3 
21.8 
3 
20.1 19.8 
19-5 
4 Dexamethasone 
2 mg. /day 17-9 
17-1 
17-5 
Oral 
5 Dexamethasone 2 mg. 
/day 8.5 
9 8 
8-7 
Oral . 
6 
7-0 794 
7-8 
7 
12.7 13.1 
13-5 
8 
16-7 17-0 
17.2 
9 
15-5 15.6 
15-7 
19250 pg. / 13-8 13.9 10 Dexamethasone isonicotinate day 13-9 
Inhaled 
1,250 Pg. / 11.1 10.2 11 Dexamethasone isonicotinate day 9-3 
Inhaled 
12 
7.6 
8.2 
7-9 
- 13 
12.8 
12.2 
12-5 
14 
14.2 14.6 
15-0 
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APPEnIX - TABLE 26 
Urinary 17-Oxogenic Steroid Excretion Values 
Subject D. R. 
Day Dose Urine 17-Oxogenic 
of Drug and 
Steroid mg-/24 hours 
Trial Route Individual Mean 
1 13-1 13-1 13-1 
2 14.2 14-1 14-0 
3 15-1 15-3 15-5 
4 Dexamethasone 2 mg. 
/day 11.9 11.8 Oral 11-7 
5 Dexamethasone 2 mg. 
/day 6.6 6.2 
Oral 5-8 
6 4-3 4-4' 4-5 
7 6.4 6-4 6.4 
8 11-5 11-5 11-5 
9 14.2 13.6 13-0 
19250 Pg-/ 11.6 10 Dexamethasone isonicotinate day 11-5 
Inhaled 11-4 
19250 pg-1 5-8 11 Dexamethasone isonicotinate day 6. o 5.9 Inhaled 
12 5*2 
4.6 4-9 
13 11.0 11.2 11-4 
14 12.0 12.1 12*2 
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APPEnIX - TABLE 27 
Plasma Corticosteroid and Cortisol Concentrations of Human Subjects 
Inhaling 1 mg. /day for Seven Days of Beclomethasone-17-Propionate 
t S b 
Sample 
Ti 
pg. Cortisol/100 ml. Plasma 
jec s u me 
Days Protein Binding Fluorometric 
0 9.0 -- 
3 8-4 14-0 
H. D. 5 9-4 14.4 
7 7-5 13.6 
10 9.1 15.2 
0 
3 13-7 
M. T. 5 15.4 
7 10.6 
10 12.7 
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APPENDIK - TABLE 28 
Plasma Corticosteroid and Cortisol Concentrations of Human Subjects 
Inhalingýl mg. /Uy for Seven Daysof Beclomethasone 
Subjects 
Sample 
Tim 
pg. Cortisol/100 ml. Plasma 
e 
Days 11'rotein Binding Fluorometric 
0 7.2 -- 
3 8.8 11.2 
D. R. 5 9.8 11.2 
7 10.8 11-7 
10 15.6 15-5 
0 12.8 -- 
3 13.6 9.9 
G. H. 5 12.1 11.2 
7 13-7 11-7 
10 16.6 15-5 
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APPENDIX - TABLE 29 
9.00 a. m. Plasma Cortisol Concentrations of Three 
Subjects Inhaling Increasing Doses of Beclomethasone Dipropionate 
Subject D. M. Subject D. R. Subject G. H. 
Date Total pg. 1100 M10 
Total 
pg. 1100 mie 
Total 
pg. 1100 ml. Dose Dose Dose 
mg. /24 - Ing. /24 mg-/24 
ho-urs* Fluor IPB hours* Fluor PB hours* Flu Fluor or PB 
12.6-72 Control 23-0 15.2 Control 15-0 7.5 Control 14-10 14-0 0 7-9 
14.6-72 Control 15.5 11-5 Control 11-5 6.6 Control 10. 10.0 10.0 0 6.9 
16.6-72 Control 13.0 11.8 Control 8.0 7-3 Control 11-5 9.8 
19.6-72 1 Mg. 18.0 14-4 1 Mg. 9-3 6.8 1 Mg. 11-4 7-8 
21.6-72 1 Mg. 14-0 12.2 1 Mg. 14.6 7-8 1 Mg. 16.0 8-5 
23.6-72 1 Mg. 10-0 10-0 1 Mg. 10-5 9.2 1 Mg, 4.6 5-4 
26.6-72 2 Mg. 20.0 10-4 2 Mg. 5.4 5-5 1 Mg. 15-0 13-4 
28.6-72 2 Mg. 12.0 9.5 2 Mg. -- 8.4 2 Mg* 8.1 7-1 
30.6-72 2 Mg. B-7 5.2 2 mig. 3.6 2.0 2 Mg. 12.0 13.2 
3-7-72 4 mg- <0-5 <0.1 2 Mg. <0-5 0.5 4 mg. -- 8.1 
4-7-72 Control 16.0 15-3 Control 16.0 7-5 Control 7.4 7.2 
5-7-72 Control 21.0 13-0 Control -- -- Control 16,. 3 14-3 
7-7-72 Control 11.8 12.9 Control 10.0 6-7 Control 15-0 15.6 
10-7-72 4 mg- <0-5 <0-1 4 mg. <0-5 <0-1 
1 11,7.72 1 Control 116-3 116-5 1 Control 113.6 1 9-5 1 1- I 
Fluor = As determined by fluoremetric assay 
PB = As determined by protein binding assy 
The first dose of drug was inhaled at midnight 
and then at six hourly intervals thereafter. 
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APPENDIK - TABLE 30 
9.00 a. m. Plasma Cortisol Concentrations of Two Subjects who 
Inhaled a Total Dose of 1 mg. /#y f or a Period of One Month 
Subject M. T. Subject A. 0. 
D 4-- ate 
Total Dose 
mg-/24 hours* Pg-AOO mi- pg. 
1100 ml. 
Fluor PB Fluor PB 
12.6-72 Control 17.0 17.2 20*0 18-3 
14.6-72 Control 14-5 15-5 25-0 21-7 
16.6-72 Control 15-5 17.9 19-5 22-3 
19.6-72 1 Mg. 20.0 20.0 22.0 18-4 
21.6-72 1 Mg. 14.6 12.4 12.0 16.1 
23.6-72 1 Mg. 13.2 13.6 13.2 15-7 
26.6-72 1 Mg. 16.0 18.0 21.0 11-7 
28.6-72 1 Mg. 18.2 14.8 15-7 16.8 
30.6-72 1 Mg. 10-7 13-4 15-0 13-9 
3-7-72 1 Mg. 18.0 19.0 23-0 17-7 
5-7-72 1 Mg. 14-3 14-7 26.0 17.9 
7-7-72 1 Mg. 13-7 17-1 17-0 13-5 
10-7-72 1 Mg. 14-3 16-3 15.0 14-4 
12-7-72 1 Mg. 12.8 15-3 15-7 13-4 
14-7-72 1 Mg. 24-0 12-4 19.0 15.1 
Pluor w As determined by fluorometric assay 
PB = As determined by protein binding assay 
The first dose (250 Pg-) of drug was inhaled at 
midnight and the other doses at six hourly 
intervals thereafter. 
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APPENDIX - TABLE 31 
9.00 a. m. Plasma Cortisol Concentrations in Two Healthy 
Male Subjects Followirg Oral Beclomethasone Dipropionate 
Date Total Dose 
mg-/24 hours 
Subject M. T. 
pg. 1100 mi. 
Subject D. B. 
pg. 1100 mi. 
8-1-73 Control 16.2 16.6 
10-1-73 Control 11.7 14-7 
12.1-73 Control 11.9 14.9 
15-1-73 1 Mg. 11-5 11-4 
17-1-73 1 Mg. 10-3 15.4 
19-1-73 1 Mg. 9.2 13-7 
22*1-73 1 Mg. 12.6 17-4 
24-1-73 1 Mg. 10.1 15-9 
26.1-73 1 Mg. 11-3 12-7 
29.1-73 1 Mg. 10-3 15-7 
31.1-73 1 Mg. 11-5 16.8 
2.2-73 1 Mg. 12.6 14-7 
5.2-73 1 Mg. 13-8 16.8 
7.2-73 1 Mg. 9-3 13-1 
9.2-73 1 Mg. 12.6 14.2 
12.2-73 4 mg. 12*8 5.6 
14.2-73 4 mg. 6.6 7.6 
16,2-73 4 mg. 6.1 4*2 
19.2-73 6 Mg. 8-7 4-8 
21*2-73 6 mg. 6-3 2-7 
23.2-73 8 Mg. * 8.1 15-3ý 
26.2-73 18 Mg** 1 13-5 1 ll. gx I 
* Subject M. T. only 
x Control Values 
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APPENDIX - TABLE 32 
9.00 a. m. Plasma Cortisol Concentrations in Two Hea 
Male Subjects Pollowing Oral Beclomethasone I)ipropionate 
Date Total Dose 
mg-/24 hours 
Subject D. R. 
pg. 1100 mi. 
Total Dose Subject D. M. 
mg-/24 ho=s pg. 1100 mi. 
8-1-73 Control 10-7 Control 17-0 
10-1-73 Control 8.0 Control 13-4 
12*1-73 Control 8.8 Control 15.2 
15-1-73 1 Mg. 10.6 1 ng. 14-1 
17-1-73 1 Mg. 11-3 1 Mg. 10.9 
19-1-73 1 Mg* 10.2 1 Mg. 12.3- 
22.1-73 2 mgO 12*1 2 Mg. 14.6 
24-1-73 2 Mg. 13.2 2 Mg. 11-5 
26.1-73 2 Mg. 2 Mg. 9.6 
29.1-73 3 Mg. 9.2 3 Mg. 10.3 
31-1-73 3 Mg. 11-4 3 Mg. 10-4 
2*2-73 3 mg. 3 mg. 7.1 
5.2-73 4 mg. 9.2 4 mg. 9.8 
7.2-73 4 mg. 4-4 4 mg. 1.8 
9.2-73 4 Mg, 7o9 4 Mg. 2.1 
12*2-73 6 mgo 1-3 3 mg. 3-8 
14,243 6 mgO 7.6 3 Mg. 5o2 
16.2*73 6 mg. 5.6 3 mg. 7-1 
1go2-73 8 mgO 2*8 3 Mg. 15-0 
2lo2-73 8 Mg. 6.8 Control 12-5 
23o2-73 Control 91.0 Control 
* Subject could not attend on t4ese days 101, venepuncture 
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APPENDIX - TABLE 33 
9.00 a. m. Plasma Cortisol Concentrations 'in Healthy. Male Subjects Pollowing 
Increas#g Doses of Beclomethasone Dipropionate Administered Intra-Nasally 
Date 
Total Dose 
Subjects 
A. 0. and G. H. 
zg-/24 hours 
Subject 
AeO* 
pg. 1 
100 ml. 
Subject 
G. H. 
pg. 1 
100 M10 
Total Dose 
Subjects 
H. D. and T. C. 
mge/24 hours 
Subject 
H. D* 
pg. 1 
100 ml. 
Subject 
T. C. 
pg-1 
100 ml* 
B-1-73 Control 13-7 15-7 Control 17-7 14-9 
10-1-73 Control 10.6 14-5 Control 12-3 11.2 
12-1-73 Control 9-7 15-3 Control 13-0 13-4 
15-1-73 1 Mg. 10-4 16-4 1 Mg. 11.9 12-4 
17-1-73 1 Mg. 8.6 15.2 1 Mg. 11.1 13-3 
19-1-73 1 Mg. 9-4 17-0 1 Mg. 13-3 13-1 
22.1-73 1 Mg. 8.8 16.0 2 Mg. 17-0 12*0 
24-1-73 1 Mg. ge2 12*2 2 Mg. 11.2 11.6 
26.1-73 1 Mg. 9-5 10.8 2 Mg. 11-4 9.8 
29.1-73 1 Mg. 10.9 14-8 3 mg. 11.6 1295 
31-1-73 1 Mg. 12.6 15.4 3 Mg. 11.9 14.6 
2.2-73 1 Mg. 10.9 15-8 3 mg. 12.0 15-1 
5,2-73 1 Mg. 12.2 16.0 4 mg. 13-5 14-1 
7*2-73 1 Mg. 9.1 12-7 4 mg. 12-7 13-7 
992-73 4 mg. 10.6 16.9 4 mg. 12.8 13-5 
12,2-73 4 mg. 11.0 6 mg. 10.6 11-4 
14.2-73 4 mg. 8.9 15-0 6 mg. 13-1 12-5 
16*2-73 4 mg. 6.6 13-8 6 mg. 9.6 8.6 
19.2-73 6 mg. 10.8 19.6 8 Mg. 13-7 13-9 
21*2-73 8 Mg. 5-5 16-3 8 mg. 7.2 10-3 
23*2-73 8 Mg. 10-3 14-8 8 Mg. 4-5 10.0 
26.2-73 Control 
_ 
9_-7 13.8 control 15-7 1 
* This subject was unable to attend for venepuncture on this day 
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APPENDIX - TABLE 34 
9.00 a. m. Plasma Cortisol Concentrations in Five Healtýy Male Subjects, 
following the Inhalation of 1 mg. Beclomethasone Dipropionate per da, y 
together with the Simultaneous Administration of Increasing Doses of 
Beclomethasone DiZopionate by the Intra-Nasal Route of Administration 
Date 
Inhaled 
Dose 
, */24 Mg hours 
Intra- 
Nasal 
Dose 
mg-/24 
hours 
Subject 
D. M. 
Pg* / 
100 mie 
Subject 
D. C. 
pg-1 
100 Mi. 
Subject 
M. S. 
pg-1 
100 Mi. 
Subject 
A*M* 
pg-1 
100 Mi. 
Subject 
D. P. 
pg-1 
100 Mi. 
3.9.73 1 mg. 11.0 11.1 12-3' 11-5 15-0 
5.9.73 1 mg. 12*-5 8.8 10-3 8-3 14-7 
7- 9-73 1 Mg. 8-7 7-7 5-4 7-9 
10.9.73 1 mg. 1 mg. 9-3 9.0 11.1 14-0 14-0 
12.9.73 1 mg. 1 Mg. 12.8 13-0 11.6 13-3 12.1 
14.9.73 1 mg. 1 Mg. 11.0 12-7 10.8 12*2 13-3 
17.9.73 1 mg. 2 Mg. 8-3 7-8 11-5 12*4 15-1 
19.9.73 1 mg. 2 Mg. 10.6 8-0 3-8 7-9 7-9 
21.9.73 1 mg. 2 Mg. 7-9 6. o 6-5 7-8 
24- 9-73 1 mg. 3 mg. 7-3 5-5 7-4 8.1 
26.9-73 1 mg. 3 mg. 4.2 5-7 6.2 7-3 8.9 
28* 9-73 1 mg. 3 mg. 5.5 12.2 
1-10-73 1 mg. 4 mg. 7-7 6*2 5-7 9.1 
3.10-73 1 mg. 4 mg. 5-7 3-3 4-1 6.9 6-3 
1 5-10-73 11 mg. 14 mg- 1 5-7 1 6.3 1 --* I-. 6-3 
- 
1 10-3 
_j 
* The subjects were unable to attend on these days for venepuncture 
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APPENDIX - TABLE 35 
9.00 a. m. Plasma Cortisol Concentrations Following Inhaled 
Dexamethasone-Disodium-Phosphate (Respihaler Decadronp 
Merckq Sharp and Dohme) in Three Healthy Male Subjects 
Date Dose 
mg-/24 hours 
Subject 2 
pg. 1100 ml. 
Subject 3 
Pg-AOO ml- 
Subject 7 
Pg-AOO ml- 
4e6-73 Control 12 15 11 
6.6-73 Control 10 13 11 
a. 6-73 Control 9 11 13 
11.6-73 0.9 Mg. * l 9 4- 
13.6-73 0.9 Mg. * 3 6 3 
15.6-73 Control 14 13 10 
18.6-73 Control. 14 17 11 
* Approximately 0--756 mg. Dexamethasone daily 
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APPENDIX - TABLE 36 
9_. 00 a. m. Plasma Cortisol Concentrations Following Inhaled 
Dexamethasone-21-Isonicotinate (kuxilosone, Thomae) in 
Three Healýhy Male Subjects 
Date Dose 
mg-/24 hours 
Subject 4 
pg. 1100 ml. 
Subject 5 
pg. 1100 mi. 
Subject 6 
pg. 1100 ml. 
4*6-73 Control 18 13 14 
6.6-73 Control 17 11 11 
8*6-73 Control 15 12 10 
11.6-73 19250 mg. * 5 3 2 
13.6-73 lp250 Mg. * 4 1 1 
15.6-73 Control 18 13 17 
18.6-73 Control -- 
x 15 14 
* Approximately 0.960 mg. Dexamethasone daily 
X Subject could not attend on this day 
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APPENDIX - TABLE 37 
9.00 a. m. 
_Plasma 
Cortisol Concentrations tollowing_Inhaled 
Betamethasone-17-Valerate (Glaxo IaboratOries) in Three 
Healthy Male Subjects 
Date Dose 
mg-/24 hours 
Subject 1 
Pg-AOO mi- 
Subject 8 
Pg-AOO mi- 
Subject 9 
P'g. 1100 mi. 
496-73 Control 13 11 8 
6.6-73 Control 12 12 7 
8.6-73 Control 13 12 8 
1: 1.6-73 1 Mg. 15 12 9 
13.6-73 1 mg. 12 10 9 
15.6-73 1 Mg. 13 11 10 
18.6-73 2 Mg. - 13 6 8 
20.6-73 2 Mg. 10 4 11 
22.6-73 2 Mg. 9 5 7 
25.6-73 3 Mg. 12 2 5 
27.6-73 3 Mg. 13 2 7 
29.6-73 3 Mg. 9 4 4 
2-7-73 Control 10 11 6 
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APPENDIX - TABLE 38 
9.00 a. m. Plasma Cortisol Concentrations Following Inhaled 
Beelomethasone-17,21-Dipropionate (Becotide, Allen and 
Hanburys Limited) in Three Healthy Male Subjects 
Date , Dose mg-/24 hours 
Subject 10 
pg. 1100 ml. 
Subject 11 
pg. 1100 ml. 
Subject 12 
pg. 1100 mi. 
4.6-73 Control 8 12 
6.6-73 Control 9 11 17 
8.6-73 Control 10' 12 17 
11.6-73 1 mg. 10 10 
13.6-73 1 Mg. 9 11 17 
15.6-73 1 Mg. 8 10 20 
18.6-73 2 Mg. 9' 11 
20.6-73 2 Mg. 8 6 20 
22.6-73 2 Mg. 8 21 
25.6-73 3 Mg. 9 9 
27.6-73 3 Mg. 4 7. 20 
29.6-73 3 Mg. 5 3 20 
2-7-73 Contr ol 10 11 15 
* This subject could not attend on these days 
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APPENDix - TABLE 39 
9.00 a. m. Plasma Cortisol Concentrations Following Various Doses of 
Inhaled 3)examethasone. Isonicotinate--(A-qxilosone - Thomae) in Three 
Healthy Male Stibjects 
Date 
Daily Dose Subject 10 
mg-/24 hours pg. /100 mi. 
Subject 11 
gg. /100 mi. 
Subject 12 
pg. /100 mi. 
17- 9-73 0.25 mg- 10.6 14-4 10-5 
19.9-73 0.25 mg- 10.6 10*2 11.0 
21o 9o73 0.25 m9o 6.9 lOo2 7o5 
24- 9-73 0-50 mg- -7-9 9.8 7., 6 
. 26.9-73 
0-50 m9o 7-0 6.6 7-8 
28.9o73 Oo5O mg- 4.12 9.0 54 
1.10-73 0.75 mg. 2.0 7-8 6.6 
3-10-73 0.75 mg. 0.8 8.6 2.6 
5-10-73 Control 6.6 6-5 9-5 
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APPENDIX - TABLE 45 
The Absolute Eoeinophil Count before 
--- 
(aom. ) and Five Hours after(p. m.. ) 
Various Inhaled Doses of Beclomethasone Dipropionate (Three Subjects) 
Dose 100 pg. 
Absolute Eosinophil Count 
tN b S b = er jec u 
a. m. POMO 
3 105 93 
6 179 
ý184 
12 70 70 
Dose 200 pg. 
Absolute Eosinophil Count 
b er Subject Num 
a. m., POM4, 
3 155 126 
6 263 201 
12 96 31 
Dose 300 Pg. 
Absolute Eosinophil Count 
tN b S b L= er jec u 
a. m4p POMO 
3 88 84 
6 241 196 
12 140 70 
Dose 400 Pg. 
Absolute Eosinophil Count 
tN b S b um er u jec 
a. m. POMO 
3 89 58 
6 413 187 
12 144 93 
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The following four tables are the corrected ýmean f igures from the 
Appendix Tables 41,429 43v 44,50(pages 228 to 231) and page 238- In 
ChapterVI on page 100 the reasons for preparing these mean figures are 
explainedp and Table 7 (page 99) shows the dosage regimen. 
The corticosteroids are designated. by letter in the tables, the key 
being: - 
A- Oral Dexamethasone 2 mg. 
B- Placebo 
C- Oral Prednisone 5 mg 
D- Oral Prednisone 10 Mg. * 
E- Oral Beclomethasone Dipropionate 1 Mg. 
F- Oral Beclomethasone Dipropionate 4 mg. 
G- Inhaled Beclomethasone Dipropionate-, 500 Pg- 
H- Inhaled Beclomethasone'Dipropionate 2-mg* 
In the fasting blood glucose experiment the 10 mg. dose of Prednisone 
was increased to 20 mg. 
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APPENDIX - TABLE 46 
The Corrected Mean Values of the Total White Cell Counts 
(Appendix Table 41) for each Grau , P-of 
Three Subjects* 
v 
A. M. 
Subject Groups 
Steroid 
1,2P 3 4,5,6 7P 8,9 10,11,12 
Mean 
A 7,700 7P566 7,033 6,933 7t3O8 
B 8t033 7,366 6t7OO 6t3OO '7,100 
C 8,161 7,171 79206 5,806 7PO86 
D 8,961 7,671 6P85.6 7,206 79674 
E 8,506 7P761 71911 6,891 7P767 
P 79556 7t661 61,811 5041 69967 
G 71231 79566 79031 6s751 7,145 
H 89031 7PO16 6P031 69701 
A 7,445 
P. M. 
Subject Groups 
Steroid 
It 2P 3 49 5,6 7P 89 9 lot 11,12 
Mean 
A 1OP500 10,400 9,133 99033 9P766 
B. 9t2OO 7,86ý 6,800 8,233 89025 
C 9605 8,783 8v566 8,168 8v755 
D 99355 9683 8,666 9v768 9P343 
E 9PO35 99278 '6,1ý1 89438 89235 
99985 9,628 7P841 99038 99123 
G 10,060 9t288 8., '541 8,343 9,058 
8t260 9,438 99,39l 8,893 8,995 
* please refer to the explanatory note on page 233* 
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APPENDIX - TABLE 47 
The Corrected Mean Figu res of the Neutroph il Countg3 
(Appendix Table 42 for each Group of Three Subjects* 
A. M. 
Su: ýjeýt Groups'- 
St id M ero ean 
1,29 3 49 5l 6 79 89 9 l0l 119 12 
A 49833 49033 59033 4, '833 4,683 
B 4P766 4P700 4,266 2Y533 4YO66 
c 69295 4,761 4,330ý 49433 4P955 
D 69345 5j211 4,130 5PO33 5P180 
E 4P865 5PP46 4,850, 3,6.28 4,587 
P 49715 5PP46 4,, 650 4,7 
* 
78 4,797 
G 5,140 49591 4P120 4,088 4,485 
H 4,640 4, 
ý941 
4,. 920 
. 
4,138 4,669 
P. M. 
Subje'ct'Groups 
M Steroid ean 
1,2P 3 4v 5,6 7,81 9 10,11,12 
A 7,933 6,700 79900 8,066ý 7,650' 
B 5,766 5,066 5,000 -5#300 8,283 , 
c 89490 5v498 69365 5 503 6 464 
D 8040 MO. 7j215, 7,303 7P726 
E 5,475 5,368 59905 5Yý808_ 5,639 
F 5,575 5,518 6,955 8,115ý 6651 
G 6o435 6,733 6,580 6,13 8 6., 471 
69535 6P333 6f280 , 1 6,688 69459 
please refer to the explanatory note o. n page, 233 
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APPENDIX - TABLE 48 
The Corrected Mean Figures'6f the Iymphocyt e Ca=ts 
(App endix Table 43) for each Graup' - 6f Three Subjects* 
A. M. 
Subject Groups- 
Steroid Mean 
19 2v 3 As 5,6 7899 103,111, -12 
A 4600 5v566 49466 -4,833 4,841 
B 4433 4P900 59200 79133 5P416 
C 39241 4993 5s258 59198 4,672 
29891 4,643 5P508 4048 4s472 
E 4,676 4643 4903 6,153 5,058 
4276 '4v493 5., 103 4,953 4706 
G 4,281 5_, 013 ý, 488 5.6ý48 5PO80 
49731 49763---, 5* 398- 9 49855 
P. M. 
--subjept, Groups Steroid Mean 
lp 2p, 3 4s -5,6 -79,69 9 109- 119 -. 12 
A lp966 39166 2 9033 11900 23,241 
B 3,600 4,660 _ 4,600 4533 4,349 
C 1P308 4196 39531 49421 39338 
D lv458 119846 29781 2,621 2476 
E 4P123 4021 3P926 4,040 
4ol23 49021 29941. 1P776 3,9'? 17 
G 3PO_68 3t-1181 39026 39701 39244 
H 3l2l8__ 39381-_-, - I---3p426 3t 201 3s, 408 
pleace refer to the exPlanatorv note on page 233 
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APPENDIX - TABLE 49 
The Co=ected Mean Pigur2s of the Absolute Eosinophil Counts, 
(Appendix Table 44 ) for each Group of Three Subjects* 
Subject Groups 
St id M ero ean 
it 2,3 4P 5,6 79 8t 9 10,110 12 
A 376 186 235 136 233 
B 532 223 242 138 284 
C 358 196 279 141 243 
D 551 210 258 107 281 
E 367 143 262 lig 223 
F 476 160 210 160 252 
G 365 334 221 160, 270 
H 512 191 231 166 2 75 
P. M. 
St oid 
Subject Groups 
E 
Mean er 
ly 29 3 4P 5,6 7P 8P 9 109 Ol 
A 32 5 15 6 14 
B 447 207 162 76 223 
C 64 
. 
85 44 23 54 
D 30 85 11 7 33 
E 291 116 120 53 145 
F lig 34 87 24 
66 
G 206 170 145 46 1422 
H -219 21 35 27 
75 
please refer to the explanatory note on page 233 
238 
k 
43 
0 
ri 
?4 
; 2; 
r 
ca 
0 
a 
0 
19 
0 
H 
Fq 
En "0 
ca 
Id 
. r-I 0 
0 
V 
, rj 
43 
P 
0 
9 
r4 ýtj 
"0 
ý: t l 
UN t- CD U% 
C% 
UN 
C\i 
U-N 
Ln 
C\i 
Cl % \M 
t2 cli 
00 
- - i e r 1 r 
C) Pf r-i 0 \M \M "0 t- ! i? l% CD o 0 Ln Z %ýo LC-% Ict Igt t U-N 
9 
t- Lr CD et 
m a) Lr% 
% 
Pr\ 
Co 
LC'\ CD 
r-1 %Z 
!N 
ID 
0 P 4 ' H O -e to 0 LN 0 LC, % Xt %ID GD %I0 C\i -e CM 
02 0 H cli \. 0 %Z C) cm 0 
_H C%i u"% ý, 0 GD OD C) t- M) 
19 ri r-i 
-ri U'\ Co C) Co C) %0 c% 0 CD 
LA 
0 00 (D r-i C) A OD 
LCI% 
r-i 
Lr\ 
OD 
U'% 
r4 
U'It 
cm 
%ýo 
Co 
u, \ 
0 CD 
U-N 
t- 
Lt, 
et 
LC% 
9 C: ) 
U'% 
94 
A 
cli C) 0 %0 -zj* %10 0 %Z et C: ) 0 0, % p cli CN 1-0 u'% 1,0 H a'ý t-- -t-- «e t-- cc) 0 
r>A r-i CM K'\ «e LrIt \io t, - CD C% C) r-1 C\j 
239 
APPENDIX - TABLE 51 
The Co=ected Mean Values of the Fasting Blood Glucose Levels 
(Appendix Table 50 )_ for each Group of Three Subjects* 
Subject Groups 
Me n Steroid 
19 29 3 4s 5, - 6 7P 8s 9 10, Up 12 
a 
A 67-3 92.0 63-3 73-0 73-9 
B 55.6 57-0 48-3 5o. 6 52*9 
C 5292 54-0 58-5 78.9 6o. 9 
.D 
75-7 74-0 89.0 65-9 76.2 
E 49-7 77-3 48-8 31-0 51-7 
P 46-7 54-8 68.8 68-5 59-7 
G 56-5 55.6 47-5 57-4 54-3 
H 66.0 61.6 56-5 50-4 58-7 
I 
please refer'to the expL-matory note an page 233 
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APPENDIX - TABLE 52 
Changes in the Total White Blood Cell Count following the Administration 
of Various Steroids (Twelve Subjects - Mean Values) 
Steroid* Dose Route Count 
Before 
Steroid 
Count Five 
Hours After 
Steroid 
Change 
A 2.0 mg. Oral 7P308 9P766 + 2,458 
B 7vlOO 81025 925 
C 5.0 mg. Oral 79086 89755 + 1,669 
D 10.0 Mg. Oral 7,674 9,353 + 1,669 
E 1.0 Mg. Oral 79767 8j235 + 468 
F 4-0 mg- Oral 6, ý67 , 91123 + 2,156 
G 500 Pg- Inhaled 7J45 99058 + 1P913 
H 2.0 mg. Inhaled 7t445' 8v995 + 1,550 
Mean Increase in Total White Blood Cell Count - 1,601 
* please refer to the explanatory note on page 233 
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APPENDIX - TABLE 53 
The Response of the Absolute Eosinophil Count to Single Doses of Various 
Steroids (Mean Counts - Twelve Subjects) 
. 
Steroid* Count Before Steroid 
Count Fiiýe 
Hours Af ter 
Steroid 
Fall in Count % Fall 
A 233.6 14-9 218-7 93-7 
B 284.2 223-4 60.8 21-4 
C 243-9 54-7 189.2 77.6 
D 281.9 33-9 248-0 88.0 
E 223-0 145-3 77-7 35-0 
F 252sO 66-3 185i, 7 74-0 
G 270*2 142-5 127-7 48-0 
H 275-5 75-9 199.6 72-5 
-1 
please refer to the explanatory note-on page 233 
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APPENDIX - TABLE 54 
Dose of Beclomethasone Dipropionate 
P. go 
Mean Fall -in Eosinophils 
Expressed as a Percentage 
Control 21-4 
100 3-0 
200 37-0 
300 24-0 
400 41-0 
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APPMIX - TABI 55 
The Ratio of Afternoon Count to Morning Count of the Absolute Eosinophil 
Counts Recorded on Page 
SubJect Dose of Beclomethasone Dipropionate 
(pg. ) 
t l C Number ro on 
100 200 300 400 
3 0.996 0.886 0-813 0-955 0.652 
6 0.673 1.028 0-764 0.813 0.453 
12 0-564 1.000 0.323 0-500 0.656 
Mean 0-740 0-970 0.630 0.760 0-590 
Overall Moan Ratio - 0-71 
with Standard E=or - 0-045 
giving P<0.001 
The Ywan Ratio is Significantly Less than 1.0 
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APPENDIX - MLE 56 
Fast#K Blood Glucose Values Nine Hours after Single Doses of Various 
Steroids (Means of TwelveSubjects) 
Steroid* Blood Glucose mg. AOO mi. Ch=ge from Control 
A 73-9 + 21'. 0+ 
B 52.9 
C 6o. 9 + 8.0 
D 76.2 4-. 2 3. 
E. 51-7 - 1.2 
-F 59-7 +, 6.8 
G 54-3 + 1-4 
H 58-7 5-8 
Significantly greater than Control 
please refer to the-explanatory note on page 233 
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